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ABSTRACT
Adenosine triphosphate is an ubiquitous extracellular messenger, which 
activates P2 purinergic receptors in the plasma membrane of eukaryotic cells.
Activation of P2 receptors regulates many cellular functions ranging from 
survival and proliferation to apoptosis. The final effect of extracellular ATP on a 
cell depends on the composition of P2 receptor expressed on its surface. We 
showed that T effector/memory (TEM) cells express high levels of P2rx7
encoding for the ATP-gated ionotropic P2X7 receptor subtype. The deletion of 
the gene in these cells results in increased survival and cell proliferation both in 
vitro and in an in vivo model of homeostatic expansion. P2rx7-/- TEM cells are 
characterized by a bioenergetic advantage with respect to wild-type (WT) cells
and morphometric analysis of mitochondria revealed that P2rx7-/- TEM cells are 
characterized by a fused mitochondria network, while WT TEM cells have more 
fissed mitochondria. Microarray gene expression analysis showed that P2rx7-/-
TEM cells clustered together and separately from WT cells. Among differentially 
expressed genes we identified cyclin-dependent kinase inhibitor 1A (Cdkn1a), 
encoding for p21Waf1/Cip1, as a transcript upregulated in WT cells. P21 inhibits 
progression through G1 to S phase in mammalian cells and it is upregulated in 
senescent cells. We demonstrated that P2X7 signaling directly upregulated 
Cdkn1a in TEM cells and this resulted in a block in cell cycle progression. We 
hypothesize that P2X7 receptor could induce premature senescence in TEM 
FHOOV $FFRUGLQJO\ WKH DQDO\VLV RI ȕ-galactosidase, a marker of senescence, 
revealed that P2X7 induces an increase in the enzyme activity in TEM cells. 
Moreover, WT TEM cells stimulated with a pharmacological agonist of P2X7 are 
characterized by increased in Trp53 and Gadd45b expression as well as p38 
MAPK phosphorylation. Moreover, P2X7 stimulation induces an increase in 
mitochondrial ROS and an increase in histone H2AX phosphorylation as a 
marker of DNA damage and cellular senescence. The tumor microenvironment 
is reach in extracellular ATP; we hypothesized this feature could affect TEM 
cells survival and function. In fact, we show that lack of P2X7 promoted 
expansion and accumulation of both CD4 and CD8 tumor infiltrating 
lymphocytes in a melanoma mouse model, thus favoring the control of tumor 
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size. Altogether our results point to P2X7 as a checkpoint for limiting CD4 TEM 
cells expansion in inflammatory environments that might be targeted to 
implement cytotoxic T cell responses in cancer immunotherapy. 
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INTRODUCTION
In mammals, the protection of the organism from invasion by pathogens is 
mediated by the two branches of the immune system. Innate immunity provides 
the early response against infections whereas adaptive immunity subsequently 
contributes the pathogen-specific immune response. Innate immunity consists 
of cellular and biochemical defense mechanisms that are in place also before 
infection and respond as soon as in contact with the pathogen. The principal 
components of the innate immune system are physical and chemical barriers, 
phagocytic cells (neutrophils and macrophages), dendritic cells and natural killer 
cells and other innate lymphoid cells, blood proteins including proteins of the 
complement system and other mediators of inflammation. In contrast to innate 
immunity, adaptive immunity is stimulated by protracted exposure to infectious 
agents, enhances the efficacy of the immune response and confers specific 
memory. In fact, the most important characteristics of the adaptive immune 
system are the specificity of the response, and the ability to respond more 
vigorously to repeated exposures to the same microbe (i.e. memory). T and B 
lymphocytes are the cellular components of the adaptive immune system.  
1.T lymphocytes
1.1 T cell development in the thymus
T cell development begins in the bone marrow from a common lymphoid 
hematopoietic progenitor that migrates to the thymus. The thymus supports 
multistage lineage commitment and differentiation steps to yield mature and 
self-tolerant T cells. Thymopoiesis is initiated and maintained during fetal and 
neonatal life. In adulthood the thymus is smaller and possess limited T cell 
developmental potential (Donskoy and Goldschneider, 1992). In the thymus, T 
cell sub-lineages can be divided into two laUJH FODVVHV QDPHO\ Įȕ DQG Ȗį7
cells, which are distinguished on the basis of the T cell receptor (TCR). The
FKRLFH EHWZHHQ Įȕ DQG Ȗį IDWHV LV likely the first lineage decision made by 
progenitors and is instructed by TCR signaling. Stronger TCR signaling favors 
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Ȗįwhereas weaker signaling IDYRUVĮȕOLQHDJHGHYHORSPHQW(Haks et al., 2005; 
Hayes et al., 2005); (Kreslavsky and von Boehmer, 2010). Thymocytes 
development proceeds through a series of steps that are broadly characterized 
by coreceptor expression, by TCR gene rearrangement and expression, and by 
expression of other markers such as cytokine receptors or activation molecules. 
Immature thymocyte precursors do not express either CD4 or CD8 coreceptor 
molecule and are defined as double negative (DN). At this stage, TCR genes 
rearrangement is initiated and cells become committed either WRWKHĮȕor Ȗį7
cell lineage (Petrie et al., 1992). Development of Įȕ7FHOOs is characterized by
expression of the pre-TCR, which induces differentiation to the early CD4/CD8 
double positive (DP) stage. Upon rearrangement of the 7&5Į-chain gene, the 
Įȕ TCR is expressed on the cell surface and the interaction with self-MHC 
molecules expressed on cortical thymic epithelial cells (cTECs) will determine 
the thymocyte fate. Initial TCR stimulation would eventually lead to 
downregulation of CD8 (CD4+8int stage) and upregulation of the TCR. 
Modulation of CD8 would allow the thymocyte to detect whether its TCR is 
restricted by MHC class I (MHCI) or MHC class II (MHCII) molecule. Loss of 
signal strenght would implement the differentiation program related to MHCI 
restriction, whereas sustained signaling would result in differentiation of MHCII 
restricted CD4 cells (Singer et al., 2008). A TCR signal above a certain 
threshold induces thymocyte survival and differentiation, referred to as positive 
selection (Starr et al., 2003), whereas a strong signal causes activation-induced 
cell death (apoptosis), leading to negative selection of potentially self-reactive 
cells (Gascoigne et al., 2016; Palmer, 2003; Stritesky et al., 2012).
In the thymus we can distinguish four sequential phenotypes within DN cells; 
stages DN1 to DN4 based on expression of CD44, CD25 and CD117 (c-kit) 
(Godfrey et al., 1992). The DN1 subset (CD44+c-kit+CD25-) has high 
proliferative capacity and is able to give rise to ERWK Įȕ DQG Ȗį cells. DN1 
thymocytes differentiate into DN2 cells (CD44+c-kit+CD25+) that migrate 
outwards the thymus in the perimedullary cortex to the inner cortex (Lind et al., 
2001). At this stages thymocytes can still be diverted to become dendritic cells 
(DCs) or natural killer cells (NKs). After migration in the outer cortex, they 
further differentiate into the DN3 cells (CD44-c-kit-CD25+). These cells are 
characterized by large-VFDOH UHDUUDQJHPHQW RI 7&5ȕ 7&5Ȗ DQG 7&5į loci,
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orchestrated by non-redundant recombinase activating genes (RAG1 and 
RAG2) (Godfrey et al., 1994). Only cells that efficiently rearrange TCR genes
proceed throughout the differentiation process, while those that fail to do so die
(Michie and Zuniga-Pflucker, 2002)  6RPH '1 FHOOV GLIIHUHQWLDWH LQWR Ȗį 7
cells, whereas other DN3 cells intensely proliferate and JHQHUDWH Įȕ OLQHDJH
committed CD4+CD8+ double positive (DP) thymocytes (Ciofani et al., 2006),
which are the most abundant cells in the thymus. Double positive thymocytes 
initiate the UHDUUDQJHPHQW RI WKH 7&5Į ORFXVand are selected based on the 
specificity of their clonotypic TCR. MHCI and MHCII specific T cells will develop
into CD4 and CD8 single positive (SP) immunocompetent T cells, respectively,
that will leave the thymus to seed the periphery (Petrie and Zuniga-Pflucker, 
2007) (Bhandoola et al., 2007).
1.2 T cell activation
Mature T cells that have differentiated in the thymus are released into the 
bloodstream. These cells are considered immunologically naïve and are 
characterized by the high expression of L-selectin (CD62L) and chemokine 
receptor CCR7, both key molecules for the entry of T cells into lymph nodes 
through high endothelial venules (HEVs) (Berard and Tough, 2002). In lymph 
nodes, naïve T cells become activated and start to proliferate and differentiate 
upon antigen recognition. This occurs as a result of the interaction between the 
TCR and CD4 as coreceptor with peptide-MHC II complex presented by antigen 
presenting cells (APCs). TCR activation promotes a number of signaling 
cascades that ultimately determine cell fate through regulating cytokine 
production, cell survival, proliferation and differentiation into effector cells. The 
differentiation process is influenced by the cytokine milieu, the type of APC, the 
strength of TCR interaction and the nature of costimulatory molecules, which 
drive and control T cell number and fate. One of the most important 
costimulatory molecule identified in the early 1980s is the membrane receptor 
CD28. It was found to enhance TCR-induced proliferation and differentiation of 
naïve T cells. B7-1 (CD80) and B7-2 (CD86), the ligands of CD28, are 
expressed at high levels by activated professional APCs (Lenschow et al., 
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1996; Pages et al., 1994). Other important costimulatory molecules are 
represented by the CD28 homologous inducible costimulatory (ICOS) and the 
members of the TNF receptor family (CD27, 4-1BB, and OX-40) (Coyle et al., 
2000; Hutloff et al., 1999). T cells also express co-inhibitory molecules and one 
of the most studied is cytotoxic T lymphocyte antigen 4 (CTLA-4), which also 
binds to CD80 and CD86. CTLA-4 is induced following T cell activation and 
suppresses T cell responses. When CTLA-4 is upregulated, the T cell
downregulates CD28 by exocytosis (Rudd et al., 2009). Expression of CD80 
and CD86 is modulated by the activation state of the APC. CD86 is 
constitutively expressed on APCs at low levels; infections, stress and damage 
recognition by innate receptors activate APCs and induce increased expression 
of both CD80 and CD86 on the cells surface (Hathcock et al., 1994; Inaba et al., 
1994). The modulation of receptors and ligands on T cells and APCs provides 
multiple levels of regulation for T cell activation (Flies and Chen, 2003). The 
earliest event in TCR activation is the phosphorylation of immunoreceptor 
tyrosine-based activation motif (ITAMs) on the cytosolic side of the TCR/CD3 
complex by Src-like protein tyrosine kinases (PTK) lck and/or fyn. The 
phosphorylated ITAM is recognized by Src homology (SH) 2 domain of the Syk 
(spleen tyrosine kinase)-family kynase zeta-chain associated protein-70 (ZAP-
70) PTK, which in turn is activated by Lck-mediated phosphorylation. ZAP-70 
phosphorylates a number of downstream target sites, including tyrosines on the 
transmembrane adapter protein LAT and the cytosolic adapter protein src 
homology 2 (SH2) domain-containing leukocyte phosphoprotein of 76 kDa 
(SLP-76) (Iwashima et al., 1994; Zhang et al., 1999; Zhang et al., 1998). These 
adaptor proteins are fundamental for the correct activation of multiple signaling 
pathways. LAT is characterized by the presence of nine distinct tyrosines, which 
become phosphorylated upon TCR activation. LAT then functions as a scaffold 
for the recruitment and activation of several different SH2-domain-containing 
VLJQDOLQJ SURWHLQV VXFK DV SKRVSKROLSDVH &Ȗ 3/&Ȗ SKRVSKRLQRVLWLGH -
kinase (PI3K) and the cytosolic adapter/linkers proteins GRB2 and Gads 
(Sommers et al., 2004; Zhang et al., 1999). SLP-76 itself has three modular 
domains: an amino (N)-terminal acidic region with three tyrosine 
phosphorylation motifs, which interact with the SH2 domains of Vav1, Nck and 
IL-2 induced tyrosine kinase (Itk), a central proline-rich domain and a carboxy 
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(C)-terminal SH2 domain. The result of SLP-76 interactions is the stabilization 
RI3/&Ȗ(Koretzky et al., 2006)3/&ȖDFWLYLW\LVLPSRUWDQWIRUWKHDFWLYDWLRQRI
different signaling pathways such as Ca2+ influx, rearrangements of the 
cytoskeleton, interaction with integrins and DAG-induced responses. Activated 
3/&Ȗ K\GURO\]HV SKRVSKDWLG\OLQRVLWRO-4,5-bisphosphate into inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG), fundamental messengers to 
sustain T cell activation (Beach et al., 2007). Ltk that has been recruited to the 
membrane by SLP-76 interacts with PIP3 that has been generated by PI3K  
(Berg et al., 2005) and is phosphorylated by lck. DAG generation is important 
IRU WKH DFWLYDWLRQRI3.&șDQG WKH DFWLYDWLRQ RI5$65$)(5. WKURXJK5$6-
GTP. Two Ras GEFs are presents in T cells, son of sevenless (SOS) and Ras 
guanyl nucleotide-releasing protein (RasGRP). RasGRP appears to be
important for early activation of Ras, as SOS cannot compensate for its 
deficiency (Dower et al., 2000; Ebinu et al., 2000) 3.&șDFWLYDWHV WKH1)ț%
transcription factor that translocates to the nucleus where it activates genes
involved in T cell functions (Schulze-Luehrmann and Ghosh, 2006) (Figure 1).
Figure 1: TCR signaling pathway. The recognition of the MHC-peptide complex by 
the TCR leads to a signaling cascade that involves the phosphorylation of proximal 
TCR components (blue), signaling by the Ras-Erk pathway (green), activation of the 
WUDQVFULSWLRQ IDFWRU1)ț% SLQN E\ 3.&ș DQG&D2+ flux-mediated signaling (yellow). 
These pathways activate transcription factors that mediate a variety of T cell 
developmental and effector programs (Morris and Allen, 2012).
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TCR-induced increases in intracellular calcium and the activation of MAPK are 
critical for the activation of T cells. IP3 JHQHUDWHG E\ 3/&Ȗ ELQGV WR ,33
receptor on the endoplasmic reticulum (ER) membrane, resulting in the release 
of Ca2+ from ER. The depletion of Ca2+ from the ER results in the opening of 
Ca2+ channels in the plasma membrane, triggered through the sensor STIM1 
that participates to the generation of CRAC channels (Hogan et al., 2010). The 
influx of Ca2+ ions leads to the activation and nuclear translocation of NFAT 
through calcineurin and calmodulin (Kannan et al., 2012; Smith-Garvin et al., 
2009). This results in the transcription of IL-2 and other genes important for
regulating T cell activation (Dolmetsch et al., 1997; Wu et al., 2006). Nuclear 
translocation of NFAT determined by increase of cytosolic Ca2+ in the absence 
of the concomitant activation of the MAPK pathway results in T cell anergy. 
Interaction with costimulatory molecules is necessary for T cell activation. CD28  
plays a major role in cytokine production, cell survival and metabolism. CD28 
ligation alone activates the PI3K pathway because it induces the 
SKRVSKRU\ODWLRQ RI WKH NLQDVHV JO\FRJHQ V\QWKDVH NLQDVH Į *6.Į DQG
*6.ȕ 7KLV UHTuires PIP3-activated AKT kinase and is sensitive to 
pharmacological inhibition of PI3K (Appleman et al., 2002). This also implies 
PI3K-dependent activation of AKT by upstream PDK1. Activation of AKT is 
LPSRUWDQWQRWRQO\IRU1)ț%DQG1)$7SDWKZD\VEXWDOVRIRUWKHH[SUHVVLRQRI
the anti-apoptotic protein BCL-XL (Acuto and Michel, 2003; Beals et al., 1997).
1.3 T cell subsets
CD4+ T cells play a fundamental role by helping B cells to produce antibodies, 
but also orchestrating CD8 T cells and macrophages functions against a wide 
variety of microorganisms (Zhu et al., 2010). CD4+ T helper (Th) cells can be 
subdivided into heterogeneous subsets on the basis of their immunological 
functions, which are supported by the expression of well-defined profiles of 
specific transcription factors, cytokines and homing receptors. For many years 
the heterogeneity of CD4+ Th cells has been limited to Th1 and Th2 cells, 
which have been considered responsible for different types of protective 
responses and for the pathogenesis of many disorders. The identification of 
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new cytokines has allowed to enlarge the series of functional subsets of CD4+ 
Th effector cells. In particular, CD4+ Th cells producing IL-17 and IL-22, named 
Th17, have been implicated in the pathogenesis of many chronic inflammatory 
disorders. More recently, two other subsets of Th cells, namely Th9 and Th22 
cells, have been described, even if their role in physiology and pathophysiology 
is still unclear (Annunziato and Romagnani, 2009; Romagnani, 1994). Another 
subset constituted by T follicular helper cells, is important for antibody 
responses, while regulatory T cells constitute a population whose function is to 
control immune reactions to self and foreign antigens. 
1.3.1 Th1 cells
Th1 cells produce high levels of IFN-ȖDQGDUHUHVSRQVLEOHIRUERWKSKDJRF\WH
activation and production of opsonizing and complement-fixing antibodies. This 
subset is responsible for the protection against intracellular pathogens 
(Romagnani, 1994). IL-12 is the key factor needed to generate Th1 cell 
differentiation, but also IFN-ȖSOD\VDQLPSRUWDQWUROHDVVKRZQE\WKHIDFWWKDW
its neutralization during IL-12 driven Th1 differentiation partially diminishes this 
polarization (Bradley et al., 1996). During Th1 differentiation both IL-12 though 
STAT4 and IFN-Ȗ WKURXJK 67$7 SURPRWH WKH DFWLYDWLRQ RI WKH PDVWHU
regulator transcription factor of Th1 subset, T-bet. T-bet activation causes a 
feedback which ends in the increased production of IFN-Ȗ DQG KLJKHU 7-bet 
expression, amplifying Th1 differentiation (Yamane and Paul, 2012). At later 
stages, IL-12/STAT4 signaling induces the upregulation of IL-5Į ,/-18 and 
IL-12 together induce IFN-Ȗ SURGXFWLRQ E\ 7K FHOOV LQ WKH DEVHQFH RI 7&5
receptor stimulation, amplifying Th1 responses (Annunziato and Romagnani, 
2009). In addition to their protective functions from pathogens, Th1 cells also 
play a role in the development of autoimmune diseases and chronic disorders 
such as experimental autoimmune encephalomyelitis (EAE), collagen-induced 
arthritis and inflammatory bowel disease (IBD)  (Cosmi et al., 2014; Hirahara et 
al., 2013) (Figure 2). 
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1.3.2 Th2 cells
Type 2 immune response confers protection against infection by extracellular 
parasites, like helminths, but can also promote acute and chronic inflammatory 
responses against allergens (Pulendran and Artis, 2012). Th2 cells regulate 
type 2 responses through the secretion of various type 2 cytokines, including IL-
4, IL-5, IL-9 IL-13, IL-10, IL-25 and amphiregulin. Th2 polarization from naïve 
CD4 T cell is achieved because of the early production of IL-4 during the 
primary response (Parronchi et al., 1992). IL-4 and IL-13 regulate the 
production and secretion of IgE by B cells during allergic responses. IgE binds 
WRORZDIILQLW\)FUHFHSWRUIRU,J()Fİ5,RQEDVRSKLOVDQGPDVWFHOOVDQGWKHLU
LQWHUDFWLRQZLWKDPXOWLYDOHQWOLJDQGLQGXFHVFURVVOLQNLQJRI)Fİ5,7KLVOHDGVWR
the secretion of mediators such as histamine and serotonin and the production 
of several cytokines such as IL-4 and IL-13. IL-5 positively regulates different 
eosinophils functions, such as eosinophilopoesis, bone marrow release and 
survival (Coffman et al., 1989). IL-9 production contributes to mast cell and IgE 
response. Moreover, it induces mucin production in epithelial cells (Faulkner et 
al., 1998; Longphre et al., 1999).
As a consequence to IL-4 production and binding to its receptor, Th2 cells 
activate STAT6, which in turn upregulates GATA-binding protein-3 (GATA3). 
This transcription factor is the master regulator of Th2 development and is 
fundamental for the production of IL-13 and IL-4 (Kaplan et al., 1996). GATA3 
alone, however, is not sufficient to induce IL-4 production. IL-2 mediated 
activation of STAT5 plays a critical role and the collaboration of STAT5 and 
GATA3 accounts for full differentiation of Th2 in vitro (Zhu et al., 2006).
Importantly, there is a mutual regulation of Th1 and Th2 polarization induced by 
IL-4 and IFN-Ȗ UHVSHFWLYely, as well as Th1-specific and Th2-specific 
transcription factors. It was shown that GATA3 can downregulate STAT4, while 
strong activation of STAT5 inhibit T-bet expression. On the other hand, T-bet
can suppress GATA3 expression (Usui et al., 2003; Usui et al., 2006; Zhu et al., 
2003) (Figure 2).
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1.3.3 Th17 cells
The Th17 subset is primarily involved in recruiting leukocytes and inducing 
inflammation. This reaction is critical for destroying extracellular bacteria, fungi 
and contribute to inflammatory diseases. Th17 have been also implicated in the 
pathogenesis of most common autoimmune diseases such as rheumatoid 
arthritis (RA), inflammatory bowel disease (IBD) and multiple sclerosis (MS) 
(Annunziato et al., 2007). Th17 cells produce main effector cytokines as IL-17A 
(referred to as IL-17), IL-17F, IL-22, and IL-21. Their differentiation requires 
retinoid-UHODWHGRUSKDQUHFHSWRU525ȖWDWUDQVFULSWLRQIDFWRULQGXFHGE\7*)-
ȕLQFRPELQDWLRQZLWKWKHSUR-inflammatory cytokines IL-6, IL-21 and IL-23, all of 
which activate STAT3 phosphorylation (Chen et al., 2007)'HVSLWH7*)ȕLVWKH
critical signaling cytokine necessary for Th17 differentiation (Veldhoen et al., 
2008; Volpe et al., 2008), is now clear that TGF-ȕ FDQ DOVR LQGXFH WKH
differentiation of inducible T regulatory (iTreg) cells depending on the cytokine 
milieu. The balance between Th17 and iTreg could be influenced by the ability 
of natural Treg (nTreg) cells to produce TGF-ȕ EXW in the presence of 
inflammatory cytokines naïve T cells differentiate into Th17 cells (Veldhoen et 
al., 2006; Zhou et al., 2009). Mice lacking TGF-ȕDUHGHSOHWHGRIERWK7KDQG
Foxp3+ Treg cells and develop autoimmunity caused by uncontrolled Th1 cell 
activity (Li et al., 2006). TGF-ȕ VLJQDOLQJ VHHPV WR SOD\ DQ LPSRUWDQW UROH LQ
STAT3 stabilization by inhibiting IL-6/IL-21-induced expression of suppressor of 
cytokine signaling 3 (SOCS3), which negatively regulates STAT3 signaling (Qin 
et al., 2009). Several other transcription factors have been implicated in 
PRGXODWLQJ WKH525ȖW)R[SEDODQFHGXULQJ7KHOSHUFHOOGLIIHUHQWLDWLRQ ,5)
is essential for Th17 differentiation both in vitro and in vivo (Brustle et al., 2007).
Mice lacking Irf4 DUH FKDUDFWHUL]HG E\ UHGXFHG 525ȖW and increased Foxp3 
expression as well as lack of IL17 production. They are protected from 
experimental autoimmune encephalomyelitis (EAE). Irf4 was also identified as a 
direct target of Foxp3 and its selective loss in Treg cells impairs the suppression 
of Th2 cells response (Zheng et al., 2009). Another transcription factor 
important for Th17 differentiation is Runx1, which was shown to form a complex 
ZLWK525ȖWWRSURmote Th17 cell differentiation (Zheng et al., 2008). However, 
in Treg cells, Runx1 interacts with Foxp3 and suppresses the production of IL-2
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and IFN-Ȗ WKXV SURPRWLQJ 7reg cells suppressive activity (Ono et al., 2007).
Runx1 is also required to maintain Foxp3 expression in nTreg and in TGF-ȕ
induced Foxp3 iTreg cells. Thus, the ability of Runx1 to cooperate with both 
525ȖW DQG)R[SPDLQWDLQV WKH IXQFWLRQDOSODVWLFLW\ RI7KDQG L7UHJ7K
cells, moreover, selectively express the aryl hydrocarbon receptor (AHR), a 
ligand-dependent transcription factor. The activation of AHR results in the 
expression of IL-22, promoting Th17 development and related cytokines. Mice 
lacking AHR are still able to develop Th17 cell responses, but they are unable 
to produce IL-22 and show defective Th17 cells differentiation (Veldhoen et al., 
2008). As previously discussed, the amplification process is necessary to mount 
a correct immune response and T cell differentiation program. IFN-ȖDQG ,/-4
are the main amplifying cytokines for the generation of Th1 and Th2 cells, 
respectively, while IL-21 plays this role for Th17 cells polarization. IL-21 with 
TGF-ȕDPSOLILHV7KFHOOVGLIIHUHQWLDWLRQ,/-6 is not required in this phase that 
is therefore independent from TCR signaling (Korn et al., 2007). IL-23, another 
fundamental cytokine, acts together with IL-ȕWRLQGXFH7EHW+525ȖW+Th17 cells 
independently of TGF-ȕ(Ghoreschi et al., 2010) (Figure 2).
1.3.4 Th22 cells
Beyond Th17 cells, a subset referred to as Th22 cells is an important source of 
IL-22. In humans, Th22 cells are characterized by the production of IL-22 with 
little or no IL-17 and have been observed in healthy caecum, where they play 
an important role in maintaining mucosal barrier function (Wolff et al., 2012).
1.3.5 Th9 cells
Th9 lymphocytes are a pro-inflammatory subset of T helper cells, which are 
involved in different inflammatory conditions,  including autoimmune diseases 
and allergic reactions. They are primed in response to TGF-ȕ DQG ,/-4. Th9 
development depend upon IL-4 activated transcription factor STAT6 (Veldhoen 
et al., 2008). It is still not clear if Th9 cells are required as a source of IL-9
during autoimmunity and how they cooperate with Th2 in promoting 
inflammation (Jabeen and Kaplan, 2012).
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1.3.6 T follicular helper (Tfh) cells
T cell help to B cell is fundamental for adaptive immunity and generation of 
immunological memory. Bcl6 is the master regulator transcription factor of Tfh 
cells (Johnston et al., 2009; Nurieva et al., 2009). Tfh cells are characterized by 
the expression of CXCR5, PD1, SAP (SH2D1A), IL-21, ICOS and absence of 
the transcription factor Blimp1. They express high levels of Bcl6, while non-Tfh 
cells express high levels of Blimp1. Blimp1 suppresses the expression of Bcl6 
and, on the contrary, Bcl6 suppresses the expression of Blimp1 (Crotty, 2011).
Tfh cells are fundamental for the formation and maintenance of germinal center 
(GC), the regulation of B cell differentiation into plasma cells and memory B 
cells (Crotty, 2011). CXCR5 is the canonical marker of Tfh and is necessary for 
the migration of Tfh cells in response to CXCL13 (Schaerli et al., 2000). The 
migration of Tfh cells to the T-B border allows Tfh differentiation thanks to the 
expression of ICOSL by B cells. ICOS engagement in Tfh cells activates PI3K 
and leads to the production of IL-21 (Rolf et al., 2010). To induce GC formation, 
Tfh cells must drive GC B cell differentiation by stimulating the expression of 
Bcl6 in activated B cells. Once the GC is formed, Tfh cells provide the signals 
necessary for the survival and the proliferation of GC B cell, promote somatic 
hypermutation and select proficient GC B cells (Allen et al., 2007). There are 
different pathways through which Tfh cells stimulate B cells, including CD40L, 
IL-4, IL-21, PD1 and BAFF, which compete with Fas-FasL interaction. In the 
absence of pro-survival stimuli, GC Tfh cells promote GC B cells death through 
Fas-FasL. The final result of GC reaction is the production of functional memory 
B cells and high affinity plasma cells. The production of high affinity antibodies 
is a fundamental process necessary to block the spread of pathogens in the 
body, so a large proportion of Tfh cells  functions is dedicated to B cell survival 
and proliferation. However, Tfh and GC B cell processes must be tightly 
regulated in order to avoid the development of autoimmunity and lymphoma 
(Crotty, 2011) (Figure 2).
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1.3.7 Treg cells 
T regulatory (Treg) cells, which constitutively express the transcription factor 
Foxp3, are indispensable for the maintenance of immune self-tolerance and 
homeostasis by suppressing aberrant or excessive immune responses that
might be harmful to the host (Rudensky, 2011; Sakaguchi et al., 2008). The 
majority of natural Foxp3+ T reg (nTreg) cells are produced by the thymus as 
antigen-primed mature T cells. Another subset differentiates in the periphery 
from naïve cells and is defined inducible Treg (iTreg). nTerg cells migrate into 
inflammation sites and suppress effector lymphocytes (Chaudhry et al., 2009; 
Chung et al., 2011). Treg cells produce IL-10, TGF-ȕ DQG ,/-35. IL-10 is a 
potent inhibitory cytokine, which suppresses inflammatory responses and limits 
tissue damage (Asseman et al., 1999; Ouyang et al., 2011). IL-10  and TGF-ȕ
exert a potent anti-allergic action and suppress the production of IgE (Jutel and 
Akdis, 2008). TGF-ȕ LV WKH FHQWUDO F\WRNLQH WKDW SURPRWHV L7UHJ FHOO OLQHDJH
commitment (Chen et al., 2003). TGF-ȕVLJQDOLQJDFWLYDWHV6PDGDQG6PDG
which are upstream of Foxp3 expression (Takimoto et al., 2010). However, it 
was demonstrate that Smad2 and Smad3 can also induce Treg cells 
differentiation via a Foxp3-independent pathway. Smad3 inhibits Th17 
GHYHORSPHQWDO SURJUDP E\ EORFNLQJ 525ȖW (Martinez et al., 2009). STAT5 is 
another important transcription factor that enhances Foxp3 expression. The 
target DNA sequence of STAT5 and STAT3 is represented by a common 
multiple site across the IL-17 locus. The two transcription factors function 
closely and antagonize each other. Defective STAT5 signaling impairs Treg 
cells differentiation and favors polarization to Th17 (Laurence et al., 2007)
(Figure 2).
15 
 
Figure 2: Effector Th cell differentiation. Upon encountering antigen presented by 
professional APCs, naive CD4 T cells differentiate into effector subsets (Th1, Th2, 
Th17, Treg and Tfh) that are characterized by specific cytokine production, expression 
of transcription factors and chemokine receptors, and immune regulatory functions
(Nurieva and Chung, 2010).
1.4 Memory T cells
T cell mediated immune responses result in the generation of antigen specific 
memory T cells, which may persist for years, even a lifetime. They are able to 
migrate to peripheral tissues and rapidly respond to antigen stimulation. 
Memory T cells are classified depending on their homing ability and effector 
functions. Until recently, memory T cells were divided in central memory T cells 
(TCM) which are restricted to secondary lymphoid tissues and blood, and have 
little or no effector function; effector memory T (TEM) cells, which migrate 
between peripheral tissues, blood and spleen, and display immediate effector 
functions (Sallusto et al., 1999). A third subset of memory T cells has been 
recently described, namely tissue resident memory T (TRM) cells (Mueller et al., 
2013). TCM cells constitutively express CCR7 and CD62L, that are also 
expressed by naïve T cells and are necessary for adhesion to high endothelial 
venules (HEV) and migration to secondary lymphoid organs (Campbell et al., 
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1998; Forster et al., 1999). Compared to naïve T cells, TCM are more sensitive 
to antigenic stimulation, less dependent on co-stimulation and upregulate 
CD40L, thus providing more effective feedback to dendritic cells (DC) and B 
cells. TCM cells produce IL-2 after antigen stimulation, and when they 
differentiate to effector cells, they produce large amount of IFN-ȖDQG,/-4. TEM 
cells have extinguished CCR7 expression, are heterogeneous for CD62L 
expression levels, and display chemokine receptors and adhesion molecules 
required for the homing to inflamed tissues. They are characterized by rapid 
execution of effector functions and produce IFN-Ȗ ,/-4 and IL-5 following 
antigen stimulation (Sallusto et al., 2004). There are mechanisms such as 
competition for cytokines and other survival factors, expression of anti-apoptotic 
genes such as BclXL and availability of space at a given site, that play a 
fundamental role in the generation of proper adaptive immune memory (Di Rosa 
and Santoni, 2003). TCR signal strength is another important factor in 
determining T cell differentiation. The strength of signaling that T cells receive 
can depend on the antigen concentration, the presence of costimulatory 
molecules and the duration of the interaction between T cells and APC (Iezzi et 
al., 1998; Valitutti et al., 1995; Viola et al., 1999). DC/T cell interactions are very 
dynamic and different levels of stimulation may be delivered at different times. 
At early stages, a high number of DC with a large dose of antigen and secreting 
a large amount of cytokines would promote a massive proliferation of antigen-
specific T cells, which become effector cells and some of them will persist as 
TEM. At later time points, fewer DC are recruited, carrying lower amount of 
antigen with exhausted cytokine-production capacity (Langenkamp et al., 2000).
This condition may lead to the expansion of non-effector cells, some of which 
will persist as TCM. According to this model, TEM cells are generated at early 
stages, whereas TCM cells at later stages of the immune response.  The 
strength of TCR signal and intensity of cytokine receptors stimulation drive T 
cells through hierarchical thresholds of differentiation (Lanzavecchia and 
Sallusto, 2002). These are stochastic events, meaning that not all the cells will 
receive the same strength of signal. As a consequence, primed T cells reach 
different stages that contain both effector cells and cells that have been 
arrested at intermediate levels of differentiation and are retained into lymph 
17 
 
nodes. This spectrum can be simply resolved into distinct subsets of TCM and 
TEM surviving after antigen clearance (Figure 3).
Figure 3: A signal strength model for T cell differentiation and memory generation. The 
progression follows a sequence of proliferation, preceding the acquisition of fitness, 
effector function and death. The duration and intensity of antigenic stimulation is 
indicated by the length and thickness of the solid arrow. Antigen-independent events 
leading to T cell proliferation and differentiation are indicated by the dotted lines. AICD, 
activation-induced cell death (Sallusto et al., 2004).
2.Regulatory mechanisms of T cell functions
2.1 T cell exhaustion
T cell exhaustion is considered a state of T cell dysfunction that arises during 
chronic infections, cancer, autoimmunity and chronic inflammation. Exhausted T 
cells are defined as effector T cells with decreased cytokine expression and 
effector functions, and resistant to reactivation. They are characterized by 
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sustained expression of inhibitory receptors and have a distinct transcriptional 
profile compared to effector or memory T cells. T cells that become exhausted 
are not able to control infections and tumors (Wherry, 2011). Loss of function of 
exhausted T cells occurs in a hierarchical manner, meaning that some functions 
are lost before others. Three immunoregulatory inducers are involved in T cell 
exhaustion: cell surface inhibitory receptors (such as PD1), soluble factors 
(such as IL-10) and immunosuppressive cell types (such as Treg and other 
cells). T cells can transiently express inhibitory receptors during activation, but 
the prolonged expression of multiple inhibitory receptors is a key features of 
exhausted T cells (Virgin et al., 2009). Inhibitory receptors are important in 
different aspects of adaptive immunity, including self-tolerance and prevention 
of autoimmunity (Freeman et al., 2006). The PD1/PD-L1 axis is one of the major 
pathway involved In T cell exhaustion and blocking this pathway during 
infections increases T cell responses against pathogens. This means that T cell 
exhaustion is an active process that could be reversed in order to improve T cell 
function (Barber et al., 2006). Other cell surface inhibitory receptors, such as 
LAG3 CD244 (2B4), CD160, TIM3, CTLA-4, are involved in T cell exhaustion 
(Crawford and Wherry, 2009). In addition to cell surface inhibitory receptors, 
Foxp3+CD4+Treg cells can affect immune responses during chronic infections 
and in tumors (Penaloza-MacMaster et al., 2014; Virgin et al., 2009). Their 
suppressive activity in the presence of immuneregulatory cytokines, such as IL-
10 and TGF-ȕDUHLQYROYHGLQWKHinduction of T cell exhaustion (Brooks et al., 
2006; Tinoco et al., 2009). The molecular pathways of exhausted T cells are 
TCR dependent, such as SPRY2 and NFAT (Agnellini et al., 2007; Martinez et 
al., 2015). Chronic antigen stimulation induces NFATc1 translocation to the 
nucleus and as a consequence the upregulation of PD1 (Oestreich et al., 2008).
Both CD4 and CD8 exhausted cells are characterized by a specific 
transcriptional profile that include major changes in the expression of 
costimulatory and inhibitory molecules, signaling molecules, transcription 
factors, cytokine and chemokine receptors and gene involved in cellular 
metabolism (Crawford et al., 2014; Doering et al., 2012; Wherry et al., 2007)
(Figure 4).
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2.2 T cell anergy
T cell anergy is defined as a state of induced hyporesponsiveness 
characterized by low IL-2 secretion, which is induced in naïve T cells following 
low co-stimulatory and/or high co-inhibitory stimulation. It serves to induce 
tolerance in the periphery and protect the host from developing autoimmune 
diseases (Schwartz, 1990, 2003). This state of anergy can be induced by a 
strong TCR signal in the absence of co-stimulation or by stimulation with low 
affinity ligand in the presence of co-stimulation (Mirshahidi et al., 2001). All of 
these conditions result in a weak or incomplete activation of the cell, but 
sufficient to induce de novo protein synthesis to maintain the anergic state (Quill 
and Schwartz, 1987). The principal signaling pathway that seems to be involved 
in the induction of anergy is NFAT translocation into the nucleus. In fact, around 
40 years ago it was shown that cyclosporine A, a selective inhibitor of NFAT, 
could block anergy induction (Jenkins et al., 1990). In some cases the anergic 
state seems to be determined by excessive calcium/NFAT signaling that results 
in transcriptional enhancement of negative regulatory elements of TCR/CD28 
signaling (Telander et al., 1999).
Anergy in T cells is characterized by an unusual pattern of cytokines expression 
in response to TCR stimulation, that suggests a state of resistance to 
proliferation (Jenkins et al., 1987; Mueller et al., 1991). When the T cell is 
restimulated by APCs and the antigen, IL-2 production is mostly affected, but 
also IL-4 and IFN-Ȗ SURGXFWLRQ DUH  FRPSURPLVHG ,QIODPPDWRU\ FKHPRNLQH
production is unaffected. These anergic T cells are characterized by the block in 
the activation of the Ras/MAP kinase pathway (Fields et al., 1996; Li et al., 
1996). Both the ERK and JNK pathways are inhibited and there is one report of 
a block in the p38 pathway (DeSilva et al., 1997). Importantly, when anergic T 
cells are transduced with constitutively active MAP kinase, IL-2 activity is 
restored (Zha et al., 1996). Diacylglicerol kinase-Į'*.-ĮSOD\VDFHQWUDOUROH
in the induction of anergy as a negative regulator of the TCR signal (Zha et al., 
2006). DGK-Į SKRVShorylate DAG, converting it into phosphatidic acid and 
depleting available DAG that otherwise could activate RASGRP1 (Tognon et al., 
1998). Future studies are directed at developing pharmacological approaches to 
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promote anergic state in autoimmunity and transplantation as well as to restore 
T cell function in cancer and chronic infections (Figure 4).
2.3 T cells senescence
Cellular senescence was first described in fibroblasts where the erosion of 
telomeres at each cell division initiates a cascade of events which lead to 
growth arrest (Akbar and Henson, 2011). The process of cellular senescence 
can also be independent of telomeres shortening, when there is an 
accumulation of DNA damage anywhere in the genome that leads to the 
upregulation of p53 gene transcription. P53 in turn induces the transcription of 
the cyclin dependent kinase inhibitors (CDKN) 1A (also known as p21) and 2A 
(p16) (Campisi and d'Adda di Fagagna, 2007) and, as a consequence, 
prolonged arrest of the cell cycle (Di Leonardo et al., 1994). Long-term 
activation of the checkpoint gene CDKN1A creates a feedback inducing 
mitochondrial dysfunction and production of reactive oxygen species (ROS) 
through serial signaling through GADD45-MAPK14(p38MAPK)-GRB2-TGFBR2-
7*)ȕ7KHVH526LQWXUQUHSOHQLVKVKRUW-lived DNA damage foci and maintain 
an ongoing DNA-damage response (DDR) (Passos et al., 2010). DNA damage 
induces the recruitment of ATR and ATM kinases, which phosphorylate the 
KLVWRQH+$;RQ6HULQH Ȗ+$;DNH\VWHS IRU WKH UHFUXLWPHQWRI''5
The intracellular sensing of DNA damage activates the machinery of DNA 
repair, which, if successful, enables the cell to survive. If DNA cannot be 
repaired, DNA damage repair foci persist within the nucleus, leading ultimately 
to growth arrest and senescence (d'Adda di Fagagna, 2008). The accumulation 
of senescent cells is associated with aging of tissues (van Deursen, 2014).
Immunosenescence is defined as the overall decline of immune function during 
ageing that involves both innate and adaptive immune system (Franceschi et 
al., 1999). T cell senescence refers to low proliferative activity, which could 
result from excessive telomeres erosion due to the induction of proliferative 
activity, or to DNA damage due in part to mitochondrial dysfunction leading to 
increased production of ROS (Henson et al., 2014). For T cells in peripheral 
blood, there is a correlation between the sequential loss of costimulatory 
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receptors and telomeres erosion. Senescent T cells with the shorter telomeres 
are characterized by lack of the expression of CD27 and CD28 (Plunkett et al., 
2007). These cells are also found in young individuals, especially if they have 
genetic defects that lead to excessive proliferation after T cell activation 
(Plunkett et al., 2005). Until now it was not clear if senescent phenotypes after 
activation was a passive or an actively maintained process involving the 
activation of inhibitory pathways. It was demonstrated that both senescent 
fibroblasts and T cells are characterized by the constitutive activation of p38 
MAPK (Davis et al., 2010; Henson et al., 2015; Lanna et al., 2014).
Table 1: Characteristics of fibroblast and T cell senescence. The majority of data 
on cellular senescence are derived from experiments on fibroblasts. While T cells also 
undergo senescence, some of the molecular features are different. The key features of 
senescence phenotype are common to fibroblasts and T cells, such as lack of 
proliferation, short telomeres and the inability to upregulate telomerase. However, a 
major difference is susceptibility to apoptosis with fibroblasts being long-lived and T 
cells succumbing to death. Furthermore, it is not known whether senescent T cells 
H[SUHVVKLJKOHYHOVRIȕ-JDODFWRVLGDVHRUȖ-H2AX (Akbar et al., 2016).
Two separate pathways have been described for p38 MAPK activation in T 
cells. The canonical MAPK cascade activated by cytokines or costimulatory 
receptors, that culminates in p38 activation (Lanna et al., 2014) and an
alternative pathway where TCR ligation induces p38 autophosphorylation 
independently of upstream canonical MAPK activity (Patterson et al., 2014).
However, it was observed that senescent T cells do not express several kinases 
and scaffold molecules that are involved in this alternative p38 activation 
pathway, and are thus unlikely to engage this second pathway for p38 activation 
(Lanna et al., 2014; Salvador et al., 2005). This suggested the existence of a 
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third unique mechanism for the activation of p38 in senescent T cells. This third 
p38 activation pathway in T cells was identified recently; it involves the 
activation of a molecular complex that contains AMP-responsive protein kinase 
(AMPK, a sensor activated by low nutrient and energy availability), the scaffold 
molecule TAB1 (TGF-ȕ-activated kinase 1 and MAP3K7-binding protein 1), and 
p38 itself. This complex induces p38 activation through autophosphorylation. 
The key point is that AMPK in T cells is activated not only by low intracellular 
glucose but also by endogenous DNA damage (i.e. senescence). This suggests 
that there is a convergence of senescence and nutrient-sensing pathways in T 
cells to activate p38 via AMPK/TAB1. Correspondingly, inhibition of either 
AMPK, TAB1, or p38 itself reconstitutes proliferation as well as telomerase 
activity in the senescent T cell population (Lanna et al., 2014) (Figure 4).
Figure 4: General characteristic for anergic, exhausted and senescent T cells. 
Anergic T cells are T cells stimulated with low co-stimulatory and/or high co-inhibitory
signaling. These cells are unresponsive to subsequent activating conditions with limited 
IL-2 expression. Exhausted T cells are effector T cells that have lost their effector 
functions including effector cytokine expression due to repeated stimulation. These 
cells express multiple regulatory receptors. Senescent T cells are described as 
unresponsive/terminally differentiated T cells. The hallmark is their cell cycle arrest 
along with limited CD28 expression and/or high levels of regulatory receptor expression 
(modified from (Crespo et al., 2013).
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2.4 T cell metabolism 
The regulation of T cell metabolism is fundamental in order to mount a correct 
immune response and to develop memory. When T cells are activated, they go 
through as series of modifications in their metabolism in order to meet the 
increased metabolic demands of cell growth. In T lymphocytes, glucose is a 
critical substrate for adenosine triphosphate (ATP) production (Greiner et al., 
1994). During glycolysis the glucose is broken down into two molecules of 
pyruvate. This process that does not require oxygen gives rise to two molecules 
of reduced nicotinamide adenine dinucleotide (NADH) and two molecules of 
ATP per molecule of glucose. The pyruvate can enter into the tricarboxylic acid 
(TCA) cycle in the mitochondria and generates NADH and reduced flavin 
adenine dinucleotide (FADH2), which the cell can use to fuel oxidative 
phosphorylation (OXPHOS), an oxygen dependent process that produces up to 
36 ATP molecules per molecule of glucose. Alternatively, pyruvate can be 
transformed into lactate, regenerating NAD+ to be used in glycolysis (Vander 
Heiden et al., 2009).
Resting naïve T cells, which never encountered the antigen, maintain low rate 
of glycolysis and utilize predominantly OXPHOS or fatty acid oxidation (FAO) to 
produce ATP, accordingly with their non-proliferative state (Figure 5). Upon 
antigen recognition, T cells have to face a massive proliferation and become 
metabolically activated. They switch to a program of anabolic growth and 
biomass accumulation to generate daughter cells, which increase the need of 
ATP and metabolic resources (Pearce et al., 2013) (Figure 5). TCR signaling 
directs the metabolic reprogramming of T naïve cells, promoting the 
upregulation of glucose and amino acids transporters (Frauwirth et al., 2002; 
Sinclair et al., 2013) in order to facilitate nutrients uptake. TCR activation 
induces the upregulation of c-Myc and estrRJHQ UHODWHG UHFHSWRU Į ((5Į
(Wang et al., 2011), which enhances the expression of genes of the metabolism 
and suppress the catabolic pathways of ATP. Activated T cells then use aerobic 
glycolysis and convert pyruvate into lactate despite the availability of oxygen for 
complete glucose oxidation. This process is known as Warburg effect in cancer
biology and is a common trait of proliferating cells (Vander Heiden et al., 2009).
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When the antigen is cleared, the majority of T effector cells die, but a subset of 
long-lived memory T cells (TM) persists. TM cells are a quiescent population 
and, as a consequence, they adopt a metabolic profile similar to that of naïve (a 
catabolic metabolism characterized by increased OXPHOS and low nutrients 
uptake compared to T effector cells) (Figure 5). However, T memory cells are 
characterized by increased mitochondrial mass and as a consequence 
increased spare respiratory capacity (SRC) (van der Windt et al., 2012). These 
characteristics of TM cells allow for a rapid mitochondrial ATP production upon 
TCR engagement, conferring a bioenergetic advantage  to TM cells when 
exposed to the antigen a second time and for this reason they are viewed as 
metabolically primed (van der Windt et al., 2013).
Figure 5: T cell metabolism changes over the course of an immune response. T
cells display distinct metabolic profiles depending on their state of activation. Naïve T 
cells (TN, blue) are metabolically quiescent; they adopt a basal level of nutrient uptake 
and use OXPHOS as their primary pathway of ATP production. Upon immune 
challenge, TEFF (green) cells shift to a state of metabolic activation characterized by 
increased nutrient uptake, elevated glycolytic and glutaminolytic metabolism, biomass 
accumulation, and reduced mitochondrial SRC. TEFF cells preferentially use glycolysis 
over OXPHOS for ATP production. Transition to the TM (orange) stage is characterized 
by a quiescent metabolism, with increased reliance on FAO to fuel OXPHOS. 
Mitochondrial mass and SRC are elevated in TM cells, suggesting that these cells are 
metabolically primed to respond upon reinfection (Pearce et al., 2013).
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Several transcription factors and signaling pathways support these changes in T 
cell metabolism after activation. IL-2 and ligation of costimulatory molecules 
promote the switch to glycolysis through the increase of nutrient transporter 
expression and the activation of the key metabolic regulator mTOR (Frauwirth 
et al., 2002; Jones and Thompson, 2007; Kolev et al., 2015). The ligation of 
CD28 enhances PI3K activity, which phosphorylates PDPK1. PDPK1 itself 
phosphorylates Akt, which activates mTORC1. Both Akt and mTOR promote 
aerobic glycolysis and support effector T cell differentiation and function 
(Delgoffe et al., 2011; Pollizzi et al., 2015) +,)Į D WUDQVFULSWLRQ IDFWRU WKDW
responds to oxygen level, also increases glucose uptake and catabolism 
through glycolysis (Kim et al., 2006). Mitochondrial are fundamental for the 
regulation of metabolic activity of T cells, antiviral responses and cell death. 
They constantly remodel their structure via nuclear-encoded GTPase (Nunnari 
and Suomalainen, 2012). Recently, it was shown that mitochondrial dynamics 
(fusion and fission) can control T cell fate through metabolic reprogramming 
(Buck et al., 2016). Fissed mitochondria increase reactive oxygen species 
(ROS) production (Yu et al., 2006), facilitate mitophagy (Frank et al., 2012),
accelerate cell proliferation (Taguchi et al., 2007) and mediate apoptosis (Youle 
and Karbowski, 2005). Mitochondrial fusion, instead, is considered a survival 
mechanism in response to stress and starvation and it is linked to longevity 
(Friedman and Nunnari, 2014; Gomes et al., 2011; Rambold et al., 2011). T 
memory cells are characterized by fused mitochondria with tight cristae, while 
mitochondria in T effector cells are fused and characterized by more separated 
cristae (Buck et al., 2016). Without tight cristae, the electron transport chain 
(ETC) of the mitochondria is less effective and electrons may loiter in the 
complexes causing an increase in ROS production (Sena et al., 2013). The 
protein optic atrophy 1 (Opa1), responsible for inner mitochondrial membrane 
fusion, is necessary for the generation of T memory cells, but not T effector 
cells. Moreover, enforcing fusion in T effector cells improves adoptive therapy 
against tumors, because T cells are characterized by increased longevity and 
persistence, without affecting the ability of producing cytokines (Buck et al., 
2016).
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3. T cell in the tumor
T cells are recruited in the tumor as a defense mechanism against it. In the past 
years, the presence of T cells in the tumor has been correlated with a favorable 
prognosis in patients with melanoma (Clark, 1991) and in more recent years in 
patients with ovarian cancer (Sato et al., 2005), bladder cancer (Sharma et al., 
2007), renal cell carcinoma (Nakano et al., 2001) and others solid tumors. It 
seems that the capacity of the immune system to respond against the tumor is 
directly correlated to the amount of tumor infiltrating lymphocytes (TILs). Over 
the past years, TILs has been identified in the primary tumor, tumor draining 
lymph nodes and metastases of numerus cancer types. Depending on the type 
of tumor, TILs can highly or poorly infiltrate it. However, cancers that express 
weakly immunogenic antigens evade killing and this can be a primary 
mechanism of tumor progression (Vesely and Schreiber, 2013). Tumors are 
also known to escape immunity via T cell dysfunction or hyporesponsiveness, 
as exhaustion, anergy and senescence, which have been all described in 
cancer patients (Crespo et al., 2013; Wherry, 2011) .
3.1 Anti-tumor activity of CD4 and CD8 T cells
TILs comprise a heterogeneous group of lymphocytes that differ in their ability 
to potentiate the anti-tumor immune response. Both CD4+ and CD8+ T cells 
were found in tumors and in vitro experiments showed that CD4+ TILs produce 
cytokines after stimulation with the tumor and CD8+ TILs exert an anti-tumor 
cytolytic activity (cytotoxic T lymphocytes, CTLs) and are dependent on CD4+ T 
helper activity (Goedegebuure and Eberlein, 1995). However, the role of CD4+ 
T cells seems to be more complicated and controversial. In particular, CD4+ T 
cells are characterized by plasticity that might results in switching from anti-
tumor to tumorigenic function (Sorensen et al., 2012). CD4+ Treg cells are 
present in the tumor and exert an immunosuppressive function. On the contrary, 
Th1 cells would play a positive role in tumor rejection through the secretion of 
IFN-Ȗ ,)1-Ȗ KDV DQ LPSRUWDQW UROH LQ LQFUHDVLQJ WKH GHQVLW\ RI PDMRU
histocompatibility complexes (MHC) I and II in tumor cells and APCs, increasing 
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the ability of T cells to reject the tumors. The lack of expression of MHC II is one 
of the causes of variable efficacy of CD4+ T cells to exert an anti-tumor function 
(Donia et al., 2013). However, IFN-Ȗ LV FRQVLGHUHG D GRXEOH HGJHd sword 
because it selectively enhances responses to tumor-associated antigens and 
reduces tumor cells susceptibility to immune-mediated cytotoxicity (Donia et al., 
2013; Zaidi and Merlino, 2011). CD4 cells can exert a direct anti-tumor activity 
by recognizing endogenously processed antigens followed by secretion of type 
1 cytokines or by providing help to CD8+ T cells (Friedman et al., 2012; 
Quezada et al., 2010). TILs are characterized by the expression of different co-
inhibitory receptors, which downregulate lymphocyte activation and effector 
function. Both CD4 and CD8 express CTLA-4, which, as described above,
shares the CD80 and CD86 ligands with CD28, but with higher affinity and may 
therefore out-compete it (Collins et al., 2002). CTLA-4 is a negative regulator of 
CD28-dependent T cell responses and, as a consequence, it contrasts anti-
tumor responses of TILs. This has been demonstrated in many pre-clinical 
models of cancer, thus suggesting that interfering with this pathway in patients 
may also result in improved survival (Quezada and Peggs, 2013). Another co-
inhibitory molecule expressed by TILs is PD1. Its ligand, PD-L1, is expressed by 
a variety of tumors such as melanoma, glioblastoma and different types of 
carcinomas (mammary, ovarian, lung, cervical, colon and renal) (Blank et al., 
2004) (Quezada and Peggs, 2013). Unlike CTLA-4, which downmodulates T 
effector responses during early phases of T cell priming, PD1 inhibits T cell 
activation at the time of an ongoing effector response (Greenwald et al., 2005).
Immunotherapies targeting these T cell inhibitory checkpoints in recent years 
obtained dramatic results in controlling incurable melanoma. The effect of PD1 
blockade would be promoting TILs expansion within the tumor and increase of
IFN-ȖSURGXFWLRQ
3.2 Tumor antigens and immunological tolerance 
The fact that endogenous T cells can antagonize tumor growth in the context of 
cancer immunotherapy implicates that T cells can recognize tumor antigens 
presented by MHC on the surface of cancer cells (Tumeh et al., 2014). These 
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antigens can derive from normal non-mutated self-proteins, to which T cell 
tolerance is impaired or alternatively they can derive from the product of DNA 
mutations that results in the generation of tumor specific neo-antigens. Mice 
cured by surgical tumor resection become resistant to subsequent tumor 
reinjection, suggesting the presence of immunological memory toward cancer 
cells (Gross et al., 1943). Tumor antigens can be divided into two categories: 
tumor specific antigens (TSAs), which are antigens expressed solely by tumor 
cells, and tumor associated antigens (TAAs), which are mostly expressed in 
tumors cells but can also be found in normal cells (Rosenberg, 1999). TAAs in 
melanoma include a group of antigens involved in melanoma differentiation, 
aptly named melanoma differentiation antigens (MDAs). TSAs are also called 
neo-antigens and are in fact mutated self-antigens (Schumacher and Schreiber, 
2015). Given their absence from the human genome, neo-antigens theoretically 
exhibit increased immunogenicity, because T cells directed against these 
molecules are unaffected by central tolerance. The evidence of their 
immunogenicity has only begun to surface due to technological advances in 
different domains of experimental cell biology. Recent studies have suggested 
that neo-antigens may mediate clinical responses to immune checkpoint
inhibitors, such as antibodies directed against CTLA-4 or PD1 (Lee et al., 2016).
Tumors possess different mechanisms to evade the anti-tumor immune 
response (Figure 6). In metastatic melanoma and in aggressive recurrent 
melanoma TAAs are often downregulated (Khong et al., 2004; Maeurer et al., 
1996). Moreover, aggressive melanoma cells express decreased levels of MHC 
I as a mechanism to avoid recognition by CTLs. In addition, tumor cells also 
express death signals, such as Fas ligand (Fas-L), and utilize Fas signaling to 
induce apoptosis in T cells (Hahne et al., 1996). Another mechanism to induce 
immunological tolerance is the secretion of inhibitory signaling molecules, such 
as the immunosuppressive cytokines TGF-ȕ DQG SURVWDJODQGLQ ( 3*(
(Gorelik and Flavell, 2001; Nicolaou et al., 2004). Tumor cells can escape the 
immune system also through the alteration of expression of co-stimulatory and 
co-inhibitory molecules. Immunological tolerance can be induced when 
dysfunctional APCs are not able to transmit positive costimulatory signals while 
presenting TAAs to T cells (Sotomayor et al., 2001), or when tumor cells 
express co-inhibitory or immune check point molecules that protect them from 
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the attack of T cells. Melanoma cells express PD-L1, which binds to PD1 on T 
cells and resist CTL-mediated cells lysis (Hirano et al., 2005). Tumors also
recruit tolerogenic CD4+CD25+Foxp3+ Treg cells to evade anti-tumor immunity. 
CTLA-4 and PD1 also enhance Treg cell immunosuppressive function (Jacobs 
et al., 2012; Wing et al., 2008). Thus, cancer cells exploit immune checkpoints,
not only to suppress tumor-specific T effector responses, but also to induce 
immunosuppressive Treg cells in order to facilitate tumor immune escape.
Figure 6: Immunological mechanisms underlying melanoma immune evasion.
Melanomas can evade rejection by CTLs by downmodulating expression of MHC class 
I or melanoma-associated antigens (MAAs) on the cell surface. Melanoma cells may 
also evade natural killer (NK)-mediated cytotoxicity by down-modulating their 
expression of activating NK receptor ligands or by inducing a decrease in expression of 
activating receptors on NK cells. Melanoma cells can also overexpress Fas Ligand 
(Fas-L) and induce apoptosis of T-effector TILs, or directly tolerise immune effector 
populations by secreting immunosuppressive factors (e.g., TGF-E or PGE-2). Cross-
presentation of MAAs by DCs incapable of adequate co-stimulation can render tumor-
specific T cells anergic. Additionally, MHCII-expressing melanoma cells might function 
as antigen presenting cells (APCs) that could tolerise tumor-reactive TILs through lack 
of co-stimulation, or by delivering a co-inhibitory or immune checkpoint signal. Finally, 
melanoma cells can actively induce and/or recruit Treg cells via the secretion of soluble 
mediators (e.g., TGF-E) or by engaging with Treg-expressed immune checkpoints (e.g., 
B7/CTLA-4, PD-1/PD-L1) to mitigate the anti-tumor immune response (Lee et al., 
2016).
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3.3 Immunoregulatory mechanisms in the tumor 
microenvironment 
TILs effector functions are strongly influenced by the tumor microenvironment 
(TME). Apart from tumor cells, TME comprises blood vessels, immune cells, 
fibroblasts, bone marrow-derived inflammatory cells, TILs and the extracellular 
matrix (ECM). The tumor can influence the microenvironment by releasing 
extracellular signals, promoting angiogenesis and inducing peripheral immune 
tolerance. On the contrary, immune cells in the microenvironment can influence 
the growth of the tumor. In 2001, it was shown that the immune system can 
control not only the magnitude, but also the quality of tumor by influencing 
tumor immunogenicity via immunoediting (Dunn et al., 2002; Shankaran et al., 
2001). This study revealed that tumors formed in mice that lacked an intact 
immune system were, as a group, more immunogenic (classified as unedited)
than similar tumors derived from immunocompetent mice (termed edited). The 
immune system not only protects the host against tumor formation, but also 
shapes tumor immunogenicity. This hypothesis is the basis for cancer 
immunoediting, which stresses the dual host-protective and tumor-promoting 
actions of immunity on developing tumors (Schreiber et al., 2011). The principal 
mechanisms through which the tumor can influence T cell effector functions are 
T cell anergy, exhaustion and senescence. In particular, an unbalance between 
inhibitory and stimulatory B7 family members in the tumor could be responsible 
for the induction of anergy (Pardoll, 2012; Zou and Chen, 2008). However, 
cellular and molecular mechanisms controlling T cell anergy are insufficiently 
understood. T cell exhaustion in tumor could be the result of the persistent 
exposure to tumor antigens. They are described as effector cells with 
decreased cytokine expression and effector function, and resistant to 
reactivation (Wherry, 2011). Exhausted CD8+ T cells were found in patients 
with melanoma, hepatocellular carcinoma, and ovarian cancer (Baitsch et al., 
2011; Curiel et al., 2003). Senescent T cells are characterized by telomeres 
shortening, phenotypic changes, like loss of CD28 expression of CD28 and cell 
cycle arrest (Adibzadeh et al., 1995; Effros, 1998). p21 and p53 expression 
increases in senescent cells (Beausejour et al., 2003; Passos et al., 2010). In 
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addition to phenotypic alteration, senescent T cells show defective killing 
abilities and the development of negative regulatory functions (Akbar and 
Henson, 2011). Beside T cell anergy, exhaustion and senescence, another 
important aspect to consider is how immune cell metabolism is altered by the 
tumor microenvironment. Tumors are a major disturbance to tissue 
homeostasis, because they create a metabolically demanding environment that 
affects the metabolism and functions of infiltrating immune cells. Cancer cell 
growth is often supported by aerobic glycolysis which is the optimal pathway to 
support effector functions of many immune cells (Pearce et al., 2013). This 
similarity generates a competition for substrates between tumors and immune 
cells. The demand of nutrients, metabolites and oxygen imposed by proliferative 
cancers cells, in combination with their immunosuppressive action, create harsh 
environmental conditions in which immune cells must navigate and adapt (Buck 
et al., 2017). During tumor growth, regions of hypoxia are established and HIF-
ĮLVLQGXFHGDnd intensifies cancer cell glucose utilization and lactate release 
(Eales et al., 2016). How this metabolic heterogeneity in tumor cells relates to 
immune cell function has not been well elucidated, but exposure of NK and T 
cells to high concentrations of lactate impairs the activation of the transcription 
factor NFAT and production of IFN-Ȗ (Brand et al., 2016). Lactic acid also 
disrupts T cell motility and causes loss of cytolytic function in CD8 T cells (Haas 
et al., 2015). Moreover, it was shown that decreasing conversion of pyruvate to 
lactate by genetic targeting of lactate dehydrogenase A (LDHA) in tumors helps 
to restore T cell infiltration and function, linking lactate production to
immunosuppression (Brand et al., 2016). Hypoxia also has drastic effects on 
TIL function, proliferation and migration (Vuillefroy de Silly et al., 2016). HIF-Į
induces the expression of PD-L1 in tumor cells (Noman et al., 2014), which 
leads to TILs suppression via PD1.
A recent work by Scharping et al., has shown that CD8 TILs lose mitochondrial 
mass, membrane potential, and oxidative capacity, which lead to a block in their 
proliferation and IFN-Ȗ SURGXFWLRQ (Scharping et al., 2016). From these 
observations it is possible to conclude that cells intrinsically more effective in 
competing for nutrients would have increased possibilities to survive in the 
tumor microenvironment. Therefore, restoring metabolic fitness and remodeling 
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hypoxic tone in tumors are promising strategies to implement the anti-tumor T 
cell effector response. 
4. Purinergic signaling in the immune system
The ability of rapidly sensing signs of distress is one of the main feature of a 
homeostatic system. This is especially important in living organisms that are 
characterized by a continuous exchange of information with the outside and 
continuous processes of self-renewal. It is important for such a homeostatic 
system to be able to constantly monitor the internal environment in order to 
detect any signs of injury or distress. Accordingly, a homeostatic system should 
be able to release a series of intracellular signaling molecules to report cell or 
tissue damage. One of the simplest way to signal distress is the presence of 
receptors that sense in the extracellular space molecules that normally reside 
intracellularly. ATP is one of the most important signal of distress and damage 
(Di Virgilio and Vuerich, 2015). Physiologically, ATP is almost exclusively 
present intracellularly, at several millimolar concentration, while in the 
extracellular space the concentration of ATP is in the low nanomolar range 
(Burnstock, 2007). ATP is the energetic currency of the cell, but it can be 
released in the extracellular space by dying cells and act as a danger 
associated molecular pattern (DAMP). In the immune system, ATP plays an 
important role in controlling both activation and differentiation of different 
immune cell types. For example, in the initial phase of inflammation, DAMP 
signaling is needed to activate DCs and to modulate the ensuing immune 
response. ATP can also be released by living cells, in a regulated fashion, 
through vesicles or specific channels such as connexin and pannexin (Bodin 
and Burnstock, 2001), to act as an autocrine/paracrine signal. In the 
extracellular space, ATP is sensed by purinergic P2 receptors. The P2 receptor 
family is further subdivided into P2Y and P2X receptors (Abbracchio et al., 
2006; Ralevic and Burnstock, 1998). The P2Y receptors are G protein-coupled 
receptors and are stimulated by nucleotides such as ATP, ADP, UTP, UDP, 
UDP glucose and UDP galactose. There are eight known P2Y receptors in 
humans: P2Y1, 2, 4, 6, 11, 12, 13, 14. The P2X ionotropic receptors are ligand-
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gated non-selective ion channels and seven members have been described in 
mice and humans: P2X1, 2, 3, 4, 5, 6, 7.  Both P2Y and P2X receptors are 
expressed by immune cells, in a cell type- and differentiation-dependent 
manner; the activation of these receptors controls different cellular processes 
ranging from survival, proliferation and cell death (Rayah et al., 2012). The 
effect of ATP on a given cells depends on the concentration of ATP in the 
extracellular space, the duration of stimulation and the level of expression and 
the composition of P2 receptors on the cell surface. In particular, ATP in the 
extracellular space can be degraded to adenosine by specific enzymes such as 
ectoapyrase (e.g. CD39) and ecto-5’-nucleotidase (CD73) (Yegutkin, 2008).
Beside its role as DAMP for the innate immune system, the role of ATP in the 
adaptive immune system has been extensively studied in the latest years. The 
importance of ATP/P2XR signaling axis at the immunological synapse has been 
recently unraveled. Upon contact of the TCR with cognate MHC/peptide 
complex, T naïve cells release ATP through pannexin 1 hemichannels during 
the capacitive calcium entry (CCE) phase of T cell activation. The ATP released 
binds to P2X receptors on the T cells in an autocrine fashion and promotes the 
activation of the MAPK pathway and the translocation of NFAT into the nucleus. 
This leads to the expression of IL- 2 and pro-inflammatory T cell activation. In 
the absence of ATP/P2XR signaling and MAPK activation, the translocation of 
NFAT in the nucleus induces a transcriptional program characteristic of T cell 
anergy (Schenk et al., 2008) (Fig. 7).
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Figure 7: Purinergic control of T cell activation. Schematic representation of a T cell 
(red) interacting with an APC (gray). The early phase of T cell activation, which is 
triggered by the interaction of the TCR with the MHC–peptide complex, is characterized
by CCE (step 1), which is accompanied by mitochondrial uptake of Ca2+ (step 2) and 
Ca2+-dependent stimulation of ATP synthesis (step 3). ATP is released from activated 
T cells through pannexin hemichannels, which open when the cytosolic [Ca2+] is 
elevated. This mechanism guarantees a high concentration of pericellular ATP, which 
by binding to P2XRs, serves as an indispensable autocrine costimulus for productive T 
cell activation (step 4). Finally, ATP released from activated T cells might also 
modulate APC function, such as secretion of IL-1ȕ (step 5) (Schenk et al., 2008).
4.1 The P2X7 receptor
The P2X7 receptor is an ATP-gated cation channel and the only member of the 
P2X receptor family characterized by low affinity for ATP, meaning that it 
requires high concentration of ATP to be activated. The P2X7 monomer has a 
short intracellular N-terminal residue, a bulky extracellular domain, two 
transmembrane helices and a long cytoplasmic carboxy-terminal tail 
(Surprenant et al., 1996), fundamental for mediating P2X7 signaling. At 
physiological concentrations of ATP in the extracellular space, the P2X7 
receptor is not active, but when the concentration of ATP increases it opens a 
channel permeable to cations such as Na+, K+, Ca2+. In the presence of high 
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concentrations of ATP or after a prolonged stimulation, the P2X7 receptor forms 
a cytolytic pore that allows the passage of molecules with a molecular weight up 
to 900 Da, including ATP itself (Scheuplein et al., 2009). P2X7 can also be 
stimulated in an ATP-independent fashion. The mechanism involves the ecto-
ADP-ribosyltransferase ARTC2.2, which, in the presence of nicotinamide 
adenine dinucleotide (NAD+), catalyzes ADP-ribosylation of P2X7 at an 
arginine residue at position 125 at the edge of the ATP-binding pocket in the 
extracellular domain of the protein (Adriouch et al., 2008; Seman et al., 2003).
Interestingly, NAD+ dependent activation of P2X7 by ADP-ribosylation provides 
a long lasting activation signal, while P2X7 activation by the non-covalent 
binding of ATP necessitates the continuous presence of ATP in the extracellular 
milieu at sufficient concentration (Scheuplein et al., 2009). At the moment ADP-
ribosylation of P2X7 has been shown only in murine cells, therefore the possible 
significance of this activation mechanism  in humans is not known. One of the 
consequences of P2X7 activation is the modification of cell volume and plasma 
membrane composition. For example, T cells respond to ATP stimulation with 
rapid sequential shrinkage and swelling and externalization of 
phosphatidylserine (PS) onto the outer membrane leaflet of the plasma 
membrane (Adriouch et al., 2001; Taylor et al., 2008). Externalization of PS is 
considered as an early indicator of the induction of apoptosis and is related to 
the influx of both Na+ and Ca2+. Interestingly, PS exposure after ATP stimulation 
is reversible if ATP is removed within the first 30 minutes of exposure 
(Mackenzie et al., 2005), while PS exposure after ADP-ribosylation is not 
reversed after removal of NAD+ (Seman et al., 2003). The formation of the 
membrane pore is another important characteristic of P2X7 receptor activation 
and it has been functionally linked to the long intracellular C-terminus region of 
the receptor (Becker et al., 2008). However, whether the formation of the pore is 
mediated by P2X7 itself and/or by other P2X7-associated proteins such as 
pannexin 1 is still unclear. Another non-selective cation channel, the 
phospholipid scramblase anoctamin 6 (ANO6), has been recently identified as 
an important element in the formation of the membrane pore following P2X7 
activation in macrophages (Ousingsawat et al., 2015). P2X7 receptor is highly 
expressed in cells of the innate immune system, and its function has been 
extensively studied. In particular, P2X7 receptor has a fundamental pro-
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inflammatory role. During inflammations, ATP activates P2X7 receptor, which 
mediates the efflux of K+, the opening of pannexin 1 channels and the activation 
of NLRP3 inflammasome. This leads to the processing by caspase 1 of pro-,/ȕ
to the mature form, which is then released (Ferrari et al., 2006). The role of 
P2X7 receptor in the adaptive immune system has been investigated more and 
more in the latest years. Regarding T cells, the expression of P2X7 depends on 
the stage of maturation and differentiation. It was shown that the ATP/P2X7 axis 
SOD\VDUROHLQWK\PRF\WHVGHDWKE\QHJOHFWDQGLQWK\PLFGLIIHUHQWLDWLRQRIȖį7
cells by promoting ERK phosphorylation (Frascoli et al., 2012). Moreover, 
mature peripheral CD4+ T cells display higher surface levels of P2X7 compared 
to CD8+ T cells. Interestingly, P2X7 surface expression also seems to be 
regulated by T cell activation. T cells expressing more activation markers show 
lower P2X7 surface levels compared to the resting counterpart (Adriouch et al., 
2007). The P2X7-dependent cell death is very important in regulating the 
homeostasis of different T cell populations both at steady state and in 
pathophysiological contexts.  In vivo studies has shown that Treg and NKT cells 
are characterized by high sensitivity to ATP- and NAD+ mediated cell death 
(Hubert et al., 2010; Kawamura et al., 2006; Rissiek et al., 2014). P2rx7 knock 
out mice exhibit a higher number of Treg cells in the spleen compared to wild-
type (WT) mice. Moreover, it has been shown that P2X7 receptor in Tfh cells is 
important in regulating the composition of the gut ecosystem. Tfh cells in the 
Payer’s Patches (PPs) of the small intestine express high levels of P2X7 
receptor, which regulates their survival and function. P2rx7 knock out mice are 
characterized by expansion of PPs at steady state, due to increased number of 
Tfh cells and germinal centers. This leads to enhanced production of high-
affinity IgA that results in alteration of the microbiota composition (Proietti et al., 
2014). Very recently, it was shown that the binding of retinoic acid through 
UHWLQRLF DFLG UHFHSWRU Į LQGXFHV WKH XSUHJXODWLRQ RI 3; LQ&'7 HIIHFWRU
cells in the gut. The intestinal effector T cells are effectively deleted by P2X7 
activation-dependent apoptosis (Hashimoto-Hill et al., 2017). It has become 
clear that ATP can be released from living cells in different physiological and 
pathophysiological conditions. Pellegatti et al. demonstrated the presence of 
ATP in the tumor microenvironment at a millimolar range (Pellegatti et al., 
2008). The role of P2X7 receptor in tumors has been recently investigated in 
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P2rx7-deficient mice. The pharmacological or genetic ablation of P2X7 results 
in the increase of tumor development in a model of colitis-associated cancer, 
due to accumulation of Treg cells in the tumor microenvironment (Hofman et al., 
2015). Another important mechanism of P2X7 activity in tumors could rely on 
the more efficient priming of anti-tumor CD8+ T cells in WT mice due to a more 
efficient DC maturation through the NLRP3-P2X7 axis, thus leading to a more 
effective-tumor antigens presentation to CTLs and more favorable T 
effector/Treg ratio for the organism (Adinolfi et al., 2015; Ghiringhelli et al., 
2009). These studies reveal the important role of P2X7 in the tumor 
microenvironment. It cannot be excluded that inhibition of P2X7 activity in other 
cell subsets could be beneficial for the anti-cancer immune response. It is 
important to consider that besides Treg cells other mature T cells subsets 
express high level of P2X7 receptor. It seems reasonable to envisage that 
blockade of P2X7 receptor concomitant with immunotherapy could be beneficial 
in promoting accumulation of pro-inflammatory T cells within the tumor, 
contributing to its rejection. In summary, it has become clear that P2X7-
mediated cell death constitutes a crucial factor for the homeostatic regulation of 
different T cell subsets and play essential role in the regulation of immune 
responses. Depending on the amount of extracellular ATP or NAD+ and/or the 
expression level of P2X7, the receptor may regulate T cell activation and 
function. Short pulse and low concentration of ATP or its restricted presence at 
only one side of the cells (for example at the immunological synapse) might 
promote T cell activation (Rissiek et al., 2015) (Figure 8). In contrast, long-
lasting whole-cell activation of P2X7 by high concentrations of ATP or NAD+ in 
cells expressing high levels of P2X7 might promote cell death.
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Figure 8: P2X7 mediated cell death and role of P2X7 in T cell activation. P2X7
stimulation can have different consequences in T cells. The extracellular concentration
of ATP, the density of P2X7, the concomitant expression of ATP degrading 
ectoenzymes, the T cell subset and the activation status of the cell are all important 
elements in shaping the response to extracellular ATP. (A) High concentrations of
extracellular ATP culminate in cell death through the induction of massive membrane
depolarization and permeabilization. (B) At lower ATP concentrations and P2X7
expression levels or in the presence of ATP-catabolizing enzymes, P2X7 stimulation
promotes T cell activation by enhancing cytosolic Ca2+ concentration. This may result
in the stimulation of NFAT and MAPK, and IL-2 secretion as well as in the activation of 
a metalloprotease that catalyzes the shedding of CD62L and possibly other cell surface 
proteins (modified from (Rissiek et al., 2015).
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AIM OF THE STUDY
The ATP-gated ionotropic P2X7 receptor is expressed by a number of 
mammalian cell types. In the innate immune system the ATP/P2X7 axis has a 
fundamental role during inflammation, as it is responsible for the release of 
mature IL-ȕLQWKHH[WUDFHOOXODUVSDce. P2X7 receptor is a signature gene also 
of effector T cell subsets, however, its role in the adaptive immune system has 
to be investigated more thoroughly. Our lab previously demonstrated that P2X7 
receptor influences T follicular helper cells survival in the gut associated 
lymphoid tissue. The aim of this study was to characterize P2X7 receptor 
function in T effector memory (TEM) cells. We used P2rx7-/- mice to analyze the 
effect of P2X7 activation on T cell proliferation and survival both in vitro and in 
vivo. We analysed transcriptional, metabolic and signaling profiles controlled by 
P2X7 activity in order to understand the effect of extracellular ATP (eATP) on 
TEM cells via P2X7. Since the tumor microenvironment is very rich in eATP, we 
addressed whether P2X7 could condition tumor infiltrating lymphocytes (TILs). 
In a chimeric model of melanoma we adoptively transferred WT or P2rx7-/- T
cells in order to understand whether lack of P2X7 could endow TILs with 
functional advantages with respect to WT cells. Finally, we performed 
morphological analysis of TEM cells in electron microscopy to characterize 
possible mitochondria features that could correlate with improved bioenergetics 
of P2rx7-/- cells.   
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MATERIAL AND METHODS
Mice
C57/BL6J, P2rx7-/- (B6.129P2-P2rx7tm1Gab/J), UBC and Cd3İ-/- mice were bred 
in specific pathogen-free (spf) facility at the Institute for Research in 
Biomedicine, Switzerland. Genotyping was accomplished by the polymerase 
chain reaction (PCR) method according to the manufacturer’s protocol. Mice 
were housed, five per cage, in ventilated cages under standardized conditions 
(20 ± 2ºC, 55 ± 8% relative humidity, 12 h light/ dark cycle). Food and water 
were available ad libitum, and mice were examined daily.
Cell isolation from mice organs
For in vitro experiments and adoptive transfer CD4 or CD8 T naïve and T
effector/memory (TEM) cells were sorted at FACSAria (BD Biosciences) from 
pooled cell suspensions of spleen, inguinal, axillary, brachial, cervical and 
mesenteric lymph nodes collected from C57BL/6J and P2rx7-/- mice. T Naïve 
cells were sorted as CD4 or CD8 +/-, CD62L+, CD44- and CD25-, while TEM 
cells were sorted as CD4 or CD8 +/-, CD62L-, CD44+ and CD25-. Magnetic 
Cell Sorting (MACS, Miltenyi Biotec) with anti-CD4 and anti-APC mAbs were 
used to purify cell subsets from complex cell mixtures.
B16 and HeLa cell lines
B16 cells were cultured in RPMI-1640, while HeLa cells were cultured in 
DMEM. Both media were supplemented with 10% heat-inactivate fetal bovine 
serum, 100 U/mL penicillin/streptomycin and 100 U/mL kanamycin. Cells were 
maintained in 5% CO2 at 37°C. Tumor cells at 70-80% confluency were 
harvested by diluting them 1:5 in 0.25% trypsin.  
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In vivo experiments
To analyse in vivo homeostatic expansion, CD4 T naïve cells were sorted from 
spleen and secondary lymph nodes of UBC and P2rx7-/- mice as described 
above. 1x106 total cells were injected into 8 week old FGİ-/- mice. Recipient 
mice were sacrificed four weeks after reconstitution and spleen, Peyer’s 
patches and mesenteric lymph nodes were analyzed at FACS. To analyse anti-
tumor response, CD4 or CD8 T naïve cells and CD4 TEM cells were sorted 
from C57/BL6J and P2rx7-/- mice as described above. 2.5x105 T naïve or TEM 
cells were injected into FGİ-/- mice. Melanoma B16 cells were harvested at 
exponential growth. After five days from reconstitution with T cells, melanoma 
cells were resuspended in PBS at a concentration of 5x106 cells/mL and a 
volume of 0.1 mL (5x105 tumor cells) was injected subcutaneously into the back 
of recipient FGİ-/- mice. Tumor growth was scored with a caliper by measuring 
the greatest tumor diameter and its perpendicular to determine an average and 
then the area was calculated as: (average/2)2ʌ. Tumor-bearing animals were 
sacrificed after 20 days or earlier when showing any sign of discomfort.
Cell isolation from tumor tissue 
Tumors were cut in small pieces and resuspended in RPMI-1640 with 1.5 
PJP/W\SH,FROODJHQDVH6LJPDȝJP/'1DVH,5RFKHDQG)%6
digested for 45 minutes at 37°C under gentle agitation. The digestion product 
was then passed through a 70 µm cell strainer to obtain a single cell 
suspension. Lymphocytes were then enriched by Percoll density gradient 
following manufacturer’s protocol.
Antibodies and flow cytometry
Anti-mouse antibodies
The following mAbs were purchased from BD Bioscience: APC conjugated anti-
CD62L (clone: MEL-14, Cat.#: 17-0621-83, working dilution 1:200), PE 
conjugated anti-Ki-67 (clone: SolA15, Cat.#: 12-5698-80, working dilution 
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1:100), APC conjugated anti-&'Į FORQH -6.7 Cat.# 17-0081-83, working 
dilution 1:200). The following mAbs were purchased from BioLegend: PE 
conjugated anti-CD44 (clone: IM7, Cat.#: 103008, working dilution 1:200), 
PE/Cy7 conjugated anti-CD25 (clone: OC61, Cat.# 102016, working dilution 
1:200), APC/Cy7 conjugated anti-CD4 (clone: RM4-5, Cat.#: 100526, working 
dilution 1:200), Pacific Blue conjugated anti-&'ĮFORQH-6.7, Cat.# 100725,
working dilution 1:200), FITC conjugated anti-7&5ȕ FORQH +-597, Cat.# 
109215, working dilution 1:200). APC conjugated anti-&'Į FORQH -6.7, 
Cat.# 17-0081-83, working dilution 1:200).
Anti-human antibodies
The following mAbs were purchased from Life Technologies: PE-Texas Red 
conjugated anti-CD4 (clone: S3.5, Cat.# MHCD0417, working dilution 1:1000), 
QD655 conjugated anti-CD45RA (clone: MEM-56, Cat#. Q10069, working 
dilution 1:1000). The following mAbs were purchased from BioLegend: PE 
conjugated anti-CCR7 (clone: G043H7, Cat#. 353204, working dilution 1:600), 
PE/Cy5 conjugated anti-CD25 (clone: BC96, Cat.#: 302608, working dilution 
1:20), PE/Cy5 conjugated anti-CD8 (clone: HIT8a, Cat.#: 300909, working 
dilution 1:20). 
Samples were acquired on a LSRFortessa (BD Bioscience) flow cytometer. 
Data were analyzed using FlowJo software (TreeStar) or FACS Diva software 
(BD Bioscience).
Real-time PCR
Total RNA from FACS sorted cells was precipitated in Trizol (Invitrogen) and 
reverse transcribed to cDNA using Random hexamers (Roche, Cat.#: R 15504) 
and M-MLV reverse-transcriptase (Invitrogen, Cat.#: 28025-013) following 
manufacturer’s protocol. mRNA samples were treated with 2 U/sample of 
DNase (Applied Biosystems). Transcripts were quantified by real-time PCR on 
an ABI PRISM 7700 Sequence Detector with predesigned TaqMan Gene 
Expression Assays and reagents according to the manufacturer’s instructions 
(https://www.lifetechnologies.com). The following probes were used for mouse 
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cells: Cdkn1a (Mm00432448_m1), Cdkn1b (Mm00432448_m1), P2rx1 
(Mm00435460_m1), P2rx2 (Mm01202368_g1), P2rx3 (Mm00523699_m1), 
P2rx4 (Mm00501787_m1), P2rx5 (Mm00473677_m1), P2rx6 
(Mm00440591_m1), P2rx7 (Mm01199500_m1), trp53 (Mm01731290_g1), 
Gadd45b (Mm00435123_m1). The following probes were used for human cells:
CDKN1A (Hs00355782_m1), P2RX7 (Hs00175721_m1).
All reactions were performed in triplicate. The relative amounts of mRNAs were 
calculated by the ǻCT method. Hprt for mouse cells and TBP for human cells 
were used as internal housekeeping genes.
Time monitoring of DAPI uptake
 
Purified T naïve or TEM cells were resuspended at 1x106 cells/mL and loaded 
with DAPI (1 µg/mL). After 30 seconds of measurement for DAPI basal level, 
cells were stimulated with BzATP ȝ0 DQG '$3, XSWDNHwas monitored 
over time (250 seconds) at LSRFortessa and the kinetics analyzed using 
FlowJo software.
Microarray data analyses
All microarray data analyses were performed in R (version 3.2.0) using 
Bioconductor libraries (BioC 3.1) and R statistical packages. Probe level signals 
were converted to expression values using robust multi-array average 
procedure RMA of Bioconductor affy package. Differentially expressed genes 
were identified using Significance Analysis of Microarray (SAM) algorithm coded 
in the samr R package. In SAM, we estimated the percentage of false positive 
predictions (i.e. False Discovery Rate, FDR) with 100 permutations. To identify 
genes associated with p2rx7 deletion, we compared the expression levels of 
WT and p2rx7-/- TEM cells and selected those probe sets with absolute fold 
FKDQJHODUJHUWKDQDVHOHFWHGWKUHVKROGHJRU-DQG)'5LQDOO
comparisons. To functionally annotate differentially expressed genes and 
identify de-regulated signaling pathways, we performed over-representation 
analysis using Fisher test and Gene Set Enrichment Analysis on gene sets 
derived from previously published gene signatures and from gene set 
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databases. GSEA software (http://www.broadinstitute.org/gsea/index.jsp) was 
applied on log2 expression data of WT and P2rx7-/- cells. Genes were 
FRQVLGHUHG VLJQLILFDQWO\ HQULFKHG DW )'5   ZKHQ XVLQJ 6LJQDO1RLVH DV
metric and 1,000 permutations of gene sets. Finally, we investigated the 
average expression was calculated as the standardized average expression of 
all signature genes in sample subgroups (e.g. WT/P2rx7-/-).
Ki-67 staining
For detection of nuclear antigen Ki-67, sorted TEM cells or purified tumor 
infiltrating lymphocytes (TILs) were fixed and permeabilized using the BD 
Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) 
according to the manufacturer’s recommendations, followed by staining with Ki-
67 mAb.
In vitro monitoring of cell survival and proliferation
T naïve or TEM cells were grown in a 96 flat-bottom well plate in RPMI-1640 
supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL 
penicillin/streptomycin and 100 U/mL kanamycin and maintained in 5% CO2 at 
37°C. Cells were labeled with CellTrace violet (Thermo Fisher, Cat.#: C34557) 
and stimulated by plate-bound anti-CD3İ mAb (2µg/mL) with co-immobilized 
anti-CD28 mAb (2µg/mL) (eBioscience); for stimulation with cytokines, cells 
were cultured with IL-2 at 50 U/mL. CellTrace dilution was measured in viable 
cells through the exclusion of dead and apoptotic cells by electronically gating 
PI and Annexin V negative cells. FACS acquisitions were standardized by fixed 
numbers of calibration beads (BD Biosciences). Half-life and cell cycling activity 
was calculated as previously described (Hawkins et al., 2007).
4XDQWLILFDWLRQRIȕ-galactosidase and mitochondria-associated ROS
To measure cellular senescence, purified TEM cells were stimulated for 3 days 
with anti-CD3İ and CD28 mAbs in the presence or absence of 70 µM BzATP.
Cells were then harvested and incubated for 2 h with 100 nM bafilomycin A1 to 
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inhibit lysosomal ȕ-galactosidase before adding the ȕ-galactosidase substrate 
C12FDG (Thermo Fisher). Relative ȕ-galactosidase activity was assessed as 
fluorescence emission at FACS (with 488 nm laser). Mitochondria-associated 
ROS levels were measured by staining cells with MitoSOX red (Molecular 
Probes/Invitrogen) at 5 µM for 40 min at 37ºC. Cells were then washed and 
resuspended in PBS for FACS analysis (with laser for PE).
Transmission electron microscopy
WT and P2rx7-/- TEM cells were stimulated 3 days with anti-CD3 and anti-CD28 
antibodies and then fixed in 2% paraformaldehyde and 2% glutaraldehyde in 
sodium cacodylate 0.1 M. Following fixation, samples were washed in 
cacodylate buffer and post fixed in 1% osmium tetroxide. After extensive 
washing in H2O, samples were stained with uranyl acetate saturated in ethanol 
20% for 1 hour and then washed again. Samples were then dehydrated in 
increasing concentration of ethanol (70%, 80%, 90%, 100%) and propylene 
oxide and embedded in Eponate 12 resin (Ted Pella). The resin-embedded 
samples were cut using an ultramicrotome (Leica Microsystem) with a diamond 
knife (DiATOME, Switzerland), collected on copper grids (EMS), and counter-
VWDLQHGZLWKXUDQ\ODFHWDWHVROXWLRQIRUௗPLQXWHVDQGOHDGFLWUDWH(06
for seven minutes, before being observed through a transmission electron 
microscope (Philips) equipped with a digital camera (Morada, Olympus). The 
area, perimeter and circularity of about 100 mitochondria per sample were 
measured on electron micrographs acquired at 10500x using ImageJ64 
software.
Seahorse metabolic analysis
WT and P2rx7-/- TEM cells were stimulated 3 days with anti-CD3 and anti-CD28 
antibodies, then collected and plated on Seahorse 96 well plate coated with 
Cell-Tak (Corning, Cat# 354240) and analyzed with Seahorse XF Cell Mito 
Stress kit (Seahorse Bioscience). Oxygen consumption rate (OCR) was 
measured in XF media (non-buffered RPMI-1640 supplemented with 10mM 
glucose, 2mM L-glutamine and 1mM sodium pyruvate) under basal condition 
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DQG LQ UHVSRQVH WR  ȝ0 ROLJRP\FLQ  ȝ0 IOXRUR-carbonyl cyanide 
phenylhydrazone (FCCP)  and Q0URWHQRQHȝ0DQWLP\FLQ$XVLQJD
well XF or XFe Extracellular Flux Analyzer (EFA) (Seahorse Bioscience). Data 
were analyzed with Wave software.
Western blotting
For western blot analysis TEM cells were washed with ice cold PBS and lysed 
with RIPA buffer 1x (Sigma) or with Urea 9 M to detect nuclear protein, both 
supplemented with phosphatase inhibitor cocktail (Sigma-Aldrich) and protease 
inhibitor cocktail (Roche). Samples were centrifuge at 14.000 rpm for 10 min at 
4°C and snap frozen. Cleared protein lysate was denatured with loading buffer
supplemented with DTT 0.1 ȝM for 10 min at 65°C. Samples were run on 
precast 4-12% bis-tris protein gels (BioRad) and then transferred onto PVDF 
membranes using Trans-Blot Turbo Transfer System (BioRad). Membranes 
were blocked with 10% (wt/vol) nonfat dry milk (Bio-Rad) and 0.1% Tween-20 in 
TBS and incubated with appropriate antibodies in TBS with 0.1% Tween-20 for 
16 h at 4°C. The following antibodies were purchased from Cell Signaling 
Technology: anti-p38 MAPK (rabbit, Cat. #9212), anti-phospho p38MAPK 
(T180/Y182) (rabbit, clone: D3F9, Cat. #4511), anti-phospho H2A.X (S139) 
(rabbit, clone: 20E3, Cat. #9718), anti-Opa1 (rabbit, clone: 2D6U6N, Cat. # 
80471), anti-Drp1 (rabbit, clone: D6C7, Cat. # 8570). Anti-P2X7 antibody was 
purchased from Alomone Labs (rabbit, Cat. #APR-004); anti-actin antibody was 
purchased form Sigma (rabbit, Cat. #A2066); anti-GAPDH antibody was 
purchased form Millipore (mouse, clone: 6C5 Cat. #MAB374). All incubations 
with primary antibody were followed by incubation with secondary HRP-
conjugated anti-rabbit (Cat. #7074, Cell Signaling Technology), or anti-mouse 
(Cat. #7076, Cell Signaling Technology) IgG antibodies in TBS with 0.1% 
Tween-20. Membranes were developed using the Pierce ECL Western blotting 
substrate (Thermo Scientific, Cat.# 32209), signals were detected with the 
ImageQuant LAS 4000 system in the standard acquisition mode (GE 
Healthcare Life Sciences), and bands were quantified using the Multi Gauge 
Analysis tool (Fujifilm).
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Immunohistochemistry and digital image analysis
To assess the number of tumor infiltrating T cells, 4 ȝm sections from each 
sample were immunostained with a primary goat polyclonal antibody against 
CD3H (Santa Cruz Biotechnology; #Sc-1127). For each sample, serial sections 
incubated with a 10% solution of normal rabbit serum served as negative 
controls. The number of CD3H+ cells per area of the tumor was evaluated using 
the ImageJ analysis program (http://rsb.info.nih.gov/ij/) in four 200X
microscopic fields. The number of T cells per mm2 of intestinal mucosa was 
then calculated.
Transfection of human TEM cells
Peripheral blood mononuclear cells (PBMCs) were isolated from blood by 
density-gradient centrifugation using Ficoll-Paque™ Plus gradient (GE-
Healthcare). CD4+ T cells were enriched by positive selection using human 
CD4 MicroBeads (Miltenyi Biotec) and then CD4 TEM cells were sorted with a 
FACSAria (BD) as CD4+, CD8-, CCR7-, CD45RA-, CD25-. TEM cells were 
electroporated with Neon transfection kit and device (Invitrogen). A total of 5,0 
x105 TEM cells were washed three times with PBS before resuspension in 10 
ȝ/ RI %XIIHU 7 1HRQ NLW ,QYLWURJHQ). 40 pmol of P2RX7 Silencer Select Pre-
designed siRNA (Ambion) or, as a control, siGLO Green Transfection Indicator 
'KDUPDFRQZHUHDGGHGWRWKHFHOOVWRDILQDOYROXPHRIȝ/DQGPL[HG
ȝ/ RI WKH VXVSHQVLRQ ZDV HOHFWURSRUDWHG ZLWK 1HRQ HOHFWURSRUDWLRQ 'HYLFH
(Invitrogen; 2150 V, 30 ms, 1 pulse). Electroporated cells were then transferred 
in RPMI-1640 supplemented with 10% FBS and without antibiotics for 24 hours.
For analysis of cell proliferation, electroporated TEM cells were labelled with 
CellTrace violet (Thermo Fisher, Cat.#: C34557) and plated on 96 well NUNC 
immunoplate coated with anti-&'ȝJDQGDQWL-&'ȝJ antibodies for 5 
GD\VZLWKRUZLWKRXWȝ0%]$73
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Statistical analyses
Statistical analysis was performed with the Prism software (GraphPad). 
Comparisons of two groups were calculated using nonparametric Mann Whitney 
test or Student’s unpaired t test. Comparisons for more than two groups were 
calculated using Kruskall-Wallis test followed by Dunn’s multiple comparison 
test. Results are presented as mean values ± SEM of at least 5 mice per group 
from the same experiment and are representative of at least three independent 
experiments. Values of P<0.05 were considered significant.
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RESULTS
P2X7 receptor regulates CD4+ TEM cell survival and proliferation both in 
vitro and in vivo
We previously reported that Tfh cells express high levels of P2rx7 transcript, 
which influences Tfh cell proliferation and survival within the Peyer’s patches 
(PPs) of the small intestine (Proietti et al., 2014). The data obtained in these 
cells prompted us to investigate P2rx7 expression in other T cell subsets, 
including T naïve and effector memory (TEM) cells. Real-time quantitative 
reverse transcription PCR (qRT-PCR) for the different P2rx genes revealed that,
in both naïve and TEM cells, P2rx7 is the most expressed member of the P2X 
family (Figure 1A). Nevertheless, qRT-PCR and western blot revealed that TEM 
cells express significantly increased levels of both P2rx7 transcript (Figure 1B) 
and P2X7 protein (Figure 1C) as compared to naïve cells. In order to correlate 
P2X7 receptor expression with its functionality, we tested DAPI permeability at 
FACS upon stimulation with the selective P2X7 agonist 3’-O-(4-benzoyl) 
benzoyl ATP (BzATP), as a measure of P2X7 receptor pore opening. These 
experiments showed that only a small fraction of T naïve cells is sensitive to 
P2X7-mediated DAPI uptake, while the majority of TEM cells were sensitive to 
BzATP stimulation (Figure 1D). 
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Figure 1: Effector memory express higher levels of P2rx7 than naïve T cells. A) 
Quantitative Real-Time PCR (qRT-PCR) of the seven p2rx genes (X1-X7) performed in 
ex-vivo CD4+ T naïve cells (left, white) and CD4+ TEM cells (right, black). B) qRT-PCR 
of P2rx7 transcript performed in ex-vivo CD4+ T naïve and TEM cells. Histograms 
show mean ± SEM. C) P2X7 receptor protein quantification by western blot in CD4+ T 
naïve and TEM cells. D) Time-monitoring of DAPI permeability at FACS after 
stimulation with BzATP of purified WT CD4+ T naïve and TEM cells. P2rx7-/- TEM cells 
were also tested as negative control. Data are representative results of at least three 
independent experiments with 3 to 5 mice for experiment. A.U., Arbitrary Unit. * p<0.05.
Therefore, we concentrated our efforts on the characterization of the function of 
P2X7 receptor in TEM cells. To address whether P2X7 activity affected TEM 
cell responsiveness, we analyzed in vitro cell proliferation and survival in 
response to anti-CD3 and anti-CD28 antibodies, using time series data obtained 
at FACS with CellTrace violet labeled WT and P2rx7-/- cells (Hawkins et al., 
2007). As early as 24 hours after stimulation, a significant increase in the cell 
number and half-life of P2rx7-/- TEM cells with respect to WT cells was evident 
(Figure 2A). Moreover, the analysis of violet dilution showed that P2rx7-/- TEM 
cells progress earlier in the first cell division and require less time to enter 
subsequent cell divisions (Figure 2B). Interestingly, we observed a significant 
increase in the cell number of P2rx7-/- TEM compared to the WT counterpart 
also after stimulation with IL-2 (Figure 2C). All these data suggest that the 
absence of P2X7 receptor confers a proliferative advantage and an increased 
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survival to TEM cells in vitro when stimulated either with anti-CD3 and anti-
CD28 antibodies or IL-2. 
To evaluate whether these phenomena were a peculiarity of in vitro stimulation 
or could be observed also in vivo, we analysed homeostatic expansion of WT 
and P2rx7-/- mice. Naïve T cells injected into a lymphopenic host undergo 
extensive proliferation and acquire a phenotype similar to antigen-experienced 
memory T cells (Goldrath et al., 2004). We co-injected into FGİ-/- mice CD4+ 
naïve T cells purified from P2rx7-/- and C57Bl/6-TgUBC-GFP mice, which 
express green fluorescent protein (GFP) under the control of the ubiquitin 
promoter (Figure 2D). After two weeks we collected spleens, mesenteric lymph 
nodes (MLNs) and PPs and analyzed at FACS the presence of memory-like 
CD4+ T cells originated from the different donors. The results showed that more 
than 90% of the memory cells that were recovered in the secondary lymphoid 
organs were negative for GFP, indicating they were from p2rx7-/- mice (Figure 
2E). This result indicates that lack of P2X7 confers a proliferative and survival 
advantage to TEM cells, both in vitro and in vivo.
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Figure 2: P2rx7-/- TEM cells are characterized by increased survival and 
proliferation than WT cells both in vitro and in vivo. A) Left, cell number 
quantification at FACS of purified WT and P2rx7-/- TEM cells stimulated with anti-CD3 
and anti-CD28 antibodies. In a separated histogram, the 24 hour time-point is shown in 
detail. Right, extrapolation for the rate of TEM cells death before entry into cell division. 
B) Left, representative CellTrace dilution of WT and P2rx7-/- TEM cells after 3 days of 
stimulation with anti-CD3 and anti-CD28 antibodies. Right, linear regression analysis of 
mean division number against harvest time. The table on the right shows the time 
taken for the cells to enter into each subsequent division (see Methods section). C) 
Representative CellTrace dilution of WT and P2rx7-/- TEM cells after stimulation with IL-
2 for 10 days. In the left corner of the plot the cell number of dividing cells is 
represented. The graph on the right shows the cell number at different days of 
stimulation. D) Schematic representation of the experimental design: co-injection of T 
naïve cells from WT (in green) and P2rx7-/- mice (donors mice) into the same recipient 
FGİ-/- mice. E) Dot plot (left) and statistical analysis of spleen (SPL), mesenteric lymph 
nodes (MLNs) and Peyer’s patches (PPs) from FGİ-/- mice reconstituted with purified 
WT (GFP+) and P2rx7-/- (GFP-) naïve CD4 cells at 1:1 ratio. Cells were gated for 
surface CD4 and CD3 and were analyzed for GFP expression. Histograms show mean 
percentages ± SEM. Data are representative results of at least three independent 
experiments with 3 to 5 mice for experiment. ** p<0.01, *** p<0.001.  
P2X7 receptor activation induces upregulation of p21waf1/cip1 and arrest of  
cell cycle progression
To better characterize the molecular pathway/s activated by P2X7 stimulation, 
we analysed the transcriptional profiles of ex vivo purified TEM cells from WT 
and p2rx7-/- mice with Affimetrix gene arrays. This analysis showed that P2rx7-/-
TEM cells clustered together and separately from the WT counterpart (Figure 
3A). Among the genes differently expressed by the two genotypes, we focused 
our attention on cyclin-dependent kinase inhibitor 1A (Cdkn1a), as one of the 
most downregulated transcripts in P2rx7-/- cells. Cdkn1a encodes for 
p21Waf1/Cip1, which, together with the cyclin dependent kinase inhibitor p27Kip1,
regulates the progression through G1 to S phase of the cell cycle in mammalian 
cells (Coqueret, 2003). In silico analysis performed in publicly available datasets 
showed a positive correlation between the expression of P2rx7 and Cdkn1a
genes in T cells (Figure 3B). To directly correlate P2X7 activation with induction 
of Cdkn1a transcription, we stimulated WT TEM cells with BzATP and analysed 
Cdkn1a mRNA levels. QRT-PCR showed a significant increase of Cdkn1a
transcripts in stimulated as compared to unstimulated cells. Moreover, 
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pretreatment of WT cells with the selective P2X7 antagonist A-438079 
prevented Cdkn1a upregulation, indicating that P2X7 activation regulates 
Cdkn1a transcription (Figure 3C). The effect of BzATP was specific for p21 
since the transcription of Cdkn1b, encoding for p27, was unaltered by P2X7 
stimulation (Figure 3C). 
We then analyzed the effect of BzATP on the cell cycling activity of TEM cells 
upon stimulation with anti-CD3 and anti-CD28 antibodies. The analysis of cell 
proliferation at FACS on cells labeled with CellTrace violet showed a block in 
the cell cycle progression of WT CD4+ TEM cells upon exposure to BzATP in a 
dose-dependent way, with a significant increase in the percentage of undivided 
cells. Pretreating cells with A-438079 antagonist prevented P2X7 mediated cell 
cycle block (Figure 3D). Data obtained at FACS by staining for the nuclear 
antigen Ki-67, a marker of proliferating cells, were in line with these results: WT 
TEM cells treated with BzATP showed a reduced percentage of Ki-67 positive 
cells compared to the untreated group and pretreatment with the antagonist A-
438079 allowed the recovery of the proliferating phenotype (Figure 3E). We 
also confirmed that ex vivo isolated P2rx7-/- TEM cells proliferate more than WT 
cells (Figure 3E and 2B). Together, these data suggest that P2X7 activation in 
TEM cells induces a block in cell cycle progression through the upregulation of 
p21. 
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Figure3: P2X7 stimulation induces premature senescence in TEM cells through 
Cdkn1a upregulation. A) Differential gene expression between ex-vivo WT and P2rx7-
/- TEM cells: heat map showing genes significantly downregulated (green) in P2rx7-/-
compared to WT TEM cells (red). Each row represents one gene and each column one 
sample. B) Correlation analysis between Cdkn1a and P2rx7 performed in silico for 
mouse T cells. C) Quantitative RT-PCR of Cdkn1a (left) and Cdkn1b (right) transcripts. 
The analysis was performed on purified WT TEM cells either untreated or stimulated 
ZLWK %]$73  ȝ0 RU SUHWUHDWHG ZLWK $-  ȝ0 DQG WKHQ VWLPXODWHG ZLWK
BzATP. Histograms show mean ± SEM. D) Representative CellTrace dilution and 
statistical analysis of purified WT TEM cells stimulated with anti-CD3 and anti-CD28 
DQWLERGLHVIRUGD\VDQGWUHDWHGZLWK%]$73RUȝ0RUSUHWUHDWHGZLWK$-438079 
ȝ07KHQXPEHUVLQWKH)$&6 plots and in the histogram represent the percentage 
of undivided cells. E) Dot plots of FACS staining and statistical analysis for the nuclear 
antigen Ki-67 performed on purified WT and P2rx7-/- TEM cells stimulated with anti-
CD3 and anti-CD28 antibodies for 3 days and treated as indicated. The numbers in the 
plots and in the histogram represent the percentage of Ki- SRVLWLYH FHOOV ) ȕ-
galactosidase staining at FACS of WT and P2rx7-/- TEM cells stimulated with anti-CD3 
and anti-CD28 antibodies for 3 days and treated as indicated. Numbers in the plot and 
LQWKHKLVWRJUDPUHSUHVHQWWKHSHUFHQWDJHRIȕ-galactosidase positive cells. Histograms 
shows mean percentages ± SEM. Data are representative results of at least three 
independent experiments with 3 to 5 mice for experiment. A.U., Arbitrary Unit. ** 
p<0.01, *** p<0.001.  
P2X7 receptor induces premature senescence in CD4 TEM cells 
High expression of p21 has been associated to senescent cells (Herbig et al., 
2004). Thus, we investigated whether P2X7 receptor might induce premature 
senescence in T cells by measuring the presence of the well-known 
senescence-assRFLDWHG PDUNHU ȕ-galactosidase (Akbar et al., 2016). FACS 
DQDO\VLV UHYHDOHGDQ LQFUHDVHGSHUFHQWDJHRIȕ-galactosidase positive cells in 
ex vivo WT compared to P2rx7-/- TEM cells (Figure 3F). Moreover, treating WT 
FHOOV ZLWK %]$73 LQGXFHG D VLJQLILFDQW LQFUHDVH LQ WKH SHUFHQWDJH RI ȕ-
galactosidase positive cells, which was abolished by the pretreatment with A-
438079 antagonist (Figure 3F). These results prompted us to characterize the 
molecular pathway/s associated to the induction of senescence by P2X7 
receptor activity in TEM cells. 
Senescent  T cells are characterized by constitutive activation of p38 MAPK 
(Davis et al., 2010). Accordingly, western blot analysis of TEM cells treated with 
BzATP revealed an increased phosphorylation of p38 MAPK at site 
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Thr180/Tyr182 (Figure 4A). Moreover, pretreating WT TEM cells with the p38 
antagonists PD169316 and SB239063 prevented Cdkn1a upregulation 
mediated by P2X7 stimulation (Figure 4B). Next, we assessed the expression of 
other senescence-associated genes, including trp53 and the growth arrest and 
DNA damage inducible 45 beta (gadd45b) (Akbar et al., 2016). qRT-PCR 
revealed a significant increase both in trp53 and gadd54b transcripts in WT 
TEM cells treated with BzATP and, again, the pretreatment with A-438079 
restored the basal transcriptional level (Figure 4C).
The increase of ROS production is often seen in prematurely senescent cells
(Passos and Zglinicki, 2012). We measured mitochondrial ROS production at 
FACS in WT and P2rx7-/- TEM cells labelled with MitoSOX dye. Ex vivo WT 
cells produced higher levels of mitochondrial ROS compared to P2rx7-/- cells 
(Figure 4 D). When we stimulated WT cells with BzATP, we saw a significant 
increase in the percentage of MitoSOX positive cells that we prevented by 
pretreatment with A-438079 (Figure 4D). These data are consistent with the 
hypothesis that P2X7 receptor activity induces premature senesce in TEM cells. 
To further confirm this idea, we measured the phosphorylation of the histone 
+$; DW VHULQH  Ȗ-H2AX) (Siddiqui et al., 2015). Western blot analysis 
revealed an increaVH LQ Ȗ-H2AX at steady state in WT compared to P2rx7-/-
TEM cells. Moreover, P2X7 stimulation with BzATP further increased the 
PDJQLWXGH RI Ȗ-H2AX, while pretreatment with A-438079 abolished it (Figure 
4E). All these results clearly show that the absence or pharmacological 
inhibition of P2X7 prevent the induction of premature senescence in TEM cells.          
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Figure 4: P2X7 receptor signaling pathway. A) Western blot analysis on cell protein 
extracts from WT and P2rx7-/- TEM cells stimulated with anti-CD3 and anti-CD28 
antibodies for 3 days and treated as indicated. Samples were probed for p38 MAPK 
phosphorylated at Thr180/Tyr182 (Pp38), p38 total protein and GAPDH. Histograms 
represent the densitometric analysis of Pp38 normalized on total p38. Histograms 
shows mean ± SEM. B) Quantitative RT-PCR of Cdkn1a transcript performed on WT 
TEM cells either untreated, treated with BzATP, or treated with BzATP together with 
PD 169316 and SB 239063 and on P2rx7-/- TEM cells. Histograms show mean ± SEM. 
C) Quantitative RT-PCR of Trp53 and Gadd45b transcripts. The analysis was 
performed on purified WT and P2rx7-/- TEM cells stimulated as indicated. Histograms 
show mean ± SEM. E) Representative FACS plots and statistical analysis of WT TEM 
FHOOV ODEHOOHGZLWK0LWR62;DQG VWLPXODWHGZLWK%]$73ȝ0RU SUHWUHDWHGZLWK$-
ȝ0DQGP2rx7-/- TEM cells. Numbers in the plots indicate the percentage of 
MitoSOX positive cells and the histogram shows percentage mean ± SEM. F) Western 
blot analysis on cell protein extracts from WT and P2rx7-/- TEM cells stimulated with 
anti-CD3 and anti-CD28 antibodies for 3 days and treated as indicated. Samples were 
SUREHG IRU KLVWRQH +$; SKRVSKRU\ODWHG DW VHULQH  Ȗ-H2Ax), and GAPDH. 
Histogram represHQWV GHQVLWRPHWULF DQDO\VLV RI Ȗ-H2Ax normalized on GAPDH. 
Histograms show mean ± SEM.  Data are representative results of at least three 
independent experiments with 3 to 5 mice per experiment. A.U., Arbitrary Unit. * 
p<0.05, ** p<0.01, *** p<0.001.
Deletion of P2X7 receptor in CD4 T cells results in their accumulation in 
the tumor microenvironment
The tumor microenvironment imposes metabolic restriction that can mediate 
hyporesponsiveness of TILs through different mechanisms, including T cell 
senescence (Crespo et al., 2013). It was demonstrated that the tumor 
microenvironment is rich in ATP (Pellegatti et al., 2008), so we hypothesized 
that P2X7-mediated premature senescence through the upregulation of p21 
might limit TILs anti-cancer response. To address this, we reconstituted FGİ-/-
mice with CD4+ CD25- TEM cells deriving from WT or P2rx7-/- mice. After five 
days we injected subcutaneously B16 tumor cells and monitored the tumor 
growth for the next twenty days, when the mice were sacrificed (Figure 5A).  
FACS analysis of the tumor revealed a significant increase in the percentage of 
CD4+ TILs in mice injected with P2rx7-/- cells (Figure 5B). Histological analysis 
of tumor samples further confirmed an increased accumulation of P2rx7-/- than 
WT TEM cells in the tumor (Figure 5C), suggesting that the absence of the 
receptor confers a survival/proliferation advantage to TEM cells. Moreover, 
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FACS analysis of TILs showed a significant increase in the percentage of Ki-67 
positive in mice adoptively transferred with P2rx7-/- T cells compared to WT cells 
(Figure 5E), indicating that lack of P2X7 endow TEM cells with increased 
expansion potential within the tumor. Consistent with these results, qRT-PCR 
revealed a reduced expression of Cdkn1a transcripts in P2rx7-/- compared to 
WT TILs (Figure 5D). Despite the significant advantage of P2rx7-/- over WT 
TEM in tumor infiltration, the tumor size was not different in FGİ-/- mice 
reconstituted with TEM cells of the two genotypes (Figure 5F). 
Reconstitution of FGİ-/- mice with WT or P2rx7-/- CD4+ T naïve cells in the 
same experimental setting resulted in analogous outcome (Figure 5G). By 
FACS analysis we observed an increase in the percentage of CD4+ TILs in 
mice reconstituted with P2rx7-/- compared to WT cells (Figure 5H) and qRT-
PCR showed a reduction in Cdkn1a transcripts in P2rx7-/- cells (Figure 5I). Our 
results suggest that lack of P2X7 receptor supports the survival and the 
accumulation of CD4 T cells in the tumor microenvironment. However, in spite 
of enhanced infiltration we could not detect any difference in tumor size 
between mice injected with P2rx7-/- or WT cells. We hypothesized this 
phenomenon could be due to the absence of a direct cytotoxic effect of CD4 T 
cells against the tumor.
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Figure 5: P2rx7-/- CD4 T cells survive and accumulate more within the tumor than 
WT CD4 T cells. A) Schematic representation of the experimental procedure: 250.000 
WT or P2rx7-/- CD4+CD25- TEM were injected intravenously (i.v.) into FGİ-/- mice. 
After 5 days, 500.000 B16 tumor cells were injected subcutaneously (s.c.) and after 20 
GD\VWKHPLFHZHUHVDFULILFHG%)$&6SORWIRUVXUIDFH&'DQG7&5ȕDQGVWDWLVWLFDO
analysis of TILs from FGİ-/- mice reconstituted with WT or P2rx7-/- CD4 TEM cells. 
1XPEHUV LQ WKHSORW UHSUHVHQW WKHSHUFHQWDJHRI&'7&5ȕSRVLWLYHFHOOVZLWKLQ WKH
tumor. Histogram shows percentage mean ± SEM. C) Immunohistochemistry of tumor 
samples from FGİ-/- mice reconstituted with CD4 WT (left) or P2rx7-/- (right) TEM cells, 
labeled for CD3+ TILs (arrowhead). Histogram shows mean ± SEM of the number of 
CD3+ TILs per field analyzed. D) Quantitative RT-PCR for Cdkn1a transcript performed 
RQ&'7&5ȕ7,/V IURP cdİ-/- mice reconstituted with CD4 WT or P2rx7-/- TEM 
cells. E) Dot plots of FACS staining and statistical analysis for the nuclear antigen Ki-67
SHUIRUPHGRQ&'7&5ȕSRVLWLYHFHOOV LQWKHWXPRURIFGİ-/- mice reconstituted with 
CD4 WT or P2rx7-/- TEM cells. Numbers in the plot represent the percentage of Ki-67
positive cells. The histogram shows the mean percentage ± SEM. F) Analysis of tumor 
size (area in cm2) over time in FGİ-/- mice transplanted with 500.000 B16 tumor cells 
and injected with 250.000 CD4 WT or P2rx7-/- TEM cells. G) Schematic representation 
of experimental procedure: 250.000 WT or P2rx7-/- CD4+ CD25- T naive cells were 
injected intravenously (i.v.) into FGİ-/- mice. After 5 days, 500.000 B16 tumor cells 
were injected subcutaneously (s.c.) and after 20 days the mice were sacrificed. H) 
)$&6SORWDQGVWDWLVWLFDODQDO\VLV IRU&'DQG7&5ȕZLWKLQ WKH WXPRURIFGİ-/- mice 
reconstituted with CD4 WT or P2rx7-/- T naive cells. Numbers in the plot represent 
SHUFHQWDJHRI&'DQG7&5ȕSRVLWLYH cells. Histogram shows the percentage mean ± 
SEM. I) Quantitative RT-PCR for Cdkn1a transcript performed on CD4 TILs. Data are 
representative results of at least three independent experiments with 3 to 5 mice per 
experiment. A.U., Arbitrary Unit. * p<0.05, ** p<0.01. 
The ablation of P2X7 receptor in CD8 T cells improves their accumulation 
in the tumor microenvironment and results in reduction of tumor size
Unlike CD4 T cells, CD8 T cells exert a direct cytotoxic effect against tumor 
cells and because of this function their accumulation in the tumor is beneficial 
(Sorensen et al., 2012). This prompted us to investigate whether deletion of 
P2rx7 could contribute enhanced tumor infiltrating and cytotoxic activities to 
CD8 T cells. 
First, we analyzed P2rx7 expression in CD8 naïve and TEM cells. qRT-PCR 
revealed that both CD8 naïve and TEM cells express lower levels of P2rx7 
mRNA compared to CD4 TEM cells (Figure 6A). FACS analysis of DAPI 
permeability after stimulation with BzATP confirmed the reduced functionality of 
P2X7 receptor in CD8 compared to CD4 TEM cells (Figure 6B). 
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We measured cell proliferation at FACS after labelling cells with CellTrace violet 
and stimulating them with anti-CD3 and anti-CD28 antibodies. Interestingly, 
while 70 DQGȝ0%]$73KDGQRVLJQLILFDQWHIIHFWVRQWKHFHOOF\FOLQJDFWLYLW\
RI&'7FHOOVDKLJKHUFRQFHQWUDWLRQRI%]$73ȝ0LQGXFHGDEORFNDGH
in the cell cycle progression of CD8 TEM cells (Figure 6C), to a similar extent as 
lower concentrations in CD4 TEM cells (Figure 3D). Analysis of the expression 
of Cdkn1a by qRT-PCR showed a significant increase of transcripts when CD8 
TEM cells were treated with high concentration of BzATP and the pre-treatment 
with P2X7 antagonist A-438079 restored the basal level (Figure 6D).     
Thus, because the high concentrations of eATP present in the tumor 
microenvironment are compatible with inhibition of CD8 cells via P2X7, we 
repeated the adoptive transfer experiment on tumor bearing FGİ-/- mice with 
naïve CD8 cells derived from either WT or P2rx7-/- animals. We injected B16 
tumor cells 5 days after CD8 cells transfer and analyzed the tumor infiltrating 
cells 20 days later (Figure 6E). FACS analysis of the tumor revealed that the 
majority of TILs acquired a TEM-like phenotype. Moreover, we observed a 
significant increase in the percentage of tumor infiltrating CD8 T cells in mice 
reconstituted with P2rx7-/- cells as compared to those reconstituted with WT 
cells (Figure 6F). Interestingly, mice that received P2rx7-/- CD8 cells were able 
to control tumor growth with significantly increase efficacy than mice that 
received WT cells (Figure 6 G). These data suggest that, despite expression of 
lower levels of P2rx7 transcripts in CD8 T cells, P2X7 receptor influences the 
survival and proliferation of CD8 cells in the tumor microenvironment, which is 
very rich in eATP, Lack of P2X7 in both CD4 and CD8 T cells is beneficial in 
adoptive cellular immunotherapy against tumor, suggesting that inhibition of 
P2X7 receptor might be exploited for enhancing tumoricidal effect of adoptively 
transferred T cells in cancer immunotherapy.     
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Figure 6: P2rx7-/- CD8 T cells exert enhanced control on tumor size than WT cells.
A) Quantitative RT-PCR for P2rx7 transcript performed on CD4+ and CD8+ T naïve 
and TEM cells. Histogram shows the mean ± SEM. B) Time-monitoring of DAPI 
permeability at FACS after stimulation with BzATP of purified WT CD4 and CD8 T 
naïve and TEM cells. CD8 P2rx7-/- TEM cells were also tested as negative control. C) 
Representative CellTrace dilution and statistical analysis of purified CD8 WT and 
P2rx7-/- TEM cells stimulated with anti-CD3 and anti-CD28 antibodies for 3 days. CD8 
WT TEM cells were treated with increasing concentrations of %]$73ȝ0ȝ0
DQGȝ07KHQXPEHUV LQ WKH)$&6SORWVUHSUHVHQW WKHSHUFHQWDJHRIXQGLYLGHG
cells and the histogram shows the percentage mean ± SEM. D) Quantitative RT-PCR 
of Cdkn1a performed on CD8 WT TEM cells either untreated, treated with BzATP 200 
ȝ0 RU SUHWUHDWHG ZLWK $-  ȝ0 ( 6FKHPDWLF UHSUHVHQWDWLRQ RI WKH
experimental procedure: 250.000 WT or P2rx7-/- CD8+ CD25- T naive cells were 
injected intravenously (i.v.) into FGİ-/- mice. After 5 days, 500.000 B16 tumor cells 
were injected subcutaneously (s.c.) and after 20 days the mice were sacrificed. F) Dot 
SORWVRI)$&6VWDLQLQJIRU&'DQG7&5ȕSRVLWLYHFHOOVLQWKHWXPRUDQGGLVWULEXWLRQIRU
CD44 and CD62L staining from FGİ-/- mice reconstituted with CD8 WT or P2rx7-/- T
naïve cells. Numbers in the plots represent the percentage of TILs and the histograms 
show the mean percentage ± SEM. G) Analysis of tumor size (area in cm2) in FGİ-/-
mice reconstituted with CD8 WT or P2rx7-/- T naïve cells and injected with B16 tumor 
cells. Data are representative results of at least three independent experiments with 3 
to 5 mice per experiment. A.U., Arbitrary Unit. * p<0.05, ** p<0.01 *** p<0,001.
P2RX7 silencing confers an advantage in cell proliferation and survival to 
human CD4 TEM cells
In order to see if P2X7 receptor has the same function in human T cells, we 
isolated human CD4 TEM cells and transfected them with P2RX7 siRNA to 
silence its expression, and then analyzed cell proliferation. After siRNA 
transfection, we measured by qRT-PCR a partial but significant downregulation 
of P2RX7 transcript in human TEM cells compared to cells transfected with a 
control siRNA (Figure 7A). Thus, we analyzed at FACS cell proliferation of 
transfected TEM cells labeled with CellTrace violet, after stimulation with anti-
CD3 and anti-CD28 antibodies. After five days, CellTrace dilution clearly 
showed that TEM cells transfected with P2RX7 siRNA proliferated significantly 
more than cells transfected with control siRNA (Figure 7B). 
Thus, we measured CDKN1A expression by qRT-PCR and we observed a 
significant reduction of the transcript in TEM cells transfected with P2RX7
siRNA compared to control cells (Figure 7C). Interestingly, when we stimulated 
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control TEM cells with BzATP we measured a significant increase in CDKN1A
expression, as detected in mouse P2rx7-/- TEM cells (Figure 7C and 3C), 
suggesting that also in human cells P2X7 stimulation controls the transcription 
of CDKN1A and could be involved in the induction of premature senescence of 
T cells. 
To see whether P2X7 activity could condition human TEM cells function in the 
tumor microenvironment, we cultured human TEM cells in medium conditioned 
with HeLa cells supernatant and measured the percentage of dead cells. FACS 
staining for annexin V and propidium iodide (PI) revealed a significant reduction 
in the double positive population in TEM cells transfected with P2RX7 siRNA 
compared to TEM cells transfected with control siRNA (Figure 7D), indicating 
that silencing of P2RX7 conferred resistance to cell death induced by ATP 
released by tumor cells. These data shows that inhibition of P2X7 activity
confers a survival and cell proliferation advantage to human TEM cells, making 
P2X7 receptor a possible target to enhance tumor immunotherapy.  
67 
 
Figure 7: P2RX7 silencing in human TEM cells promotes cell survival and 
proliferation. A) Quantitative RT-PCR for P2RX7 transcript performed on human CD4 
TEM cells transfected with P2RX7 siRNA (siRNA) or with a control siRNA (Ctrl). 
Histograms show the mean ± SEM. All values were normalized on Ctrl values. B) 
Representative CellTrace dilution and statistical analysis of purified human TEM cells 
(transfected as indicated above) stimulated with anti-CD3 and anti-CD28 antibodies for 
5 days. The graph represents means ± SEM (Y axis) of cell percentages within each 
cell division (X axis). C) Quantitative RT-PCR for CDKN1A transcript performed on Ctrl 
&'7(0FHOOVZLWKRUZLWKRXW%]$73ȝ0DQG7(0FHOOVWUDQVIHFWHGZLWKP2RX7
siRNA. Histograms show the means ± SEM. D) FACS plot and statistical analysis of 
Annexin V and propidium iodide (PI) staining performed on human Ctrl and P2RX7
siRNA TEM cells cultured with HeLa cells supernatant. Numbers in the plots represent 
the percentage of Annexin V and PI positive cells. The histograms show the 
percentage means ± SEM. A.U., Arbitrary Units. * p<0.05, ** p<0.01 *** p<0,001.
Lack of P2X7 receptor results in increased mitochondrial fusion and 
metabolic advantage of TEM cells
Morphological changes in mitochondria represent a primary signal in metabolic 
reprogramming during cellular quiescence or activation. In particular, 
mitochondrial fusion is considered a survival mechanism that enhances 
longevity in T cells (Gomes et al., 2011). This prompted us to characterize the 
morphology of mitochondria in TEM cells. Transmission electron microscopy 
performed on WT or p2rx7-/- TEM cells stimulated with anti-CD3 and anti-CD28 
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antibodies revealed significant differences in mitochondrial dimensions between 
the two genotypes (Figure 8A). We measured a significant increase in both the 
mitochondrial area and perimeter of P2rx7-/- TEM cells (Figure 8B and 8C), 
while no differences were seen in the circularity of the organelles (Figure 8D).
We therefore analyzed by western blot the levels of mitochondrial inner 
membrane fusion protein Opa1, which was demonstrated to be fundamental for 
memory T cells generation (Buck et al., 2016), and fission protein Drp1. 
Consistent with morphological data, we detected an increase in Opa1 and a 
decrease in Drp1 levels in P2rx7-/- compared to WT TEM cells (Figure 8E). 
These data suggest that mitochondria are poised to fusing in P2rx7-/- TEM cells.
Recent work demonstrates that fused mitochondria are characterized by tighter 
cristae compared to fissed mitochondria. Tight cristae favor electron transport 
chain activity, therefore mitochondrial fusion favors oxidative phosphorylation 
(Sena et al., 2013). Given the different phenotype of mitochondria, we analyzed 
the bioenergetic profile of P2rx7-/- and WT TEM cells with the Seahorse 
technique in response to secondary stimulation with oligomycin (ATP synthase 
inhibitor), followed by FCCP (oxidative phosphorylation uncoupler) and 
rotenone with antimycin A (ETC complex I and III inhibitors), all drugs that 
stress the mitochondria. From the analysis of the metabolic profile we could 
reveal an increase in metabolic activity in P2rx7-/- compared to WT TEM cells, 
shown by the increased oxygen consumption rate (OCR) (Figure 8F). These 
data indicate that lack of P2X7 confers a metabolic advantage by using 
mitochondrial respiration over glycolysis.  
Altogether these results unravel an inhibitory function for P2X7 receptor in TEM 
cells unraveling a novel role for P2X7 as a checkpoint inhibitor molecule.
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Figure 8: : P2rx7-/- TEM cells are characterized by fused mitochondria and 
metabolic advantage. A) Electron micrographs showing the entire cell (above) and a 
detail of mitochondria (below) of WT and P2rx7-/- 7(0 FHOOV 6FDOH EDUV  ȝP %
Statistical analysis of area, perimeter (C) and circularity (D) of mitochondria in WT and 
P2rx7-/- cells. Histograms show the mean ± SEM. E) Protein quantification by western 
blot of inner membrane fusion protein Opa1 and fission protein Drp1. Histograms 
represent the densitometric analysis of the proteins normalized on GAPDH. F) 
Seahorse metabolic profile showing OCR measurement of WT and P2rx7-/- TEM cells 
at baseline, after stimulation with oligomycin, FCCP and rotenone plus antimycin A 
(R+A). Shown are means ± SEM. Data are representative results of two independent 
experiments with 5 mice for experiment. *** p<0,001.
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DISCUSSION 
Nucleotides such as ATP or UTP are mainly found inside cells, nevertheless 
they are also released in the extracellular space by different mechanisms and 
play important functions in intercellular communication. An important
mechanism of nucleotide release is represented by cell damage and death: 
apoptotic and necrotic cells release ATP as a danger signal or damage 
associated molecular pattern (DAMP) (Idzko et al., 2007). In the absence of cell 
death, mechanical stimulation, hypoxia or pathogens invasion, or specific 
release pathways such as membrane channels, vesicular transport and 
exocytosis of granules, are involved in the secretion of ATP outside the cell 
(Burnstock and Boeynaems, 2014). ATP released during tissue damage acts as 
a DAMP for the cells of the innate immune system through stimulation of P2X7 
receptor. P2rx7, which encodes for the P2X7 receptor, is a signature gene of 
effector T cell subsets (Choi et al., 2013 J of immunology; (Hale et al., 2013; 
Hashimoto-Hill et al., 2017; Hill et al., 2008), but its role in these cells has been 
poorly investigated. Early studies suggested that CD4 T cells in peripheral 
lymph nodes are sensitive to P2X7-induced cell death (Haag et al., 2002; 
Seman et al., 2003), but it is unclear whether there is any specificity in P2rx7 
expression for specific T cell subsets or differentiation stages. We have shown 
that P2rx7 is the most expressed member of the P2rx gene family both in T 
naïve and T effector/memory (TEM) cells, but it is selectively and robustly 
upregulated in TEM cells. P2rx7 expression correlates with its functionality. 
Indeed, TEM cells stimulated with a selective P2X7 agonist becomes 
permeable to DAPI, in agreement with the formation of a cytolytic pore, which is 
permeable to molecules with size up to 1.4 nm (Browne et al., 2013).
Effector memory T cells are generated following priming of naïve clones in 
secondary lymphoid organs by antigen presentation though class II major 
histocompatibility complex  (MHC II) on antigen presenting cells (APC). Once 
the pathogen is cleared during primary response, the majority of effector cells 
are eliminated during the contraction phase of the adaptive immune response, 
but a small population of long-lived cells will constitute the memory pool of 
antigen experienced T cells. This pool of memory T cells can be classified as 
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TEM and T central memory (TCM) cells. TEM cells migrate to inflamed 
peripheral tissues and provide immediate effector response, while TCM cells 
home to secondary lymphoid organs and differentiate to effector cells in 
response to a second antigenic stimulation (Sallusto et al., 2004). Memory T 
cells differ from naïve cells because of their lower activation threshold and more 
vigorous expansion following antigen encounter. Moreover, TEM cells can 
proliferate in the absence of antigen in response to cytokines (Kondrack et al., 
2003). Understanding cell intrinsic programs that regulate TEM cells lifespan 
and expansion have implications in both physiological and pathological 
conditions, such as autoimmune diseases, transplant rejection, cancer and 
aging of the immune system. 
It was recently demonstrated that P2X7 receptor mediates cell death within the 
intestinal effector T cells pool, preventing aberrant buildup of activated T cells 
(Hashimoto-Hill et al., 2017). According to that, our results show that the 
absence of P2X7 receptor confers an increased half-life and survival to TEM 
cells in vitro. Moreover, we uncovered a role for P2X7 receptor in regulating T 
cell cycling activity. We found that both in antigen-driven and cytokine-driven 
expansion P2rx7-/- TEM cells are characterized by a proliferative advantage 
compared to WT TEM cells. This feature was also confirmed in vivo in a model 
of homeostatic expansion. 
Interestingly, P2X7 activation promotes a block in the cell cycle progression in a 
dose dependent manner, while absence of P2X7 receptor or pharmacological 
antagonism unleashes TEM cells from the homeostatic control of survival and 
expansion.  We demonstrated that P2X7 activation regulates the transcription of 
Cdkn1a as a key negative regulator of cell cycle progression and inducer of 
premature senescence in TEM cells. Cdkn1a encodes for p21waf1/Cip1 protein 
and its expression correlates with P2rx7 expression. The P21waf1/Cip1 signaling 
pathway actively contributes to the stability of the G0 arrest in senescent cells 
and is constantly upregulated after the induction of senescence (d'Adda di 
Fagagna et al., 2003). We found that P2X7 signaling results in the activation of 
p38 MAPK, the upregulation of Trp53 and Gadd45b expression as well as in 
triggering of a DNA damage response induced by increased mitochondrial ROS 
production, all features associated to cellular senescence (Passos et al., 2010).
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It is naturally thought that senescence is associated with the physiological aging 
process, however, tumor cells for example can induce premature T cell 
senescence. In addition to phenotypic changes, senescent T cells are 
characterized by defective cytotoxicity and development of immunosuppressive 
regulatory functions, thereby becoming less efficient in controlling tumor burden 
(Akbar and Henson, 2011; Appay et al., 2000). Senescent CD8 T cells were 
observed in patients with lung (Meloni et al., 2006) as well as head and neck 
cancers (Tsukishiro et al., 2003). The microenvironment of solid tumors is 
characterized by high levels of extracellular ATP (Pellegatti et al., 2008), which 
is important for the activation and the recruitment of immune cells and improves 
efficacy of chemotherapy (Michaud et al., 2011). Moreover, ATP activates 
NLRP3 inflammasome in tumor infiltrating DCs driving IL-1ȕ secretion that in 
turn promotes the polarization of IFNȖ-producing CD8 T cells, thus eliciting anti-
cancer immune response (Aymeric et al., 2010). With a chimeric model of 
melanoma we demonstrated that adoptively transferred P2rx7-/- CD4 TEM or 
naïve cells, despite their lack of effect on the control of tumor size, proliferate 
more vigorously and accumulate to a greater extent within the tumor than WT 
cells. Notably, we showed that the adoptive transfer of CD8 T cells from P2rx7-/-
mice, in addition to the increased infiltration of the tumor microenvironment, also 
resulted in a significant reduction of tumor size. CD8 TEM cells express a lower 
level of P2rx7 transcripts and they are less sensitive to BzATP stimulation as 
compared to CD4 TEM cells. However, when stimulated with high amounts of 
BzATP, as found in the tumor microenvironment (Pellegatti et al., 2008), CD8 
TEM cells upregulate Cdkn1a, which mediates a block in cell cycle progression. 
This evidence suggests that P2X7 is a general regulator of T cell senescence 
and function that might be targeted in cancer immunotherapy to achieve 
enhanced tumoricidal effect by TILs.
In the last years the function of P2X7 receptor in cancer biology has been 
intensively investigated (Di Virgilio and Adinolfi, 2017; Roger et al., 2015).
Recently, it was proposed that cancer cells can undergo immunogenic cell 
death upon exposure to selected chemotherapeutic drugs or radiotherapy. This 
process would rely on the release by dying cells of  factors that facilitate antigen 
presentation to T cells by DCs (Galluzzi et al., 2017). The immunogenicity of 
this kind of cell death depends on the release of intracellular molecules such as 
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different proteins and ATP (Ghiringhelli et al., 2009). Immunogenic cell death 
turned out to be important for understanding the mechanisms whereby the anti-
cancer immune response could affect the outcome of anti-cancer therapy. 
Within this framework, the P2X7 receptor should have a prominent role in 
conditioning the host immune system towards a beneficial inflammatory 
response against the tumor. Our results show that the selective targeting of 
P2X7 in T cells infiltrating the tumor might avoid premature senescence and 
promote T cell anti-tumor response. Therefore, while contributing to tumor 
eradication by synergizing with chemotherapy, extracellular ATP might act in an 
opposite way on the adaptive branch of the anti-tumor response by limiting the 
lifespan and function of T cells.
Interestingly, human TEM cells, in which P2RX7 is silenced, are characterized 
by increased proliferation and downregulation of CDKN1A. These data show 
that blocking P2X7 receptor in tumor infiltrating lymphocytes may be a 
translatable treatment for enhancing human cancer immunotherapy.
It was recently shown that metabolic programming in T cells is regulated in part 
by mitochondria remodeling. Memory T cells are characterized by fused 
mitochondria, which correlate with more efficient OXPHOS, thanks to a tighter 
cristae organization. This feature is associated to longevity and improves 
adoptive cellular immunotherapy against tumors (Buck et al., 2016; Klein 
Geltink et al., 2017). In line with this, we demonstrated that P2rx7-/- TEM cells 
are characterized by enlarged mitochondria as compared to WT TEM cells, 
likely due to increased expression of the mitochondrial fusion protein Opa1 and 
a decrease in the mitochondrial fission protein Drp1. This results in a more 
efficient OXPHOS as revealed by increased OCR in P2rx7-/- compared to WT 
TEM cells. Our data suggest a model where P2X7 receptor is an important 
molecule for the regulation of TEM cells survival and function. It is primarily
involved in the activation of the p38 MAPK/p53/p21 signaling pathway and 
mediates the induction of premature senescence in TEM cells. All these 
features unravel a new role for P2X7 receptor as a check point inhibitor in TEM 
cells and a possible new target in cancer immunotherapy.     
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Abstract 
The melastatin-like transient-receptor-potential-7 protein (TRPM7), harboring a cation 
channel and a serine/threonine kinase, has been implicated in thymopoiesis and cytokine 
expression. Here we show, by analyzing TRPM7 kinase-dead mutant (Trpm7R/R) mice, 
that the enzymatic activity of the receptor is not essential for thymopoiesis, but is 
required for CD103 transcription and gut-homing of intraepithelial lymphocytes (IEL). 
Defective T cell gut colonization reduces MHCII expression in intestinal epithelial cells. 
Mechanistically, TRPM7 kinase activity controls TGF-β-induced CD103 expression and 
pro-inflammatory T helper 17 cell (TH17), but not regulatory T cell (Treg), 
differentiation by modulating SMAD2. Notably, we find that the TRPM7 kinase activity 
promotes gut colonization by alloreactive T cells in acute graft-versus-host disease. Thus, 
our results unravel a function of TRPM7 kinase in T cell activity and suggest a 
therapeutic potential of kinase inhibitors in averting acute graft-versus-host disease. 
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Introduction 
The antigen-rich environment of the gut interrelates with a highly specialized mucosal 
immune system, mastering the challenge of preventing invasion and systemic spread of 
microbes while avoiding unnecessary immune reactions to commensal bacteria. Besides 
representing a physical barrier, the intestinal epithelium constitutes also a dynamic 
interface between the host immune system and the luminal environment, which harbours 
potentially harmful microbes. Therefore, maintenance of the protective barrier is essential 
in mucosal immunity, and intraepithelial lymphocytes (IEL) have an important function 
in maintaining this barrier function1. The intestinal mucosa is composed of a single layer 
of columnar epithelial cells, the underlying lamina propria and the muscularis mucosa. 
Tight junctions, components of the apical junctional complex, seal the paracellular space 
between epithelial cells. IELs are located above the basement membrane, but are 
subjacent to tight junctions. The lamina propria is located beneath the basement 
membrane and contains immune cells, including macrophages, dendritic cells and lamina 
propria lymphocytes (LPL)2. Intestinal T cells are highly heterogeneous in phenotype and 
function and include both conventional and unconventional subpopulations. Conventional 
mucosal T cells express the  T cell receptor (TCR) together with CD4 or CD8
 as co-receptors, whereas unconventional mucosal T cells express either TCR 
or TCR together with CD8 homodimers1. During their activation in specialized 
mesenteric lymph nodes or Peyer’s Patches, naïve T cells acquire gut-homing properties 
through the upregulation of distinct adhesion receptors including the integrins 47 and 
E7 (CD103)
3, 4. Moreover, the resident microbiota regulates the development of 
specific lymphocyte subsets in the gut. CD4+ T helper 17 (TH17) cells preferentially 
accumulate in the intestine, indicating a developmental regulation by gut-intrinsic 
mechanisms5. Forkhead box P3 (FoxP3) expressing regulatory T (Treg) cells represent 
another CD4+ T helper (TH) cell subset that preferentially accumulates in the intestine and 
contributes to gut homeostasis. The regulated induction of pro-inflammatory TH17 and 
immunosuppressive Treg cells in the gut illustrates the importance of an equilibrium 
between effective immunity and tolerance to preserve tissue integrity1. However, the 
mechanisms responsible for this physiologic balance are not well understood. The 
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induction of both these TH subsets depends on TGF-, which is abundantly present in 
the intestine6, 7.  
Among the mammalian transient receptor potential (TRP) superfamily of unselective 
cation channels, the TRPM subfamily, named after its founding member melastatin, 
TRPM18, comprises 8 members including the dual-function protein, TRPM7. TRPM7 is 
a divalent selective cation channel, mainly conducting Mg2+, Ca2+ and Zn2+, fused to a C-
terminal -kinase domain9, 10. TRPM7 has been implicated in cell survival, proliferation, 
apoptosis as well as migration and immune cell function. However, the physiologic 
function of TRPM7 ion channel or enzymatic activity is poorly understood11, 12. Unlike 
conventional kinases, TRPM7 kinase does not recognize known specific amino acid 
motifs but phosphorylates serines (Ser) and threonines (Thr) located within alpha-
helices10. TRPM7 contains a Ser/Thr-rich autophosphorylation site, which aids in 
TRPM7-substrate binding13. In vitro, TRPM7 kinase phosphorylates annexin A110, 14, 
myosin II isoforms15, eEF2-k16 and PLCγ217. 
Deletion of the ubiquitously expressed TRPM7 protein is embryonic lethal18, 19. Deletion 
of the exons encoding only the TRPM7 kinase domain (Trpm7K/K) also causes early 
embryonic death, most probably attributable to reduced channel function in this mutant19. 
However, heterozygous mice (Trpm7+/  K) are viable and develop severe hypo-
magnesaemia upon Mg2+ restriction, causing increased mortality, susceptibility to 
seizures, and prevalence for allergic hypersensitivity19. Interestingly, homozygous mice 
with genetic inactivation of TRPM7 kinase activity by a point mutation within the active 
site of the kinase (K1646R, Trpm7R/R) have no obvious phenotype20, 21, indicating that the 
Trpm7+/K phenotype, is due to decrease in both channel and kinase activity. Moreover, 
analysis of these mouse models revealed that TRPM7 kinase activity regulates mast cell 
degranulation and histamine release, implicating TRPM7 in the hyper-allergic phenotype 
observed previously22. Tissue-specific deletion of Trpm7 in the T cell lineage disrupts 
thymopoiesis and results in altered chemokine and cytokine expression profiles18, 
indicating that TRPM7 channel and/or kinase are important for T cell function.  
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Here we show that the ubiquitous kinase-dead mouse model, Trpm7R/R, with a single 
point mutation at the active site of the kinase21 has an exquisite requirement for TRPM7 
kinase activity in intra-epithelial T cell homeostasis. We find that gut colonization by 
alloreactive T cells in acute graft-versus-host disease depends on TRPM7 kinase activity 
indicating a therapeutic potential of kinase inhibitors in averting this condition. 
Results 
TRPM7 kinase does not affect channel activity 
To investigate the impact of the TRPM7 kinase on T cell function, we utilized a mouse 
model carrying a point mutation at the active site of the enzyme21. Mutating lysine at 
position 1646 to arginine (Trpm7R/R) disrupts ATP-binding and thereby kinase activity 
(Supplementary Fig. 1a)21. Using immunoprecipitation and Western Blot analysis, we 
were able to confirm that the mutation indeed disrupted native kinase activity and thus 
auto-phosphorylation at serine 1511 in primary splenocytes (Supplementary Fig. 1b). 
Unlike mice lacking the entire kinase domain19, homozygous Trpm7R/R mice are viable20, 
21. They are normal in size, weight, and Mendelian inheritance ratio compared to WT20, 21. 
To test whether inactivation of TRPM7 kinase has any effect on Mg2+ and Ca2+ 
homeostasis, we used inductively coupled mass spectrometry (ICP-MS), biochemical as 
well as calcium-imaging techniques. By ICP-MS we observed no changes in serum Mg2+ 
and Ca2+ concentrations (Supplementary Fig. 1c,d). Cellular ATP levels are often taken as 
an estimate for intracellular Mg2+ contents23. Therefore, we performed a luciferin 
luciferase assay and found no alterations in intracellular ATP levels between WT and 
Trpm7R/R primary naïve CD4+ T cells (Supplementary Fig. 1e). To determine basal 
intracellular free Ca2+ concentrations ([Ca2+]i), we used ratiometric Fura-Red imaging. No 
significant differences in [Ca2+]i between WT and Trpm7
R/R primary naïve CD4+ T cells 
were detected (Supplementary Fig. 1f). Further, we assessed the potential function of 
kinase activity in the regulation of biophysical features of the TRPM7 channel. Whole 
cell patch-clamp experiments revealed that the channel function is unaltered in primary 
peritoneal mast cells (Supplementary Fig. 1g,h) as well as in naïve CD4+ T cells 
(Supplementary Fig. 1j), which is in line with previous reports on peritoneal macrophages 
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and mast cells, as well as embryonic fibroblasts isolated from Trpm7R/R mice20, 21, 22. 
Trpm7R/R channels display slightly decreased Mg2+-sensitivity without obvious 
consequences for the channel activity at physiologic Mg2+ levels (Supplementary Fig. 1i). 
As already shown, serum Mg2+ and Ca2+ concentrations were unaffected (Supplementary 
Fig. 1c,d)21. This overall constellation allowed us to independently investigate TRPM7 
kinase function.  
TRPM7 kinase affects serum cytokines but not thymopoiesis 
Tissue-specific deletion of Trpm7 in the T cell lineage was shown to disrupt 
thymopoiesis and resulted in altered chemokine and cytokine expression profiles18, 
indicating that TRPM7 channel and/or kinase are important in T cell development. Our 
TRPM7 kinase-dead mouse model, Trpm7R/R, allows us to specifically address the 
function of TRPM7 kinase activity in T cells. The total numbers of thymocytes, as well 
as the percentages of double negative (DN, CD4-CD8-), double positive (DP, CD4+CD8+) 
and single positive (SP, CD4+CD8-, CD4-CD8+) thymocytes were similar in both 
genotypes (Fig. 1a-c). Tissue-specific deletion of Trpm7 in the T cell linage affected 
thymopoiesis through a block in the transition from the DN3 (CD25+CD44-) to the DN4 
(CD25-CD44-) stage18. However, in the kinase-dead Trpm7R/R mutant the distribution of 
DN3 and DN4 thymocytes was unaltered with respect to WT (Fig. 1d-f), indicating that 
the kinase activity is not responsible for the thymic phenotype observed previously.  
In spite of normal T cell development and similar to T cell specific conditional Trpm7-/- 
mice18, the Trpm7R/R mutant had a significant reduction of pro-inflammatory cytokines in 
the serum, including G-CSF and IL-17A. Also IL-1ß, IL-3, IL-4, IL-9, IL-10, IL12p70, 
IL-13, GM-CSF, IFN-γ and TNF were reduced, albeit not significantly (Fig. 1g), thus 
indicating a function of the TRPM7 kinase in shaping the cytokine secretion profile.  
In vitro activation of CD4+ T cells derived from Trpm7R/R mice using αCD3/αCD28 
coated plates resulted in slightly reduced intracellular Ca2+ signalling compared to WT 
cells (Supplementary Fig. 2a). Although Trpm7R/R T cells had similar kinetics of receptor-
operated Ca2+ entry (ROCE) compared to WT T cells, Ca2+ amplitudes in Trpm7R/R T cells 
were significantly different at 150 seconds compared to WT (Supplementary Fig. 2a). 
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Nonetheless, the proliferation rates were similar between the two genotypes, indicating 
no primary defect of Trpm7R/R mice in T cell activation (Supplementary Fig. 2b,c).  
TRPM7 kinase promotes T cell colonization of gut epithelium 
While T cell subsets in the spleen and peripheral lymph nodes were distributed normally 
in Trpm7R/R mice (Supplementary Fig. 3a,b), we found a strong reduction of all T cell 
subsets in the intestinal epithelium (Fig. 2a,c) and the lamina propria (LP) (Fig. 2b,d) by 
FACS analysis. Notably, LPLs as well as CD4+ TCRαβ+ IELs were particularly affected 
by the lack of TRPM7 kinase activity (Fig. 2a,b). In line with these findings, the analysis 
of the distribution of CD3+ T cells in tissue sections of the small intestine from Trpm7R/R 
mice revealed a significant reduction of IELs compared to WT (Fig. 2e). The presence of 
IELs correlates with the induction of MHCII expression on epithelial cells24. Consistent 
with the significant reduction of IELs, we detected a dramatic reduction of MHCII 
expression in EpCAM+ intestinal epithelial cells in Trpm7R/R compared to WT mice (Fig 
2f). Analysis of the transcriptional profile of the few IELs that were present in Trpm7R/R 
mice revealed no differences in T-bet or FoxP3 expression when compared to WT, 
indicating a normal TH1 and Treg polarization, respectively. However, the signature 
transcription factor for TH17 cells, Rorc, was significantly reduced in Trpm7
R/R IELs 
compared to WT that was also reflected by significantly reduced IL-17 expression (Fig. 
2g). These findings were confirmed by intracellular staining via FACS for IFN-γ and IL-
17A in IELs isolated from WT and Trpm7R/R mice. While IFN-γ secreting cells were 
comparable between Trpm7R/R and WT IELs, IL-17A secreting cells were significantly 
diminished in Trpm7R/R compared to WT IELs (Fig. 2h).  
Defect in gut epithelium colonization is T cell intrinsic 
In the intestinal epithelium the up-regulation of CD103 is required, specifically integrin 
αEβ7, which in turn interacts with E-cadherin on the epithelial cells and thus facilitates the 
retention of IELs into the epithelial layer25, 26. Interestingly, CD103 and integrin β7 
expressing CD4+ IELs were highly significantly reduced in Trpm7R/R mice, while CD8+ 
IELs were only slightly, albeit significantly, reduced and α4β7 expressing cells were 
unaffected (Fig. 3a). The analysis of CD4+ and CD8+ LPLs revealed a similar reduction in 
CD103 expression in Trpm7R/R mice compared to WT (Fig. 3b). However, integrin β7 
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expressing CD8+ LPLs were unaffected in Trpm7R/R mice compared to WT (Fig. 3b). 
Also the mean fluorescence intensity (MFI) of CD103 expression was significantly 
reduced in Trpm7R/R CD4+ and CD8+ IELs as well as CD4+ and CD8+ LPLs compared to 
WT cells (Fig. 3c,d). Correspondingly, the MFI of the integrin β7 was similarly reduced 
(Fig. 3c,d). At the transcriptional level, analysis of the gene encoding CD103, Itgae, via 
quantitative real-time (qRT)-PCR revealed significantly reduced Itgae mRNA expression 
in lymphocytes isolated from the spleen, LP and intestinal epithelium of Trpm7R/R 
compared to WT mice (Fig. 3e). 
To rule out the contribution of other cells to the reduction of IELs and LPLs as well as 
CD103 expression, we further examined intestinal epithelial as well as dendritic cells. 
Transmission electron microscopic images of the ileum (upper panel) and the colon 
(lower panel) of WT and Trpm7R/R mice illustrate no changes in overall structure, tight 
junction, adherens junction or desmosome formation (Fig 4a), indicating no primary 
difference between the epithelial barrier of WT and Trpm7R/R mice. Interestingly, MHCII 
as well as CD103 surface expression of WT and Trpm7R/R dendritic cells was unaltered 
(Fig. 4b), suggesting that dendritic cell function is not affected by the TRPM7 kinase. 
Consistently, Trpm7 mRNA levels were strongly reduced in DCs as well as in epithelial 
cells, compared to T cells (Supplementary Fig. 3c). 
CD103 expression strongly depends on TGF-β stimulation27. The analysis of TGF-β1, 2 
and 3 mRNA levels in dendritic as well as intestinal epithelial cells, two main sources of 
TGF-β in the gut, did not reveal significant differences between WT and Trpm7R/R mice 
(Fig. 4c). Moreover, we did not detect any difference in TGF-β serum levels between the 
different mice (Fig. 4d). Notably, TGF-β1 was the most prominent isoform in serum, 
while TGF-β3 was not detectable. 
To confirm that the reduced number of IELs and LPLs in Trpm7R/R mice was T cell 
intrinsic, we adoptively transferred either WT or Trpm7R/R naïve CD4+ cells into congenic 
Rag1-/-/Il2rg-/- double mutant mice, lacking T- and B- as well as natural killer cells. While 
both WT and Trpm7R/R naïve T cells equally reconstituted the spleen, Trpm7R/R T cells 
exhibited an intrinsic defect in colonizing the intestinal epithelium (Fig. 4e). Trpm7R/R 
CD4+ IELs poorly, if at all, expressed CD103 (Fig. 4f), thereby indicating that the defect 
of IEL retention within the small intestinal epithelium was T cell autonomous. Moreover, 
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lymphopenic hosts adoptively transferred with naïve CD4+ T cells from Trpm7R/R mice 
had significantly impaired upregulation of MHCII in intestinal epithelial cells (Fig. 4g).  
TRPM7 kinase regulates TGF-β/SMAD pathways 
As Trpm7R/R IELs displayed a pronounced reduction in Rorc and IL-17 expression while 
T-bet and FoxP3 were equivalent in Trpm7R/R compared to WT IELs (Fig. 2g), we
addressed whether in vitro differentiation of naïve CD4+ Trpm7R/R T cells would 
reproduce this phenomenon. After polarization of naïve T cells into TH1 or Treg for 5 days 
using the respective cytokine and inhibitory-antibody cocktails (see methods), we 
observed no differences in the percentage of IFN-γ or CD25+FoxP3+ T cells between the 
two genotypes (Fig. 5a, left and middle panel). Interestingly, in vitro polarization of naïve 
CD4+ T cells into TH17 cells, using TGF-β, IL-6 and αIFN-γ, was significantly reduced 
in Trpm7R/R compared to WT cells (Fig. 5a, right panel), consistent with the robust 
reduction of IL-17 concentration in serum from Trpm7R/R mice (Fig. 1g) as well as the 
diminished number of IL17-producing Trpm7R/R IELs (Fig. 2h). In contrast, T-bet and Ifn-
γ mRNA levels were not different among in vitro differentiated Trpm7R/R and WT TH1 
cells (Fig. 5b). Since Rorc and IL-17 mRNA levels were significantly reduced in in vitro 
differentiated Trpm7R/R TH17 cells (Fig. 5b), we analysed STAT3 signalling as a 
signalling pathway involved in TH17 differentiation. However, Western Blot analysis of 
CD4+ T cells treated with IL-6 for 15 and 30 minutes showed no differences in STAT3 
phosphorylation at Tyr705 (Fig. 5c).  
Next, we asked whether the defect in CD103 expression in vivo was also reflected in 
vitro. To this end, naïve CD4+ T cells were treated with TGF-β1, stimulated with 
αCD3/αCD28 and analyzed for CD103 and integrin β7 surface expression by FACS. 
Interestingly, Trpm7R/R CD4+ T cells were characterized by a significant reduction in 
CD103 and integrin β7 expression (Fig. 5d). While WT naïve CD4
+ T cells increased 
Itgae gene expression two fold, Trpm7R/R naïve CD4+ T cells were unable to up-regulate 
Itgae expression after 24 hours stimulation (Fig. 5e), suggesting a transcriptional 
regulation of CD103 via the TRPM7 kinase. Since TGF-β was shown to up-regulate 
CD103 via SMAD and NFAT pathways in human T cells28, we addressed whether the 
TGF-β/SMAD signalling pathway was affected by TRPM7 kinase activity, particularly 
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as TGF-β/SMAD pathways are also crucial for the polarization of CD4+ T cells into TH17 
cells29. Importantly, Western Blot analysis of Trpm7R/R naïve CD4+ T cells treated with 5 
ng ml-1 TGF-β1 for 10 minutes revealed a strong and significant reduction in SMAD2 
(Ser465/467) phosphorylation (Fig. 5f, upper row and middle panel), while SMAD3 
(Ser423/425) phosphorylation was unaltered (Fig. 5f, middle row and right panel). 
Consistently, SMAD2 translocation into the nucleus was significantly impaired in 
Trpm7R/R T cells compared to WT (Fig. 6a). Thus, we conclude that the TRPM7 kinase 
regulates TH17 differentiation and Itgae expression via TGF-β/SMAD2 dependent 
pathways.  
To further clarify the mechanism by which TRPM7 kinase activity controls TGF-
β/SMAD2 signalling, we performed an in vitro kinase assay using highly purified 
recombinant TRPM7 kinase, SMAD2-GST, as well as C-terminally truncated SMAD2-
GST and GST-tag as controls. Remarkably, TRPM7 phosphorylates SMAD2 in a dose 
dependent manner. Moreover, TRPM7 fails to phosphorylate the truncated SMAD2 or 
the GST-tag, thereby identifying the C-terminal SXS-motif of SMAD2 as a substrate for 
TRPM7 kinase (Fig. 6b). Thus, we conclude that TRPM7 kinase can modulate SMAD2 
signalling via direct phosphorylation at the C-terminal Ser465/467 motif (Fig. 5f, 6b), 
which is essential for its transcriptional activity, while the linker region (Ser245/250/255) 
is unaffected by TRPM7 kinase (Supplementary Fig. 3d, 6b).  
Moreover, we performed a proximity ligation assay (PLA) on purified CD4+ T cells, to 
characterize the interaction of SMAD2 with TRPM7 kinase in more detail,. Figure 6c 
depicts a significant increase in SMAD2 co-localization with TRPM7 in WT T cells 
treated with 5 ng ml-1 TGF-β1 (p<0.0001, 01230*(.,4&5064,)07+& 030,+0), while Trpm7R/R T 
cells fail to recruit SMAD2 into close proximity to TRPM7 kinase (Fig. 6c). SMAD2 has 
previously been shown to bind to the Itgae promoter sequence, thereby facilitating its 
transcription25. To link the observed defect in CD103 expression of Trpm7R/R T cells to 
their defective SMAD2 signalling, we performed a chromatin immunoprecipitation 
(ChIP) assay on primary murine CD4+ T cells with and without TGF-β1 stimulation (Fig. 
6d). Our results show that SMAD2 binds to the Itgae promoter regions upon TGF-β1 
stimulation in WT T cells, but fails to do so in Trpm7R/R T cells in response to TGF-β1 
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stimulation, underscoring the indispensable requirement of a functional TRPM7 kinase in 
TGF-β/SMAD2 signalling in T cells. 
TRPM7 kinase activity promotes graft-versus-host disease 
In acute graft-versus-host disease (GVHD), naïve donor CD4 cells recognize alloantigens 
on antigen presenting cells in target organs, including skin, intestine and lung. However, 
the function of different TH subsets and signalling pathways in the pathogenesis of 
GVHD in distinct organs is incompletely characterized. We hypothesized that defective 
intestinal colonization by CD4+ cells lacking TRPM7 kinase activity could affect acute 
GVHD. To address this hypothesis, BALB/c WT mice were lethally irradiated and 
transplanted with bone marrow (BM) cells from WT C57BL/6J mice together with WT 
or Trpm7R/R splenocytes. As expected, injection of WT splenocytes resulted in massive 
intestinal damage as demonstrated by shortening of the colon (Fig. 7a) and most mice 
died within 35 days after transplantation (Fig. 7b). In contrast, injection of Trpm7R/R 
splenocytes did not cause intestinal damage and shortening of the colon in BALB/c hosts 
(Fig. 7a). Moreover, we observed a dramatically increased survival of these mice; only 
about 10 % of mice injected with Trpm7R/R splenocytes died within the first 30 days after 
transplantation (Fig. 7b).  
The analysis of intestinal epithelium by FACS with H2KB (C57BL/6J haplotype) specific 
mAb revealed a significant reduction of TCRαβ+ cells derived from Trpm7R/R splenocytes 
with respect to WT cells, suggesting an impairment of T cells lacking TRPM7 kinase 
activity in the colonization of host intestine (Fig. 7c). Also, the expression of CD103 and 
integrin β7 was significantly reduced in CD4
+ as well as CD8+ TCRαβ+ Trpm7R/R 
compared to WT cells (Fig. 7e). The reduction of gut colonization by Trpm7R/R T cells 
correlated with a significantly reduced expression of MHCII in host intestinal epithelial 
cells with respect to mice injected with WT cells (Fig. 7d). These results indicate that 
TRPM7 kinase activity in T cells is a decisive factor in the pathogenesis of GVHD by 
promoting host gut epithelium colonization.  
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Discussion 
Tissue-specific deletion of Trpm7 in the T cell lineage results in impairment of T cell 
development in the thymus and altered chemokine as well as cytokine expression 
profiles18. In contrast, mice carrying an inactive TRPM7 kinase (Trpm7R/R) have unaltered 
thymopoiesis21, indicating that the channel but not the kinase activity is important in 
regulating the progression of T cell progenitors to mature T cells. However, in these mice 
we observed a significant reduction of pro-inflammatory cytokines, including IL-17 and 
G-CSF, suggesting that TRPM7 kinase activity might be essential for immune system
homeostasis.  
While T cells in the spleen and peripheral lymph nodes of Trpm7R/R mice were distributed 
normally, conventional T cells within IELs and LPLs were reduced. In particular, CD4+ T 
cells were the most significantly reduced IELs and LPLs subsets in Trpm7R/R as compared 
to WT mice. In addition, the analysis of functional subsets in the few CD4+ cells 
recovered from the gut of Trpm7R/R mice revealed a dramatic reduction of TH17 cells, 
indicating that TRPM7 kinase activity is important for gut colonization by T cells and 
TH17 cell differentiation. In fact, experiments of in vitro polarization of naïve CD4
+ T 
cells into TH1, Treg and TH17 cells showed a selective defect of Trpm7
R/R CD4+ T cells to 
polarize into Rorc and IL-17 expressing cells. STAT3 phosphorylation is important for 
TH17 cell differentiation
29 and Trpm7 silencing was shown to affect STAT3 
phosphorylation at Tyr705 in breast cancer cells stimulated with epidermal growth 
factor30. However, IL-6 induced Tyr705 phosphorylation was unaffected in Trpm7R/R 
CD4+ T cells, suggesting that this signalling event is not involved in the defect in TH17 
polarization of Trpm7R/R cells; this result also suggests that in breast cancer cells Tyr705 
phosphorylation might be conditioned indirectly by the TRPM7 channel rather than 
kinase moiety. 
In Trpm7R/R mice, the vascular adhesion molecule integrin α4β7 was not affected in 
intestinal T cells, whereas CD103 (integrin αEβ7) was dramatically reduced. These data 
indicate that the profound reduction of intestinal T cells that characterizes these mice is 
due to the impaired retention of T cells mediated by the interaction of CD103 with E-
cadherin expressed in epithelial cells rather than emigration from blood vessels into the 
LP4. Mice lacking CD103 have selectively reduced numbers of mucosal T cells and are 
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more prone to experimentally induced colitis25, 26. However, this phenomenon was 
attributed to lack of CD103 in gut associated CD11chighMHCIIhigh dendritic cells (DCs)31, 
a cell population that was not affected by lack of TRPM7 kinase activity. Our 
observations are consistent with a selective defect of Trpm7R/R T cells in upregulating 
CD103 and gut retention, while CD103 expression is not affected in DCs by Trpm7R/R, 
pointing to different regulatory mechanism/s in DCs. We demonstrated the T cell 
intrinsic nature of the intestinal defect due to lack of CD103 upregulation by adoptive 
transfer of Trpm7R/R CD4+ cells into lymphopenic hosts. Another important consequence 
of defective TRPM7 kinase activity in T cells was the significant reduction of MHCII 
expression in intestinal epithelial cells, a IELs dependent feature essential for proper 
antigen presentation and immunological function of gut epithelial cells1, 4.  
Both TH17 cell polarization and CD103 expression depend on TGF-β-signalling
27, 28. DCs 
and intestinal epithelial cells (IEL) are the major source for TGF-β in the gut5. However, 
the relative mRNA expressions of Tgf-β1, 2 and 3 in DCs and IELs as well as serum 
concentrations for TGF-β1 and 2 were similar both in Trpm7R/R and WT mice, indicating 
no primary defect in TGF-β production or secretion by lack of TRPM7 kinase activity. 
Conversely, in vitro induction of CD103 by TGF-β in naïve Trpm7R/R CD4+ cells was 
impaired. This impairment was also evident at the transcriptional level since Trpm7R/R 
CD4+ cells failed to upregulate Itgae. In fact, according to SMAD dependence of Itgae 
expression28, we could show a reduction of the phosphorylation of the C-terminal SXS 
motif of SMAD2 but not of SMAD3 in TGF-1-stimulated Trpm7R/R CD4+ cells. 
Moreover, using ChIP we demonstrated the defective binding of SMAD2 to the Itgae 
promoter region in Trpm7R/R T cells upon TGF-1 stimulation. Interestingly, SMAD2 
activation was suggested to exquisitely regulate TH17 cell generation but to be 
dispensable for Treg cell differentiation
32, consistent with distinct control of T cell 
functions by SMAD-dependent and -independent TGF- signalling33. However, this 
notion remains controversial in the literature, as some studies report a dispensable 
function of SMAD2 in TH17 cell polarization
34, 35, 36, 37, suggesting the existence of 
compensatory mechanisms under certain circumstances. As we have not evaluated all 
possible Ser/Thr phosphorylation sites on SMAD3, we cannot exclude an effect of the 
TRPM7 kinase deletion on sites other than the C-terminal SXS motif. However, for 
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SMAD2 we can exclude other direct phosphorylation sites, as the truncated SMAD2 
mutant did not have any phosphorylation by TRPM7 kinase in our in vitro kinase assay. 
Nonetheless, our results are in line with a dispensable function of TRPM7 kinase activity 
in TGF- mediated differentiation of CD4+ cells into Treg cells.  
TGF-β signalling exerts pleiotropic effects on cell physiology via cross-talk with multiple 
signalling pathways. Imaging of TGF-β1-activated SMAD signalling revealed selective 
inhibition of SMAD2 phosphorylation by distinct tyrosine kinase inhibitors38. TRPM7 
kinase appears as a pharmacological target for inhibition of TGF-β1-mediated SMAD2 
phosphorylation in T cells, as it is capable to directly phosphorylate SMAD2. In 
summary, our study demonstrates that TRPM7 kinase contributes to TGF-β-induced 
SMAD2 phosphorylation at Ser465/467 and translocation into the nucleus. Lack of 
TRPM7 kinase activity results in impaired transactivation of SMAD2 target genes, 
including Itgae (encoding for CD103), Il-17 and Rorc, thus selectively limiting 
differentiation of the T cell along the TH17, but not Treg cell, functional program. The 
protection of Trpm7R/R mice from GVHD, we have shown, unravels the clinical relevance 
of TRPM7 kinase as a target for limiting TGF--dependent CD103 expression as a 
pathogenetic mechanism in intestinal destruction during GVHD27. Finally, our study 
demonstrates the importance of developing pharmacological inhibitors for TRPM7 kinase 
activity to prevent the devastating consequences of acute GVHD without affecting the 
development of immunosuppressive Treg cells. 
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Methods 
Mice and in vivo experiments 
Trpm7R/R mice were obtained from RIKEN, Japan21. 4-8-weeks-old male and female mice were used for all 
experiments. For ex vivo and in vitro experiments mice were euthanized using CO2 and terminated via 
cervical dislocation. All experiments involving animals at the Ludwig-Maximilians-Universität München, 
Munich, Germany were performed in accordance with the EU Animal Welfare Act and were approved by 
the District Government of Upper Bavaria, Germany, on animal care (permit no. 55.2-1-54-2532-134-13). 
The use of transgenic animals was approved by the District Government of Upper Bavaria, protocol no. 
821–8763.14.718/1210. For in vivo experiments C57BL/6J, Trpm7R/R, BALB/c and  Rag1-/-/Il2rg-/- mice 
were bred in a specific pathogen-free facility at the Institute for Research in Biomedicine, Bellinzona, 
Switzerland. For adoptive transfer of T naïve, CD4+CD8-CD62L+CD44-CD25- cells were sorted at 
FACSAria (BD Biosciences) from pooled cell suspensions of spleen, inguinal, axillary, brachial, cervical 
and mesenteric LNs of C57BL/6J and Trpm7R/R mice. Eight-week old  Rag1-/-/Il2rg-/-  mice were injected 
with 1x106 naïve T cells. Recipient mice were sacrificed 4 weeks after reconstitution. For GVHD 
experiments lethally irradiated (9 Gy, Cs source) BALB/c (H-2d) mice were reconstituted within 4–6 h by a 
single 0.2-ml intravenous inoculum containing 10 × 106 B6 BMC alone or in combination with 10 × 106 
C57BL/6J or Trpm7R/R splenocytes. All animal experiments were performed in accordance with the Swiss 
Federal Veterinary Office guidelines and authorized by the Animal Studies Committee of Cantonal 
Veterinary with authorization numbers TI-10-2013 and TI-17-2015.  
Cell isolation and primary cell culture 
Lymphocytes infiltrating the intestinal epithelium were isolated as follows: While the small intestine was 
flushed with PBS, fat and Peyer's patches were removed. The small intestine was divided longitudinally, 
cut into 2-mm sections and washed twice, in calcium- and magnesium-free HBSS containing 2% FCS (at 
4°C) to remove feces. The tissue was placed in 50 ml tubes, washed three-times in HBSS containing 2% 
FCS at 4°C, transferred to 25 cm tissue culture flasks and incubated at 37°C in HBSS containing 10% FCS, 
0.2 mmol l-1 EDTA, 1 mmol l-1 DTT. After 20 min incubation, the flasks were shaken vigorously for 30 s, 
and the supernatant containing IELs and the IEC was separated from the tissue fragments using a 40 m 
nylon filter. While the supernatant was collected and put on ice, the tissue fragments were retuned to the 
flasks and the process was repeated. To isolate LPLs, the remaining tissue was washed three-times with 
RPMI 1640, and intestinal pieces were subsequently incubated with magnetic stirring for 30 minutes at 
37°C in cRPMI supplemented with 100 U ml-1 collagenase. The epithelial and lamina propria cell 
suspensions were washed, suspended in RPMI1640 at 4°C and filtered. The cell suspension was collected 
and suspended in 40% Percoll, which was layered on top of 80% Percoll and centrifuged at 2000 rpm for 
20 min at RT. The IELs and LPLs were collected from the interface between the Percoll gradients and 
prepared for phenotypic analysis by flow cytometry. For mRNA extraction IELs and LPLs were purified by 
cell sorting as TCR+CD4+Ep-CAM- cells while IEC cells were sorted as Ep-CAM+ cells. For isolation of 
thymocytes, thymi were homogenized and washed in RPMI1640 medium containing 10% (v/v) FBS. For 
the isolation of CD4+ T cells peripheral lymph nodes were collected, smashed using a 40 m strain and 
CD4+ T cells were sorted via MACS (CD4+ isolation kit, Miltenyi Biotec). Purity was assessed via FACS 
to at least 96% CD4+ T cells before cells were subjected to experiments. For mast cell isolation, cells 
obtained from the peritoneum of WT or Trpm7R/R mice were pelleted and apportioned (Cellgro) into Petri-
dishes with PDL-coated glass cover slips. Cells were cultured in 2 ml DMEM containing 10 % FBS 
(HyClone) and 1 % Penicillin/Streptomycin (Gibco) overnight in a humidified incubator at 37°C and 5% 
CO2. For electrophysiological experiments mast cells were identified visually using light microscopy 
(phase contrast).  
Cytokine assays 
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After blood collection through cardiac puncture using a collector for serum separation and blood cells 
(Microvette, Sarstedt), samples were separated by 10.000 g centrifugation for 5min; serum was then stored 
at -80°. Collected samples were prepared for the 23-cytokines assay (BioRad) and TGFß-1, 2, 3 assay 
(R&D Systems) according to manufacturer’s instructions.  
Antibodies and Flow Cytometric Analysis 
The following mAbs were purchased from BD Biosciences: APC conjugated anti-CD62l (clone:MEL-14, 
Cat.#: 17-0621-83, working dilution 1:200), Pacific Blue conjugated anti-CD8 (clone: H35-17.2, Cat.#: 
48-0083-80, working dilution 1:200), PERCP-CYANINE5.5 conjugated anti-IL-17A (clone: 17B7, Cat.#:
45-7177-82, working dilution 1:100), FITC conjugated anti-FOXP3 (clone: FJK-16s, Cat.#: 11-5773-82,
working dilution 1:100), Pacific Blue conjugated anti-H-2KB (clone: AF6-88.5.5.3, Cat.#: 48-5958-82,
working dilution 1:200) APC conjugated anti-CD11C (clone: N418, Cat.#: 17-0114-82, working solution
1:200). The following mAbs were purchased from Biolegend (http://www.biolegend.com/): PE conjugated
anti-CD44 (clone:IM7, Cat.#: 103008, working dilution 1:200), PE/Cy7 conjugated anti-CD25 (clone:
PC61, Cat.#: 102016 working dilution 1:200), APC/Cy7 conjugated anti-CD4 (clone: RM4-5, Cat.#
100526, working dilution 1:200), FITC conjugated anti-CD8 (clone: 53-6.7, Cat.# 100706, working
dilution 1:200), PE conjugated anti-TCR (clone: H57-597, Cat.#: 109208, working dilution 1:200), FITC
conjugated anti-TCR (clone: GL3, Cat.#: 118106, working dilution 1:200), PE conjugated anti-CD103
(clone: 2E7, Cat.#: 121406, working dilution 1:200), PE conjugated anti-47 (clone: DATK32, Cat.#:
120606, working dilution 1:200), APC conjugated anti-7 (clone: FIB504, Cat.#: 321208, working
dilution 1:200), Pacific Blue conjugated anti-MHC-II (clone: M5/114.15.2, Cat.#: 107620, working dilution
1:200), FITC conjugated anti-Ep-CAM (clone: G8.8, Cat.#: 118210, working dilution 1:200), PE
conjugated anti-IFN- (clone: XMG1.2, Cat.#: 505808, working dilution 1:100). Samples were acquired
on a LSRFortessa (BD Biosciences) or Guava (Merck-Millipore) flow cytometer. Data were analysed using
FlowJo software (TreeStar, Ashland, OR), FACS Diva software (BD Biosciences) or InCyte (Merck-
Millipore) respectively.
Quantitative RT-PCR 
Total RNA from FACS sorted cells was precipitated in Trizol (Invitrogen, ThermoFisher) and reverse 
transcribed to cDNA using Random hexamers (Roche, Cat.#: R 15504) and M-MLV reverse-transcriptase 
(Invitrogen, Cat.#: 28025-013). For quantification of transcripts, mRNA samples were treated with 2 U per 
sample of DNase (Applied Biosystems). Transcripts were quantified by real-time PCR on an ABI PRISM 
7700 Sequence Detector with predesigned TaqMan Gene Expression Assays and reagents according to the 
manufacturerʼs instructions (https://www.lifetechnologies.com). The following probes were used: Trpm7 
(Mm00457998_m1), Tbx21 (Mm00450960_m1), Foxp3 (Mm00475162_m1), Rorc (Mm01261022_m1), 
Il17a (Mm00439619_m1), Itgae (Mm00434443_m1), Tgfβ1 (Mm01178820_m1), Tgfβ2 
(Mm00436955_m1), Tgfβ3 (Mm01307950_m1). All reactions were performed in triplicates. The relative 
amounts of mRNAs were calculated by the ΔΔCT method. 18S and Hprt were used as internal 
housekeeping genes. For Itgae gene upregulation CD4+ T cells were treated with 5 ng ml-1 of TGF-ß1 
(R&D) for 24 hours. Total RNA was precipitated in Trizol (Invitrogen, ThermoFisher) and cDNA synthesis 
was performed using SuperScript II RT (LifeTech, Invitrogen) and oligo-dT primers (18T, Metabion). 
Real-time-PCR was performed using a PrimePCR™ SYBR® Green Assay for Itgae (BioRad, 
qMmuCID0039603) and analyzed using LightCycler® 480 SYBR Green I Master (Roche). Hprt (Fwd: 
CTCATGGACTGATTATGGACAGG, Rev: TTAATGTAATCCAGCAGGTCAGC, Metabion) was used 
as a reference gene. Samples were detected in doublets and the mean CP (Crossing Points) values were 
analyzed as 2-CP. 
In vitro T cell polarization and integrin upregulation 
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CD4+CD8+CD62L+CD44-CD25- naïve T cells were sorted at FACSAria from pooled suspensions of spleen, 
inguinal, axillary, brachial, cervical and mesenteric LNs of WT and Trpm7R/R mice. Cells were seeded in a 
96-well, flat-bottomed plate in RPMI supplemented with 10% fetal calf serum (FCS) and 1 % penicillin 
and streptomycin. For T cell in vitro polarization Th1 cells were generated by addition of rmIL-12 at a 
concentration of 15 ng ml-1, hIL-2 30 U ml-1 and anti-IL-4 Ab (clone 11B11) at a concentration of 5 µg ml-1 
into the culture. For the generation of Th17 cells naïve T cells were cultured with rmIL-6 at a concentration 
of 20 ng ml-1, rmTGF-β at a concentration of 2 ng ml-1, anti-IFN-γ (clone XMG1.2) and anti IL-4 Ab at a 
concentration of 5 µg ml-1. For the generation of Treg cells naïve T cells were cultured with rmTGF-β at a 
concentration of 2 ng ml-1 , 30 u ml-1 hIL-2, anti-IFN-γ and anti IL-4 Ab at a concentration of 5 µg ml-1. For 
in vitro CD103 upregulation T naïve cells were stimulated in presence or absence of rmTGF-β at a 
concentration of 1 ng ml-1. After 4 days of stimulation T cells were collected and stained with anti-CD103 
and anti-β7 mAbs. 
Intracellular cytokine and transcription factor staining 
For intracellular staining of FOXP3, after surface antigens staining, cells were fixed and permeabilized 
using the Foxp3 / Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer’s 
recommendations, followed by staining with anti-FOXP3. For intracellular staining of IFN-γ and IL-17A, 
cells were stimulated for 4 hr with PMA (100 nM, Sigma-Aldrich) and ionomycin (1 μM, Sigma-Aldrich). 
Brefeldin A (BFA) was included during the last 4 hours of activation to inhibit intracellular transport. After 
surface antigens staining cells were fixed and permeabilized using the BD Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences) according to the manufacturer’s 
recommendations, followed by staining with anti-IFN-γ and anti- IL-17A mAbs.   
Immunohistochemistry and digital image analysis 
To assess the number of infiltrating T cells, 4 μm sections from each formalin-fixed paraffin embedded 
small intestinal sample were immunostained with a primary goat polyclonal antibody against CD3 epsilon 
antigen (Santa Cruz Biotechnology; #Sc-1127). A biotinylated rabbit anti-goat IgG antibody (BA-5000, 
Vector Laboratories, Burlingame, CA, USA) was added for 30 min and sections were then labeled by the 
avidin-biotin-peroxidase (ABC) procedure with a commercial immunoperoxidase kit (VECTASTAIN Elite 
ABC HRP Kit, PK-6100, Vector Laboratories, Burlingame, CA, USA). The immunoreaction was 
visualized with 3,3’-diaminobenzidine (Peroxidase DAB Substrate Kit, VC-SK-4100-KI01, Vector 
Laboratories, Burlingame, CA, USA) substrate and sections were counterstained with Mayer’s 
haematoxylin. For each sample, serial sections incubated with a 10% solution of normal rabbit serum 
served as negative controls. The number of CD3 epsilon+ cells and the area of the intestinal mucosa were 
evaluated using the ImageJ analysis program (http://rsb.info.nih.gov/ij/) in 4 200x microscopic fields. The 
number of T cells per mm2 of intestinal mucosa was then calculated. 
Transmission Electron Microscopy 
Electron microscopy was preformed as follows: mice ileum and colon was washed with phosphate buffer 
(0.1M; pH 7.2). Tissue was fixed in 2.5% glutaraldehyde in PB for 3 h, followed by washing the samples in 
phosphate buffer three-times for 3 h. Samples were treated for 1.5 h with 1% osmium in H2O and 
increasing alcohol concentrations for dehydration. Finally samples were embedded in EPON™ and 
propylenoxid (propylenoxide: EPON™ = 3:1, 1:1, 1:3; 60 min each) followed by pure EPON™ for two 
days by 60°C. Ultrathin sections were analysed in a Zeiss transmission electron microscope (EM902A).  
Western Blot Analysis 
CD4+ T cells were seeded in 24-well plates and stimulated with 10 ng ml-1 IL-6 or 5 ng ml-1 TGF-ß1 
(PeproTech or R&D Systems) for the indicated time frames. For detection of phosphorylated proteins 
following antibodies were used: pSTAT3 (Tyr705, Cat.#: 9131, Cell Signaling, MW 86 kDa, working 
dilution 1:2500), pSMAD2 (Ser465/467, Cat.#: 138D4, Cell Signaling, MW 60 kDa, working dilution 
1:200) and pSMAD3 (Ser423/425, Cat.#: C25A9, Cell Signaling, MW 52 kDa, working dilution 1:200). 
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Total proteins were used as loading controls and stained for STAT3 (Cat.#: 9132, Cell Signaling, MW 86 
kDa, working dilution 1:5000) and SMAD2/3 (Cat.#: D7G7, Cell Signaling, MW 60 kDa and 52 kDa, 
working dilution 1:1000). Cells were lysed with RIPA buffer. Lysates were subjected to SDS-PAGE, and 
proteins were transferred to nitrocellulose by Western blotting. The first antibody was incubated overnight 
at 4°C. After washing three times with TBS-T for 5 min, the membrane was incubated with a HRP-
conjugated secondary antibody diluted in TBS-T and incubated for 45-60 min at RT. Immune reactivity 
was quantified by densitometry, ratios between p-SMAD2 or 3 and total SMAD2 or 3 signals, respectively, 
were calculated, and TGF- ß1-induced SMAD phosphorylation was normalized to that of unstimulated 
cells. Data analysis was performed with the ImageJ analysis program (http://rsb.info.nih.gov/ij/). For 
analysis of the intensity of TGF-ß1-induced SMAD phosphorylation compared to untreated controls a one-
way ANOVA was used. Values of p <0.05 (#) were considered significant. CD4+ T cells were seeded in 24-
well plates and stimulated with 10 ng ml-1 IL-6, 5 ng mL-1 TGF-ß1 (PeproTech or R&D Systems) and anti-
CD3/anti-CD28 coated beads (Invitrogen) for 10 min39. For detection of phosphorylated proteins following 
antibody was used: pSMAD2 (Ser245/250/255, no. 3104, Cell Signaling, MW 60 kDa, working dilution 
1:200). Total proteins were used as loading controls and stained for SMAD2 (D43B4, Cell Signaling, MW 
60 kDa, working dilution 1:1000). Cells were lysed with RIPA buffer. Lysates were subjected to SDS-
PAGE, and proteins were transferred to nitrocellulose by Western blotting. The first antibody was 
incubated overnight at 4°C. After washing three times with TBS-T for 5 min, the membrane was incubated 
with an HRP-conjugated secondary antibody diluted in TBS-T and incubated for 45-60 min at RT. 
In vitro kinase assay 
Highly purified recombinant human SMAD2-GST, C-terminally truncated SMAD2-GST and GST were 
purchased from SignalChem (Richmond, BC, Canada, S11-30G-250, CUSTOM S11-30G-250, G52-30U-
250). The in vitro kinase assay was performed by Reaction Biology Corp. (Woodbridge, CT, USA) 
following the RBC HotSpot Kinase Assay Protocol. RBC Standard reaction buffer contained: 20 mM 
Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 2 nM MnCl2, 0.02% Brij35, 0.02 mg ml
-1 BSA, 0.1 mM 
Na3VO4, 2 mM DTT, 1% DMSO. Reactions were carried out at 4 μM ATP in duplicates and measured at 
1h and 2h, respectively. 4 µM rhSMAD2-GST was used as substrate, and 4 µM rh-trSMAD2-GST as well 
as the 4 µM GST-tag alone were used as control substrates, while the TRPM7 kinase was titrated in a serial 
dilution starting at 50 nM. Kinase alone was subtracted as background. RBC standard substrate (MBP) was 
used as a positive and substrate alone as an additional negative control. Data acquired at 2h were converted 
to nM substrate phosphorylation after background subtraction, averaged and plotted as mean values ± 
s.e.m.
In situ Proximity ligation assay 
MACS sorted CD4+ T cells from TRPM7R/R or WT mice were seeded on fibronectin coated coverslips (Carl 
Roth GmbH + Co. KG, Cat.#: H873.2) in a 6-well plate. After stimulation with 5 ng ml-1 TGF-β1 (R&D 
systems) for 10 min cells were fixed with 4% paraformaldehyde for 10 min and permeabilised with 0.2% 
Triton X-100 in PBS for 7 min. Blocking and the proximity ligation assay were performed with the 
DuoLink® In situ Red Starter kit mouse/rabbit (Sigma Aldrich, Cat.#: DUO92101) according to the 
manufacturer`s instructions (http://www.sigmaaldrich.com/technical-documents/protocols/biology/duolink-
fluorescence-user-manual.html). T cells were stained with anti-TRPM7 (self made, Dr. Chubanov, working 
dilution 1:100) and anti-SMAD2 (Santa Cruz, Cat.#: sc-101153, working solution 1:100) for 1 h at room 
temperature. DuoLink® In situ PLA® Probe anti-mouse PLUS and DuoLink® In situ PLA® Probe anti-rabbit 
MINUS were used for labelling anti-SMAD2 and anti-TRPM7 antibodies. Data acquisition was done on a 
Leica SP5 confocal microscope with a 63 × NA 1.4 PL APO objective (both Leica, Mannheim, Germany) 
by producing z-stacks of five randomly selected fields. Analysis of the data was done by production of 
maximum peak projections of the z-stacks and counting the PLA signals per cell manually. The mean 
number of PLA signals per cell was calculated per field. For comparison of two different sample groups, 
two-tailed unpaired Student’s t-test was performed in Prism 6 (GraphPad Software, La Jolla, CA, USA).  
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Chromatin Immunoprecipitation 
MACS sorted CD4+ T cells from Trpm7R/R or WT mice were treated with or without 5 ng ml-1 TGF-β1 
(R&D systems) for 10 min. In total 7 mice per genotype were used. Cells were cross-linked with 1% 
methanol-free formaldehyde and quenched with 0.125 M glycine. Nuclei were pelleted and lysed for 
10 min on ice. After washings, lysates were sonicated four times for 30 sec into DNA fragments of 200-
2000 bp. Immunoprecipitation of the sheared chromatin was performed using an anti-SMAD2 (Cell 
Signaling Technology, Cat.#: 5339S.) antibody coupled to Dynabeads Protein G overnight at 4°C. 1% of 
the sonicated chromatin was set aside as input without antibody. After washings of immune complexes and 
elution of DNA of both input and ChIP samples, qRT-PCR with specific primers for the Itgae (Fwd: 
CCTCCACAGCCCTATGTGTT, Rev: GCCTCACAGGTAGGAACTGG) and the Gapdh (Fwd: 
CCCTGCTTATCCAGTCCTAGCTCA AGG, Rev: CTCGGGAAGCAGCATTCAGGTCTCTGG) 
promoters for normalization was performed. For comparison of two different sample groups, one-way 
ANOVA was performed in Prism 6 (GraphPad Software, La Jolla, CA, USA).  
Determination of magnesium and calcium 
Content of main elements in serum samples was determined by inductively coupled plasma mass 
spectrometry (ICP-MS) by ALS Scandinavia (Sweden). Therefore, serum was collected using a collector 
for serum separation and blood cells (Microvette, Sarstedt), samples were separated by 10.000 g 
centrifugation for 5 min; serum was then stored at -80°. Collected samples were shipped on dry ice for 
further analysis via ICP-MS.  
Immunoprecipitation and Western Blotting 
Spleens were collected, smashed using a 100m strain, washed in PBS and subjected to red blood cell 
lysis. The red blood cell lysis buffer contained in mM: 160 NH4Cl, 10 KHCO3, 0.1 EDTA. After washing 
twice in PBS, splenocytes were lysed using a 1x Lysis-Buffer containing: 0.5% (v/v) Igepal 0.5% (v/v) 
PMSF 1% (v/v) Protease & Phosphatase inhibitor 5 mM NaF. Lysates were incubated with a total TRPM7 
antibody (ProScientifica, working dilution 1:50) and rotated for 2h at 4°C. Afterwards, Protein G sepharose 
beads (Dynabeads®, Invitrogen) equilibrated with lysis buffer were added at a working ratio 1:18 and 
rotated overnight at 4°C. Immuno-precipitated lysates were subjected to SDS-PAGE, and proteins were 
transferred to nitrocellulose by Western blotting. Following antibodies were used for detection: total 
TRPM7 (ProScientifica, working dilution 1:1000) pTRPM7Ser1511, working dilution 1:60). The first 
antibody was incubated overnight at 4°C. After washing three times with TBS-T for 5 min, the membrane 
was incubated with a HRP-conjugated secondary antibody diluted in TBS-T and incubated for 45-60 min at 
R, and after subsequent washing steps, the chemiluminescent signal was detected. 
Generation of pTRPM7Ser1511-specific antibody 
To generate a polyclonal pTRPM7Ser1511-specific antibody, rabbits were immunized with a 
phosphorylated peptide H2N-DSPEVD(p)SKAALLPC-NH2 coupled via its C-terminal cystein residue to 
keyhole limpet hemacyanin (Phospho-peptide immunization program Eurogentec, Belgium). The generated 
serum was subjected to two rounds of peptide affinity chromatography. First, a fraction of antibody was 
purified using the phosphorylated peptide. Second, the isolated antibody was followed by an additional 
round of chromatography using a non-phosphorylated variant of the peptide (H2N-DSPEVDSKAALLPC-
NH2) in order to deplete a fraction of antibody with cross-reactivity to a non-phosphorylated TRPM7.  The 
final fraction of anti-pTRPM7Ser1511 antibody was aliquoted and stored at -80 oC 
ATP detection 
Detection of ATP was performed using a conventional lucifern/luciferase assay, following manufacturer’s 
instructions (ATP Determination Kit, Invitrogen, Molecular Probes). Luminescence was monitored at ~560 
nm using a microplate luminometer, FLUOstar OMEGA, by BMG.  
Electrophysiology 
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Patch clamp experiments in whole-cell configuration were performed as follows: Currents were elicited by 
a ramp protocol from –100 mV to +100 mV over 50 ms acquired at 0.5 Hz and a holding potential of 0 mV. 
Inward current amplitudes were extracted at –80 mV, outward currents at +80 mV and plotted versus time. 
Data were normalized to cell size as pA pF-1. Capacitance was measured using the automated capacitance 
cancellation function of the EPC-9/10 (HEKA, Lambrecht, Germany). Values over time were normalized 
to the cell size measured immediately after whole-cell break-in. Standard extracellular solution contained 
(in mM): 140 NaCl, 1 CaCl2, 2.8 KCl, 2 MgCl2, 10 HEPES-NaOH, 11 Gluc (pH 7.2, 300 mOsm). 
Nominally Mg2+-free extracellular solution contained (in mM): 140 NaCl, 3 CaCl2, 2.8 KCl, 10 HEPES-
NaOH, 11 Gluc (pH 7.2, 300 mOsm). Divalent-free extracellular solution contained (in mM): 140 NaCl, 
2.8 KCl, 10 HEPES-NaOH, 0.5 mM EDTA, 11 Gluc (pH 7.2, 300 mOsm). Standard intracellular solution 
contained (in mM): 120 Cs-glutamate, 8 NaCl, 10 HEPES, 10 Cs-EGTA, 5 EDTA (pH 7.2, 300 mOsm). 
For MgCl2 dose response intracellular solution contained (in mM): 120 Cs-glutamate, 8 NaCl, 10 Cs-
BAPTA + appropriate amount of MgCl2 was added, as calculated with WebMaxC (stanford.edu). 
Calcium Imaging 
Intracellular calcium measurements were performed with freshly isolated naïve CD4+ T cells. 
Measurements of intracellular Ca2+ levels with Fura-Red were made using dual excitation wavelengths of 
420 nm and 470 nm (Invitrogen). CD4+ cells were loaded with 1 µM Fura-Red-AM in external solution for 
30 min at room temperature. After incubation cells were centrifuged at 1.500 rpm for 5 min at room 
temperature and resuspended in external solution containing (in mM) 140 NaCl, 2 CaCl2, 2.8 KCl, 1 
MgCl2, 10 HEPES-NaOH, 11 Gluc (pH 7.2, 300 mOsm). Cells were transferred into a cell culture dish with 
glass bottom and kept in the dark at room temperature for 20 min. Then the dish was positioned in in the 
recording chamber. For basal Ca2+ concentrations, the mean of 5 ratio values recorded within the first 
minute after establishing a baseline was calculated. Images were analyzed via the ZEN Software. 
Alternatively, naïve CD4+ T cells were loaded with 2 µM Fura-2-AM, 1% BSA and 0.02% Pluronic® F-
127 in external solution for 15 min at room temperature in the dark. Cells were transferred into a cell 
culture dish with glass bottom, and stimulated with plate bound anti-CD3ε and anti-CD28 (5 µg ml-1 and 
2µg ml-1 respectively). Images were analysed with TILLvisION software.  
In vitro T cell proliferation 
CD4+ naïve T cells were seeded in a 96-well, flat-bottomed plate in RPMI supplemented with 10% fetal 
calf serum (FCS) and 1 % penicillin and streptomycin. In proliferation assays cells were labelled with the 
Thermo Fisher CellTrace violet (#C34557) and stimulated by plate-bound anti-CD3ε (2μg ml-1) mAb with 
or without co-immobilized anti-CD28 mAb (2μg ml-1) (eBioscence). CellTrace dilution was measured in 
truly live cells through the exclusion of dead cells by electronic gate of Propidium Iodide negative cells. 
FACS acquisitions were standardized by fixed numbers of calibration beads (BD Biosciences). 
Alternatively, 0.5 x106 CD4+ T cells per mL were seeded into 96-round-bottom-well plates coated with 
anti-CD3 (5 µg ml-1) as well as anti-CD28 (5 g mL-1). Every day cells were resuspended in medium and 
50 L were analysed via FACS analysis (Guava, Merck-Millipore) using the ViaCount dye (Merck-
Millipore) to count live cells.  
Statistical analysis 
Unless stated otherwise, a two-tailed unpaired Student’s t-test was used to determine the significance of 
differences between mean values (GraphPad or IgorPro). Data are presented as mean values ± s.e.m. of at 
least 3 mice. Values of p <0.05 were considered significant with * p<0.05, ** p<0.01 and *** p<0.001.  
Data availability 
The authors declare that the data supporting the findings of this study are available within 
the paper and its supplementary information file.  
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Figure Legends 
 
Figure 1 Normal T cell development in Trpm7R/R mice but altered cytokine secretion.  
(a) Total WT or Trpm7R/R cell recovery from thymus. (b) Representative dot plot analysis of 
thymocytes from WT or Trpm7R/R thymi stained with CD4 and CD8 mAb. Percentages are shown 
in each gate. (c) Dot charts comparing the total number of thymocytes in the double negative 
(DN), double positive (DP), CD4+, and CD8+ thymocytes are shown (mean ± s.e.m. n=5). (d) 
Representative dot plot analysis of thymocytes gated on DN cells from WT or Trpm7R/R thymi 
stained with CD44 and CD25 mAbs. Percentages are shown in each gate. (e) Representative 
histogram overlay of cell surface CD25 in WT or Trpm7R/R thymocytes. (f) Dot charts showing 
the number of total cells (mean ± s.e.m. n=5) of DN population found in the DN1, DN2, DN3, 
and DN4 stages. Data are representative results of 2 independent experiments with 5 mice per 
experiment. (g) Basal cytokine levels evaluated in serum of WT (black, n=3-7) and Trpm7R/R 
(grey, n=3-7) mice, respectively, and shown as pg ml-1. Bar charts indicate mean ± s.e.m.  A total 
number of 7 mice were used for each genotype. Note a significant reduction of serum levels of 
IL-17 and G-CSF in Trpm7R/R. A two-tailed Student’s t-test was used with * p<0.05; ** p<0.01 
and *** p<0.001 . 
Figure 2 Selectively reduced intraepithelial lymphocytes in Trpm7R/R mice. 
(a) Dot plot (left) and statistical analyses (right) of intraepithelial lymphocytes (IEL) from WT or 
Trpm7R/R mice stained as indicated. Percentages are shown in each gate, bar charts show mean 
percentages ± s.e.m. (WT, n=6; Trpm7R/R, n=7). (b) Dot plot (left) and statistical analyses (right) 
of LPLs from WT or Trpm7R/R mice stained as indicated. Percentages are shown in each gate, bar 
charts show mean percentages ± s.e.m. (n=7).  (c) Absolute numbers  (WT, n=6; Trpm7R/R, n=7) 
of the indicated IELs subsets. Bar charts show mean percentages ± s.e.m. (d) Absolute numbers 
(mean ± s.e.m. n=7) of the indicated LPLs subsets. (e) CD3 immunohistochemical staining of 
small intestine sections of WT or Trpm7R/R mice and relative quantification (right). Scale bars 
indicate 100 µm. (f) Dot blots and statistical analyses of MHCII expression in EpCAM+ intestinal 
epithelial cells (IEC). Percentages are shown in each gate, bar charts show mean percentages ± 
s.e.m. (n=3). (g) Quantitative real-time PCR of T-bet, Foxp3, Rorc and Il-17a expression in 
purified TCR+CD4+ IELs from WT or Trpm7R/R mice. (h) Dot plot and statistical analyses of 
IFN- and IL-17A staining in WT or Trpm7R/R TCR+CD4+ IELs. Percentages are shown in 
each gate, bar charts show mean percentages ± s.e.m. (WT, n=5; Trpm7R/R, n=8). Data are 
representative results of at least 3 independent experiments. A two-tailed Student’s t-test was 
used with * p<0.05; ** p<0.01 and *** p<0.001. 
Figure 3 Trpm7R/R mutation affects αEβ7 expression in T cells. 
(a) Representative histogram overlay of cell surface CD103, β7 and α4β7 expression of 
intraepithelial lymphocytes (IEL, left) and relative statistical analysis (right). Percentages are 
shown in each gate, bar charts show mean percentages ± s.e.m. (n=4). (b) Representative 
histogram overlay of cell surface CD103, β7 and α4β7 expression of lamina propria lymphocytes 
(LPL, left) and relative statistical analysis (right). Percentages are shown in each gate, bar charts 
show mean percentages ± s.e.m. (n=4). (c) Surface CD103, β7, and α4β7 expression in IELs, bar 
charts show Mean Fluorescence Intensity ± s.e.m. (n=5). (d) Surface CD103, β7 and α4β7 
expression of LPLs, bar charts show Mean Fluorescence Intensity ± s.e.m. (n=5). (e) Quantitative 
real-time PCR of Itgae expression in purified TCR+CD4+ lymphocytes from spleen (SPL), 
lamina propria (LPL) or intraepithelium (IEL). Data are representative results of at least 3 
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independent experiments. A two-tailed Student’s t-test was used with * p<0.05; ** p<0.01 and 
*** p<0.001.  
Figure 4 TRPM7 kinase dead T cell autonomous defect in in vivo CD103 expression and 
intraepithelial localization. 
(a) Transmission electron microscopic (TEM) images of small intestine (upper panel) and colon
(lower panel) sections from WT or Trpm7R/R mice. Note no changes in tight junction, adherens
junction or desmosome formation between the two genotypes. Scale bars indicate 500 nm and
200 nm, respectively. (b) Dot plot (left) and statistical analyses (right) of CD11c+MHCII+ DC and
relative CD103 expression. Percentages are shown in each gate, bar charts show mean
percentages ± s.e.m. (n=3). (c) Quantitative real-time PCR of Tgf-1, Tgf-2 and Tgf-3
expression in WT or Trpm7R/R purified CD11c+MHCII+ DC cells (left) or in EpCAM+ IEC (right).
(d) TGF-1 and TGF-2 levels measured in serum harvested from WT or Trpm7R/R mice (n=4).
Data are shown as mean ± s.e.m. (e) Dot plot and statistical analyses of spleen (SPL), lamina
propria (LPL) and intraepithelial (IEL) TCRαβ+ CD4+ lymphocytes from  Rag1-/-/Il2rg-/- mice
reconstituted with purified WT or Trpm7R/R naïve CD4 cells. (f) Cells were gated for surface CD4
and TCRαβ and were analyzed for CD103 expression. Percentages are shown in each gate, bar 
charts show mean percentages ± s.e.m. (n=4). (g) Dot plots and statistical analyses of MHCII 
expression in EpCAM+ intestinal epithelial cells (IEC) from  Rag1-/-/Il2rg-/- mice reconstituted 
with purified WT or Trpm7R/R naïve T cells. Percentages are shown in each gate, bar charts show 
mean percentages ± s.e.m. (n=4). Data are representative results of at least 3 independent 
experiments. A two-tailed Student’s t-test was used with * p<0.05; ** p<0.01 and *** p<0.001. 
Figure 5 Trpm7R/R T cells have autonomous defect in in vitro Th17 polarization and CD103 up-
regulation. 
(a) Representative dot plots and statistical analyses of IFN-γ, IL-17A, CD25 and FOXP3
expression in stimulated naïve T cells under Th1, Treg or Th17-polarizing conditions after 5 days
of in vitro culture. Percentages are shown in each gate, bar charts show mean percentages ± s.e.m.
(n = 4) (b) Quantitative real-time PCR of T-bet, IFN-γ, Rorc, and IL-17A expression in naïve T
cells stimulated under Th1 or Th17-polarizing conditions after 5 days of culture in vitro. (n = 3)
(c) Western Blot analysis of STAT3 phosphorylation (Tyr705) of control and IL-6 treated WT
and Trpm7R/R (R/R) naïve T cells, respectively. Blots are representatives of at least 3 independent
experiments. (d) Histogram overlays and statistical analyses of CD103 and β7 staining by flow
cytometry in WT or Trpm7R/R naïve T cells stimulated with anti-CD3ε/anti-CD28 in the absence
or presence of TGF-β (10 ng ml-1) for 4 d. Histograms show Mean Fluorescence Intensity (MFI)
± s.e.m. (n=4). Data are representative results of at least 3 independent experiments. (e)
Quantitative real-time PCR of Itgae (CD103) in control (CTRL) and WT or Trpm7R/R naïve T
cells stimulated with anti-CD3ε/anti-CD28 in the presence of TGF-β (5 ng ml-1) for 24 h. Data are
shown as 2-ΔΔCP ± s.e.m. (n=3). (f) Western Blot and statistical analysis of SMAD2 (Ser465/467)
and SMAD3 (Ser423/425) phosphorylation. Blots are representatives of at least 4 independent
experiments. The semi-quantitative analysis was done via ImageJ software and plotted as percent
increase in intensity of pSMAD/total SMAD compared to control. Bar charts show mean
percentages ± s.e.m. for SMAD2 and SMAD3 (n=4-5). A two-tailed Student’s t-test was used
with * p<0.05; ** p<0.01 and *** p<0.001. To demonstrate a significant increase in TGF-β-
induced SMAD phosphorylation compared to untreated controls a one-way ANOVA was used
with # p<0.05.
Figure 6 TRPM7 kinase affects SMAD2 translocation via direct phosphorylation. 
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(a) Analysis of pSMAD2 translocation into the nucleus. WT and Trpm7R/R naïve CD4+ T cells
were co-stimulated with αCD3/αCD28 and 5 ng ml-1 TGF-β1 for 10 min. Representative Western 
Blot images depicting that pSMAD2 and total SMAD2 in the nuclear fraction (right panel) were 
strongly reduced in Trpm7R/R T cells compared to WT. In the respective cytosolic fraction (left 
panel) the pSMAD2 was not detectable, however amounts of total SMAD2 were comparable 
between Trpm7R/R and WT. (b) Concentration dependent phosphorylation of human recombinant 
SMAD2-GST by TRPM7 kinase. Data have been obtained via RBC hotspot in vitro kinase assay 
using 4 µM ATP and 4 µM substrate at 2 h. RBC standard substrate was used as a positive 
control, substrate alone as a negative control and kinase activity alone was subtracted as 
background. Data have been converted to nM substrate phosphorylation and are plotted as mean 
± s.e.m. Truncated recombinant SMAD2 (trun. SMAD2-GST) as well as the GST-tag alone were 
not phosphorylated, suggesting specific phosphorylation of SMAD2 at the c-terminal SXS motif. 
(c) Analysis of interaction between SMAD2 and TRPM7 in CD4+ T cells via Proximity Ligation
Assay (PLA). Scale bar indicates 10 µm. Note a significant increase in SMAD2 co-localization
with TRPM7 in WT T cells treated with 5 ng ml-1 TGF-β1 (#### p<0.0001; two-tailed Student’s
t-test). Trpm7R/R T cells fail to recruit SMAD2 into close proximity to the TRPM7 kinase upon
TGF-β1 stimulation compared to WT (**** p<0.0001; two-tailed Student’s t-test). Bar graphs
show mean PLA signals per cell counted in five fields of vision ± s.e.m. (d) ChIP assay was
performed in untreated and TGF-β1 (5 ng ml-1) stimulated CD4+ T cells using a specific antibody
against SMAD2 for immunoprecipitation. Primers for Itgae and Gapdh were used for qRT-PCR;
Gapdh was used for normalization. Note a significant increase in -fold enrichment in TGF-β1-
treated WT T cells compared to untreated controls (#, p<0.05, one-way ANOVA) as well as a
reduction in -fold enrichment of TGF-β1-treated Trpm7R/R T cells compared to WT (* p<0.05,
one-way ANOVA). Bar graphs show mean ± s.e.m.
Figure 7 TRPM7 kinase activity promotes destruction of the host intestinal epithelium by T cells 
during GVHD. 
(a) Representative picture of colon specimens at day 25 after BMT in recipients of WT or
Trpm7R/R splenocytes or (CTRL) bone marrow cells alone (left) and relative statistical analyses
showing colon length (right). Bars represent mean ± s.e.m. (n=5)  (b) Survival of lethally
irradiated BALB/c recipients of C57BL/6J bone marrow cells (BMC) alone (Ctrl, triangle, dashed
line) or in combination with WT (black circles) or Trpm7R/R (R/R, grey squares) splenocytes
(n=10). (c) Dot plot and statistical analyses of TCR+H-2b+ IELs cells from BALB/c mice
reconstituted with WT or Trpm7R/R splenocytes. Percentages are shown in each gate, bar charts
show mean percentages ± s.e.m. (n=3). (d) Dot plot and statistical analyses of MHCII expression
in EpCAM+ IEC from BALB/c mice reconstituted with WT or Trpm7R/R splenocytes. Percentages
are shown in each gate, bar charts show mean percentages ± s.e.m. (n=3). (e) Dot plot and
statistical analyses of CD103 and β7 expression in electronically gated H-2b+TCR+CD4+ or
H-2b+TCR+CD8+ IELs. Percentages are shown within each gate, bar charts show mean
percentages ± s.e.m. (n=3).
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Supplementary Figures and Figure Legends 
Supplementary Figure 1 
Phenotype of Trpm7R/R mutant mice (a) Targeting strategy for the generation of Trpm7R/R mutant 
mice. (b) Immuno-precipitation (IP) and Western Blot (WB) analysis of primary splenocytes isolated 
from WT or Trpm7R/R mice, respectively. (c,d) Mg2+ and Ca2+ concentrations in WT and Trpm7R/R sera. 
Ions in the serum of individual mice were measured with inductively coupled plasma mass 
spectrometry (ICP-MS). Data are shown as average concentrations in mM (WT: black, Mg: n = 7, Ca: 
n = 13 and Trpm7R/R: grey, Mg: n = 8, Ca: n = 14). Error bars indicate s.e.m. (e) Bar graph showing 
averages of luciferase luminescence detecting ATP levels in cell lysates of CD4+ T cells. Averages of 
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WT (black, n = 4) and Trpm7R/R (grey, n = 4) are shown and error bars indicate s.e.m. (f) Bar graphs 
comparing average Fura-Red ratios of WT (black, n = 28) and Trpm7R/R (grey, n = 31) CD4+ T cells 
indicating cellular, free Ca2+ concentrations at rest. Error bars indicate s.e.m. (G-J) Electrophysiological 
characterization of TRPM7 in WT and Trpm7R/R derived immune cells. Whole-cell currents were 
recorded in freshly isolated primary peritoneal mast cells, or CD4+ T lymphocytes. Voltage ramps were 
elicited from −100 to +100 mV over 50 ms, acquired at 0.5 Hz and recorded at an interval of 2 s. 
TRPM7 current amplitudes were assessed at +80 mV for outward currents and at -80 mV for inward 
currents, averaged and normalized to cell size (pF). Error bars indicate s.e.m. (g) Whole-cell patch 
clamp analysis of TRPM7 current development in WT (black, n = 6) and Trpm7R/R (grey, n = 8) mast 
cells. In the left panel the current densities at +80 and -80 mV are plotted versus time of the experiment 
in seconds (s). Representative current-voltage relationships extracted at 500 seconds of WT (black) and 
Trpm7R/R (grey) cells are shown in the middle panel. Bar graphs of current densities at +80 mV 
extracted at 300 and 500 seconds (right panel). Measurements have been conducted in absence of 
extracellular and intracellular Mg2+ to elicit maximal TRPM7 currents. (h) To estimate functional 
channel expression, we perfused WT (black, n = 12) and Trpm7R/R (grey, n = 9) mast cells with 
divalent-free solution (DVF, left panel). Current densities were plotted versus time of the experiment. 
Representative current-voltage relationships extracted at 300 s (middle panel). Bar graphs of mean 
current densities at +80mV extracted at 200 s and 300 s. WT (black, n = 5-12) and Trpm7R/R (grey, n = 
6-12). (i) Mg2+-dose-response curve of outward current densities plotted against different [Mg2+]i
concentrations. (j) Experiments and analysis were performed as in (g,h), using, WT (black, n = 5) and
Trpm7R/R (grey, n = 5) primary, murine CD4+ T cells.
!"#$%&'()*+,&()&!&-,..&+(/)*.()/&
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Supplementary Figure 2 
Ca2+ signaling and proliferation of CD4+ T cells.  (a) Ratiometric Ca2+ measurements of WT (black, 
n = 28) and Trpm7R/R (grey, n = 31) CD4+ T cells stimulated with αCD3/αCD28 were plotted over time 
(s). In total 3 WT and 3 Trpm7R/R mice were used. A bar graph extracted at 150 s shows mean values ± 
s.e.m. (right panel). (b) T cell proliferation shown in cell numbers plotted versus time (days). CD4+ T
cells isolated from WT  (black, n = 3-4) and Trpm7R/R (grey, n = 3-4) were stimulated with
αCD3/αCD28 antibodies. A total number of 5 animals were used each. In the right panel data at day 5
are shown as average cell numbers ± s.e.m. (c) Representative overlay (left) showing the CellTrace
profile of WT or Trpm7R/R naïve T cells stimulated for 3 days with αCD3/αCD28 and statistical
analysis (right) of the total number of recovered cells at the indicated day. Data are representative
results of at least 3 independent experiments. * p<0.05; ** p<0.01 and *** p<0.001.
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Supplementary Figure 3 
Lymphocyte distribution in peripheral lymphoid organs and TRPM7 expression. (a) Dot plot and 
statistical analyses of lymphocytes derived from spleen (SPL) of WT or Trpm7R/R mice stained as 
indicated. Percentages are shown in each gate, histograms show mean percentages ± s.e.m. (WT, n=5; 
Trpm7R/R, n=5). (b) Dot plot and statistical analyses of lymphocytes from peripheral lymph nodes 
(PLN) of WT or Trpm7R/R mice stained as indicated. Percentages are shown in each gate, histograms 
show mean percentages ± s.e.m. (WT, n=5; Trpm7R/R, n=5). Data are representative results of at least 3 
independent experiments. (c) Quantitative real-time PCR of TRPM7 expression in WT purified 
CD11c+MHCII+ dendritic cells (DC), EpCAM+ epithelial cells (EC), naïve T cells as well as effector 
memory T cells (TEM) (n=3). Note that T cells express substantially more TRPM7 transcripts 
compared to DC or EC. (d) Representative Western Blot analysis of SMAD2 phosphorylation at the 
linker region (Ser245/250/255) induced via co-stimulation of naïve T cells with 5 ng ml-1 TGF-β1, 10 
ng ml-1 IL-6 and αCD3/αCD28 for 10 min. 
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Supplementary Full Blots 
Supplementary Figure 4 
Original data of immunoblots of Figures 3, 5 and 6. 
!"#$%&'()*+,&()&!&-,..&+(/)*.()/&
7 
Supplementary Figure 5 
Original data of immunoblots of Supplementary Figures 1 and 3. 
Supplementary Table 
Gene Name species Oligonucleotide sequence or catalogue 
number 
Trpm7 mouse Assay ID: Mm00457998_m1 
Tbx21 mouse Assay ID: Mm00450960_m1 
Foxp3 mouse Assay ID: Mm00475162_m1 
Rorc mouse Assay ID: Mm01261022_m1 
Il17a mouse Assay ID: Mm00439619_m1 
Itgae mouse Assay ID: Mm00434443_m1 
Itgae mouse Assay ID: qMmuCID0039603 
Itgae mouse Fwd: CCTCCACAGCCCTATGTGTT 
Rev: GCCTCACAGGTAGGAACTGG 
Tgfβ1 mouse Assay ID: Mm01178820_m1 
Tgfβ2 mouse Assay ID: Mm00436955_m1 
Tgfβ3 mouse Assay ID: Mm01307950_m1 
Hprt mouse Fwd: CTCATGGACTGATTATGGACAGG, 
Rev: TTAATGTAATCCAGCAGGTCAGC 
Gapdh mouse Fwd:CCCTGCTTATCCAGTCCTAGCTCAAGG 
Rev:CTCGGGAAGCAGCATTCAGGTCTCTGG 
Supplementary Table 1 
List of all oligonucleotide sequences or catalogue numbers used in qRT-PCR or ChIP-PCR. 
1 
7KH-RXUQDORI([SHULPHQWDO0HGLFLQHVXEPLWWHG
Impaired P2X7 receptor activity promotes the expansion of T follicular 
helper cells in systemic lupus erythematosus 
Caterina E. Faliti
1,2
, Roberta Gualtierotti
3,4
, Elsa Rottoli
1,5
, Maria Gerosa
3,4
, Lisa Perruzza
1,2
, Andrea 
Romagnani
1,2
, Giovanni Pellegrini
6
, Riccardo L. Rossi
7
, Emilia M.C. Mazza
8
, Silvio Bicciato
8
, 
Elisabetta Traggiai
9
, Pier Luigi Meroni
3,4,10,*
 and !"#$%&'("))$*+,+-+.& 
1
Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland. 
2
Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland. 
3
Department of Clinical Science and Community Health, University of Milan, Milan, Italy. 
4 
Lupus Clinic,
 
IASST-Istituto Gaetano Pini, Milan, Italy. 
5
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy. 
6
Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of 
Zurich, Zurich, Switzerland. 
7
Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy. 
8
Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy 
9
Novartis Institute for Biomedical Research, Basel, Switzerland.
10
Istituto Auxologico Italiano, Milan, Italy. 
*
Corresponding authors: fabio.grassi@irb.usi.ch; pierluigi.meroni@unimi.it
ABSTRACT  
Altered control of T follicular helper (Tfh) cells can lead to generation of autoantibodies and 
autoimmune manifestations. Signaling pathways that selectively limit pathogenic responses 
without affecting the protective function of Tfh cells are unknown. Here we show that the ATP-
gated ionotropic P2X7 receptor restricts the expansion and B cell helper activity of Tfh cells in 
mice with pristane-induced lupus but does not affect Tfh cells response to conventional foreign 
antigens, such as ovalbumin. P2X7 stimulation promotes caspase-mediated pyroptosis of Tfh cells 
and controls the development of pathogenic ICOS
+
 IFN-γ-secreting cells. Circulating Tfh cells 
from patients with systemic lupus erythematosus (SLE) but not primary anti-phospholipid 
syndrome (PAPS), a non-lupus systemic autoimmune disease, were hyporesponsive to P2X7 
stimulation and resistant to P2X7-mediated inhibition of cytokine-driven expansion. Moreover, 
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in vitro generated Tfh cells from SLE were less sensitive to P2X7-mediated control. These data 
suggest that restoring P2X7 activity in SLE patients could selectively limit the progressive 
amplification of pathogenic autoantibodies, which deteriorate patients’ conditions. 
 
INTRODUCTION 
T follicular helper cells are a specialized subset of effector CD4 T cells that play a crucial role in the 
generation of protective antibody responses against pathogens. However, dysfunctional Tfh cells can 
activate autoantibody-producing B cells that cause autoimmunity (Craft, 2012; Crotty, 2014; Yu and 
Vinuesa, 2010). Understanding the regulatory mechanisms that ensure the homeostatic control of Tfh 
cell activation can provide insight for manipulating T cell dependent antibody responses in 
autoimmune conditions. The Tfh cell differentiation program is implemented by upregulation of 
inducible T-cell costimulator (ICOS) that induces the transcription factor Bcl6 (Choi et al., 2011; 
Nurieva et al., 2008). Bcl6 in turn promotes CXCR5 expression and migration of the developing Tfh 
cell to the B cell follicle (Choi et al., 2011; Pepper et al., 2011). The concomitant downregulation of 
CCR7 and P-selectin glycoprotein ligand 1 (PSGL-1) allows the T cell to exit the T cell zone and 
colocalize with B cells. The ICOS/ICOSL interaction is important in mediating Tfh cell migration to 
the B cell follicle (Xu et al., 2013). Antigen presentation and ICOSL expression by B cells are 
instrumental to the expansion of Tfh cells, resulting in GC formation. 
Adenosine triphosphate (ATP) is a ubiquitous extracellular messenger, which activates purinergic 
receptors in the plasma membrane termed P2 receptors. The P2X7 receptor subtype is an ATP-gated 
nonselective cationic channel characterized by dual gating: whereas P2X7 stimulation with ATP in the 
hundreds micromolar range leads to opening of a cytolytic pore and cell death, receptor exposure to 
low concentrations of ATP (e.g. micromolar range) results in small-amplitude currents (Khadra et al., 
2013). Tfh cells express high levels of P2X7 in the plasma membrane; in the Peyer’s patches (PPs) of 
the small intestine they are exposed to extracellular concentrations of ATP that promote cell death via 
3 
P2X7. Consequently, Tfh cells with deletion of P2rx7, encoding for P2X7, show resistance to 
extracellular ATP induced pore opening and cell death. The improved helper activity of P2rx7
-/-
 Tfh 
cells results in enhanced germinal center reaction, IgA secretion and binding to commensals (Proietti et 
al., 2014). 
It is not clear whether extracellular ATP might influence Tfh cells at inflammatory sites, where it is 
present at high concentrations (Wilhelm et al., 2010). We addressed this issue in chronic inflammation 
elicited by pristane-injection that causes a lupus-like syndrome in mice (Reeves et al., 2009; Satoh and 
Reeves, 1994). We show that lack of P2X7 in Tfh cells significantly worsened the disease by 
enhancing the generation of autoantibodies. Notably, circulating Tfh cells from patients with SLE were 
almost insensitive to P2X7-mediated control. In contrast, Tfh cells from patients with PAPS were 
inhibited by P2X7 stimulation suggesting that impaired P2X7 activity selectively contributes to the 
immunopathogenesis of SLE. 
RESULTS  
P2rx7 deletion exacerbates immunopathology in pristane induced lupus (PIL)  
Several key features of SLE can be induced in mice by a single i.p. injection of the hydrocarbon oil 
2,6,10,14-Tetramethylpentadecane (TMPD, commonly known as “pristane”) (Reeves et al., 2009; 
Satoh and Reeves, 1994), which provokes peritoneal inflammation, production of antinuclear 
antibodies (ANAs) and glomerulonephritis. P2rx7
-/-
 mice showed a significantly increased mortality 
with respect to WT mice after pristane administration (Fig. 1A) and more severe splenomegaly (Fig. 
1B). PIL is characterized by peritoneal lipogranulomas, ectopic lymphoid structures that sustain 
autoantibodies production (Nacionales et al., 2009; Weinstein et al., 2013). We observed more 
widespread lipogranulomas (data not shown) and enhanced glomerular damage in P2rx7
-/-
 compared to 
WT mice (Fig. 1D). Consistent with these findings, proteinuria levels (Fig. 1C), IgG 
immunocomplexes as well as complement C3 deposits in the glomeruli (Fig. 1E) were markedly 
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increased in mice lacking P2X7. Overall, these results indicate that P2rx7 deletion exacerbates 
pristane-induced immunopathology. 
P2rx7 deletion leads to enhanced GC reaction and generation of autoantibodies in PIL 
Administration of pristane results in hypergammaglobulinemia and production of ANAs, a hallmark of 
SLE (Reeves et al., 2009; Satoh and Reeves, 1994). Serum concentrations of IgG1 and IgG2B subtypes 
were significantly augmented in P2rx7
-/-
 with respect to WT mice, whereas IgG2C, IgM and T-
independent IgG3 were comparable in the two groups of animals (Fig. 2A). Immunofluorescence of 
HEp-2 cells revealed dominant homogenous and mixed homogeneous/nucleolar staining patterns with 
sera from P2rx7
-/-
 mice, suggesting robust generation of autoantibodies directed against nuclear 
components, whereas sera from WT mice preferentially showed cytoplasmic and mixed 
cytoplasmic/nucleolar patterns (Fig. 2B). Semi-quantitative detection of IgG reactive to SLE-specific 
self-antigens showed significant increases in sera from P2rx7
-/-
 mice, which showed values more 
similar to those of autoimmune-prone MRL/lpr than to WT mice (Fig. 2C).  
The analysis of splenic B cell compartment at 8 months after pristane administration did not reveal 
differences in the distribution of follicular and marginal zone B cells between WT and P2rx7
-/-
 mice 
(Fig. S1A). Conversely, splenic plasma cells (Fig. S1B) as well as IgG secreting cells (Fig. 3B) were 
more abundant in P2rx7
-/-
 mice. Splenic PNA
+
Fas
+
 GC B cells were unaltered in pristane treated WT 
mice with respect to untreated animals at this time after pristane administration. However, these cells 
were significantly increased in P2rx7
-/-
 mice (Fig. 3A), as were GCs detected in immunofluorescence 
staining on spleen cryosections (Fig. 3C). These experiments suggest that protracted GC reaction could 
be responsible for the enrichment of autoreactive IgG in P2rx7
-/-
 mice.  
P2X7 activity limits Tfh cells expansion and kidney infiltration  
Pristane administration induced a significant expansion of effector/memory CD4 cells in P2rx7
-/-
 mice 
as compared to WT mice (Fig. S2A, B). Tfh cells expressing ICOS and PD-1 were dramatically 
increased both as frequency and absolute number (Fig. 4). ICOS amplification results in spontaneous 
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autoimmune manifestations in sanroque mice (Vinuesa et al., 2005) and increased IgG production as 
well as multi-organ inflammation in autoimmune-prone MRL/lpr mice (Odegard et al., 2008; 
Teichmann et al., 2015). ICOS-expressing CD4
 
cells promote nephritis in lupus-prone mice (Odegard 
et al., 2009) and were detected in renal biopsy of patients with lupus nephritis (Cohen et al., 2008; 
Hutloff et al., 2004). In P2rx7
-/-
 mice, kidney-infiltrating ICOS
+
 CD4 cells were significantly increased 
following pristane administration (Fig. S3A, B). The expansion of ICOS
+
 cells in P2rx7
-/-
 mice was 
associated with decreased frequency of ICOSL
+
 GC B cells and ICOSL mean fluorescence intensity 
(MFI) (Fig. S1C), as described both in murine (Iwai et al., 2003) and human (Her et al., 2009; Hutloff 
et al., 2004) lupus. These findings suggest that P2X7 activity exerts a crucial function in controlling 
ICOS
+
 Tfh cells to prevent autoimmune responses.  
Immunosuppressive T regulatory cells (Tregs) limit the expansion of autoreactive cells and their defect 
might contribute to lupus pathogenesis, albeit a specific role in human SLE is debated (Ohl and 
Tenbrock, 2015). We did not detect differences in Tregs representation in the spleen between pristane 
injected WT and P2rx7
-/- 
mice (Fig. S2C). We addressed whether T follicular regulatory (Tfr) cells, 
which represent specialized Tregs controlling GC reaction (Chung et al., 2011; Linterman et al., 2011; 
Wollenberg et al., 2011) were affected in P2rx7
-/-
 mice. However, we did not detect differences in 
Tfh/Tfr cells or GC B/Tfr cells ratios in the spleen of treated animals (Fig. S2D), suggesting that 
P2rx7
-/- 
Tfr cells efficiently expanded concomitantly to enhanced Tfh and GC B cells expansion. 
Specific defect of P2X7 in Tfh cells enhances the generation of autoantibodies  
We addressed whether P2rx7
-/-
 Tfh but not other cells contributed to the phenotype of pristane-treated 
P2rx7
-/-
 mice by analyzing the impact of the treatment in Icos
-/-
P2rx7
-/-
 mice, which are devoid of Tfh 
cells (Proietti et al., 2014). In double knock-out mice we did not detect variations in GC B cells 
abundance with respect to untreated animals (Fig. 5A), while we observed a slight but significant 
increase in serum autoantibodies, likely representing Tfh and GC independent responses. Nevertheless, 
the concentration of autoreactive IgG in Icos
-/-
P2rx7
-/-
 mice was markedly reduced with respect to 
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P2rx7
-/-
 mice, indicating that P2X7 deficient Tfh cells are important for the enhanced autoreactive 
response observed in P2rx7
-/-
 mice (Fig. 5B). Consistent with a pathogenic role of Tfh cells in lupus 
nephritis, Icos
-/-
P2rx7
-/-
 mice showed significantly reduced proteinuria with respect to P2rx7
-/-
 mice 
(Fig. 5C).  
Bcl6 dependent downregulation of P-selectin glycoprotein ligand-1 (PSGL-1) is part of the Tfh cell 
differentiation program (Poholek et al., 2010). In MRL/lpr mice, ICOS-dependent interaction with B 
cells was shown to promote PSGL-1 downregulation and autoantibodies production (Odegard et al., 
2008). Analogously, we found a significant increase of PSGL-1
lo/-
 cells in pristane-treated P2rx7
-/-
 mice 
(Fig. 5D). Concomitant ICOS deletion abolished PSGL-1 downregulation in these mice and resulted in 
unaltered PSGL-1
lo/-
 CD4 cells with respect to untreated mice (Fig. 5D), suggesting ICOS dependent 
and protracted functional activity of P2rx7
-/-
 Tfh cells.  
Augmented IFN-γ secretion by PSGL-1
lo/-
 committed Tfh cells in pristane-treated P2rx7
-/-
 mice 
Expression of IL-21 is considered a key feature of normal (Nurieva et al., 2008) as well as pathogenic 
Tfh cells (Kim et al., 2015; McGuire et al., 2011; Yang et al., 2013). However, other proinflammatory 
cytokines such as IFN-γ (Domeier et al., 2016; Jackson et al., 2016; Lee et al., 2012) or IL-17 (Ding et 
al., 2013) were implicated in aberrant Tfh cell function. Intracellular staining for IL-21, IL-17 and IFN-
γ showed a preferential increase in the percentage of IFN-γ
 
secreting CD4 cells in pristane treated 
P2rx7
-/-
 mice that was abolished by Icos deletion (Fig. S3C). Accordingly, we observed a selective 
enrichment of IFN-γ
 
secreting cells in ICOS
+ 
and PSGL-1
lo/-
 CD4 cells (Figure 5E and Fig. S3D). 
According to previous data showing the relative resistance of P2rx7
-/-
 CD4
+
 T cells to differentiate 
along the Th17 pathway (Schenk et al., 2011), we detected decreased percentages of IL-17 secreting 
cells in pristane-treated P2rx7
-/-
 mice as well as decreased percentages of  IL-21 secreting cells with 
respect to WT mice (Fig. S3C). These observations are consistent with the reported role of IFN-γ 
secreting Tfh cells in contributing to lupus pathology (Lee et al., 2012).
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P2X7 mediated pyroptosis of Tfh cells via caspase-mediated activation of Gasdermin D 
Online monitoring of cell permeability to YO-PRO-1 at FACS upon stimulation with the P2X7 agonist 
3’-O-(4-benzoyl)benzoyl ATP (BzATP) is used to assess cellular sensitivity to death mediated by 
cytolytic pore opening. Tfh cells from spleen of WT but not P2rx7
-/-
 mice were sensitive to P2X7 
stimulation in this assay (Fig. 6A). In T cells, P2X7 mediated pore opening and cell death was 
associated to features characteristic of pyroptosis (Taylor et al., 2008), a form of death executed by 
gasdermin D (Gsdmd) upon caspase mediated cleavage and relieve of autoinhibition of the pore 
forming N-terminus (Kayagaki et al., 2015; Shi et al., 2015). A search of gene-expression profiles in 
public data sets revealed Gsdmd as the most widely represented member among Gasdermin family in 
CD4 naïve and Tfh cells (Fig. 6B). The analysis of caspase expression in CD4 naïve versus Tfh cells 
revealed the selective upregulation of caspase-1 and -4 in Tfh cells (Fig. 6C). Since Gsdmd is a 
substrate of caspase-1 and -4, this observation suggests Tfh cells could be sensitive to Gsdmd pore-
forming activity and execute pyroptosis in Tfh cells upon exposure to BzATP. Accordingly, treatment 
of WT but not P2rx7
-/-
 Tfh cells with BzATP resulted in caspase activation (Fig. 6D) and generation of 
cleaved Gsdmd (Fig. 6E), suggesting that P2X7 limits Tfh cells survival in extracellular ATP-rich 
microenvironment via Gsdmd-mediated pyroptotic cell death.
P2X7 limits expansion of Tfh cells in PIL but not during conventional immunization  
To address whether the selective lack of P2X7 in CD4 cells was sufficient to induce Tfh cells 
expansion in PIL, we transferred CD90.2 WT or P2rx7
-/-
 CD4
 
cells from untreated mice into congenic 
CD90.1 WT animals. The analysis of donors Tfh cells at 1, 2 and 4 months after pristane injection 
revealed the significant increase of P2rx7
-/-
 Tfh cells with respect to WT cells (Fig. 7A). This result 
suggests that P2X7 limits Tfh cells expansion upon inflammation and chronic exposure to self-
antigens. Notably, Tfh cells expansion significantly correlated with GC B cells abundance (Fig. 7B). 
To address whether P2X7 mediated control of Tfh cells expansion was peculiar for the inflammatory 
environment elicited by pristane administration but not immunization with a conventional antigen, we 
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immunized WT and P2rx7
-/-
 mice with NP16-OVA in MF59, a potent ATP-releasing adjuvant (Vono et 
al., 2013). In contrast to the enhanced response to pristane, we detected an impaired expansion of Tfh 
cells and OVA-peptide329-337 specific CD4 cells (Fig. 8A) as well as NP-specific GC B cells (Fig. 8B) 
in P2rx7
-/-
 mice at 7 d post-immunization. Recall immunization at 14 d and analysis after 7 d showed 
the persistent reduction of antigen-specific B cells in the spleen of mutant animals (Fig. 8C) 
concomitant to significantly reduced abundance of both high and low affinity IgG secreting B cells 
specific for NP-4 and NP-41 antigen, respectively (Fig. 8D). Since P2X7 is important in promoting the 
proinflammatory activation of APCs during antigen priming of adaptive immunity (Wilhelm et al., 
2010), the defective antigen responsiveness of P2rx7
-/-
 mice could be due to impaired APCs activation. 
To rule out an intrinsic defect of P2rx7
-/- 
Tfh cells during antigen priming, we transferred either WT or 
P2rx7
-/-
 TCR transgenic CD90.2 OT-II CD4 cells (specific for OVA peptide 323-339) into congenic 
CD90.1 WT mice and immunized mice with NP16-OVA in MF59. The analysis of primary as well as 
re-activated memory response revealed undistinguishable frequencies of antigen-specific CD4 cells in 
mice adoptively transferred with WT or P2rx7
-/- 
OT-II cells (Fig. 7C). Altogether, these results are 
consistent with the function of P2X7 in APCs in ensuring effective antigen priming of T cells (Wilhelm 
et al., 2010). Conversely, P2X7 in Tfh cells does not influence responsiveness within a prophylactic 
immunization protocol, likely due to its robust down-regulation during TCR stimulation by cognate 
antigen (Proietti et al., 2014). Importantly, these data show that P2X7 in Tfh cells plays an exquisite 
role in limiting the expansion of potentially pathogenic cells in chronic inflammatory conditions.  
Phenotypic and functional distinction of circulating Tfh cells in SLE and PAPS donors 
As previously shown (He et al., 2013), we observed significantly increased frequencies of the CCR7
lo/-
PD-1
hi
 subset of circulating Tfh (cTfh) cells in SLE patients (Fig. 9A). The same phenotype was used 
to define immunopathogenic Tfh cells in lupus-prone sanroque mice (He et al., 2013). Analogously, 
CCR7
lo/-
PD-1
hi
 Tfh cells were significantly increased in the spleen of pristane-treated P2rx7
-/-
 with 
respect to WT mice (Fig. S4A). Interestingly, the analysis of these cells in patients suffering from 
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another systemic autoantibody-mediated disease, namely PAPS, did not reveal differences with respect 
to healthy donors (Fig. 9A)  Moreover, quantification of CXCL13 in the blood as a Tfh cells derived 
biomarker of GC activity in humans (Havenar-Daughton et al., 2016) showed the significant increase in 
SLE but not PAPS with respect to HD (Fig. 9B). These results support a role for deregulated Tfh cells 
in autoantibodies generation and pathogenesis in SLE, but not PAPS (where SLE features are not 
observed even in the presence of anti-phospholipid antibodies, including lupus anticoagulant, anti-
cardiolipin or anti-β2-glycoprotein-I antibodies) (Ruiz-Irastorza et al., 2010). To investigate possible 
differences in cTfh cells function in SLE and PAPS, we used a chemokine receptors signature, which 
classifies these cells into three majors subsets: efficient B cell helper cells, defined as cTfh2 (CXCR3
-
CCR6
-
) and cTfh17 (CXCR3
-
CCR6
+
) cells, which are increased in some autoimmune disorders, 
including SLE, and non-efficient B cell helper cTfh1 (CXCR3
+
CCR6
-
) cells (Blanco et al., 2016; Ueno 
et al., 2015). As expected, we detected a significant increase in cTfh2 concomitant to a decrease in 
cTfh1 cells in SLE patients. In contrast, PAPS patients were characterized by the increase in a 
cTfh1/Tfh17 hybrid cell subset that was negatively associated with disease activity in SLE (Choi et al., 
2015) (Fig. S4B). SLE and PAPS patients showed an opposite trend of the ratio between the sum of 
cTfh2 and cTfh17 cells with cTfh1 cells compared to healthy donors. Whereas SLE patients showed a 
significant increase of this value, as previously described (Le Coz et al., 2013), PAPS patients 
displayed a significant reduction, thereby defining a functional distinction of cTfh cells in these two 
auto-antibody mediated pathological conditions (Fig. S4C). 
Impaired P2X7 receptor activity unleashes Tfh cells expansion in SLE 
To address possible differences in sensitivity to extracellular ATP via P2X7 in cTfh cells from SLE 
versus PAPS, we tested YO-PRO-1 permeability at FACS upon stimulation with BzATP. These 
experiments revealed the significant reduction of BzATP sensitive cells and impairment of YO-PRO-1 
permeability in SLE patients with respect to both healthy and PAPS subjects (Fig. 9C). The analysis of 
P2RX7 mRNA in sorted CXCR5
+ 
circulating T cells revealed significantly reduced levels in cells from 
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SLE with respect to both healthy and PAPS donors, suggesting P2RX7 is selectively downregulated in 
SLE (Fig. S4D). YO-PRO-1 permeability by P2X7 stimulation inversely correlated with the frequency 
of CCR7
lo/-
PD-1
hi
 cTfh cells (Fig. 9D). Principal component analysis (PCA) for the frequencies of 
CCR7
lo/-
PD-1
hi
 and YO-PRO-1
+
 cells as well as YO-PRO-1 uptake at 450 sec identified two main 
clusters: while HD and PAPS segregated close to each other, SLE samples were clearly differentiated 
along the first component (Fig. 9D). These results indicate that impaired P2X7 activity might be 
responsible for the increase in cTfh cells in SLE. The propensity of effector CD4 cells to expand in an 
antigen-independent fashion can be scored in vitro by the analysis of cell proliferation in response to 
cytokines (Geginat et al., 2001). Upon stimulation with IL-7 and IL-15 CXCR5
+ 
circulating T cells 
from SLE patients proliferated more robustly than cells isolated from healthy or PAPS subjects and 
were significantly more resistant to inhibition of proliferation by BzATP (Fig. 9E). Analogous 
defective inhibition was observed also in purified CCR7
lo/-
PD-1
hi
 cells (Fig. S4E). 
It was recently shown that CD4 naïve T cells can differentiate into Tfh cells and expand in vitro upon 
exposure to activin A and IL-12 (Locci et al., 2016). The generation and expansion of Tfh cells in this 
assay was significantly inhibited by addition of BzATP (Fig. 9F). However, CD4 cells from SLE 
donors generated Tfh cells with the same efficiency irrespective to the presence of BzATP, suggesting 
Tfh cells in SLE are poised to be defective in sensing extracellular ATP as an inflammatory cue that 
should limit their function (Fig. 9F). Altogether, these results point to a role for P2X7 as a checkpoint 
regulator for Tfh cells that appears to be compromised in SLE. 
DISCUSSION  
The identification of the sanroque mutation (that disrupts a repressor of ICOS) unraveled the causal 
role of deregulated Tfh cells and GCs in developing high titres of autoantibodies and lupus pathology 
(Vinuesa et al., 2005). We hypothesize P2X7-mediated regulation of Tfh cells can limit potentially 
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pathogenic GC activity. The abundance of CCR7
lo/-
PD-1
hi
 cTfh cells in the blood correlates with active 
Tfh cells differentiation (He et al., 2013). These cells were selectively enriched and resistant to P2X7-
mediated cell death in SLE but not PAPS patients. Excessive IFN-γ promotes Tfh cells accumulation 
and lupus-associated pathology (Lee et al., 2012). Our results indicate that P2X7 activity might 
contribute to inhibition of IFN-γ secretion and offset the risk of GC-driven autoimmunity by chronic 
Tfh cells stimulation. Notably, IFN-γ deficiency did not impair Tfh cell response against immunization 
with foreign antigen (Lee et al., 2012). According to a dichotomy of P2X7 in regulating Tfh cells 
function in acute stimulation by cognate antigen versus chronic exposure to inflammatory 
environments, immunization with OVA did not result in any difference in the expansion of OT-II Tfh 
cells both in primary and secondary response. Whereas P2X7 activity does not affect Tfh cells response 
to “physiological” stimulation by exogenous antigens it appears to crucially limit immunopathological 
responses. Therefore, restoring P2X7 competence in Tfh cells might improve immunopathology in 
systemic autoimmunity. 
The progressive nature of SLE is characterized by the accumulation of new type of autoantibodies up to 
the clinical onset of the disease. Moreover, the appearance of specific autoantibodies, namely anti-Sm 
and anti–nuclear ribonucleoprotein antibodies, tends to coincide with the clinical manifestations of 
SLE. These observations led to the modeling of disease evolution into three distinct phases of benign 
autoimmunity, pathogenic autoimmunity and clinical illness (Arbuckle et al., 2003). The genetic as 
well as environmental factors influencing the development of pathogenic autoimmunity in SLE are not 
defined. SLE is a polygenic disease; strong candidate/s that may cause the disease seem to be located 
across chromosomal bands 12q24.1 to 12q24.3 (Nath et al., 2004). Together with other potential 
candidate genes in SLE pathogenesis, P2RX7 is located within this chromosomal region. Human 
P2RX7 is highly polymorphic and contains a large set of single nucleotide polymorphisms (SNPs) that 
affect P2X7 activity. Haplotypes containing the Ala348>Thr polymorphism (rs1718119) are 
characterized by a gain-of-function effect (Stokes et al., 2010). Interestingly, this polymorphism was 
 12 
associated with lower risk of SLE in a Chinese population (Chen et al., 2013). CD4 cells from patients 
with SLE, but not rheumatoid arthritis, exhibited diminished P2X7 dependent ATP-mediated cell death 
compared with healthy controls (Portales-Cervantes et al., 2010). We have shown a profoundly 
diminished sensitivity of Tfh cells from SLE but not PAPS patients to cytolytic pore opening by P2X7 
pharmacological agonist, suggesting that downregulation of P2X7 might contribute to a selective Tfh 
cells dysfunction associated with SLE. Notably, aging Fas-deficient MRL/lpr mice, which develop a 
lupus-like syndrome, show a drastically reduced sensitivity to ATP-mediated stimulation of P2X7 in T 
cells associated with progressive lymphoproliferation (Le Gall et al., 2012). In innate immune system 
P2X7 has a well-established role as a trigger for inflammatory cytokines release, a feature that fostered 
the development of P2X7 inhibitors to be used as therapeutic drugs in autoimmune diseases (Ferrari et 
al., 2006). Our results suggest P2X7 inhibition in chronic inflammatory conditions where GC activity is 
enhanced might promote the inappropriate expansion of potentially pathogenic Tfh cells. 
 
MATERIALS AND METHODS 
Mice 
C57/BL6J, P2rx7
-/-
 (B6.129P2-P2rx7tm1Gab/J), Icos
-/-
 (B6.129P2-Icostm1Mak/J), OT-II [B6.Cg-
Tg(TcraTcrb)425Cbn/J], CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) and CD90.1 (B6.PL-Thy1a/CyJ) mice 
from Jackson Lab were bred in the specific pathogen-free (SPF) facility at IRB, Bellinzona, 
Switzerland. All animal experiments were performed in accordance with the Swiss Federal Veterinary 
Office guidelines and authorized by the Cantonal Veterinary. 
Pristane-induced lupus (PIL) 
SLE was induced by a single i.p. injection of 0.5 ml pristane to 8-week-old WT or P2rx7
-/-
 female 
mice. Mice were monitored for clinical signs of SLE until the end of the study (33 weeks post dosing) 
and examined for lesions consistent with SLE by kidney histology and immunofluorescence, presence 
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of serum autoantibodies by ELISA and cell subsets composition by flow cytometry. Proteinuria was 
measured using Bayer Albustix reagent strips on collected fresh spots of urine from each mouse. Score 
from 0 to 4+ was applied as follows: 0 - none, 1+ trace, 2+ 30 mg/ml, 3+ 100 mg/ml, 4+ ≥ 500 mg/ml. 
Immunization and adoptive transfer of CD4 cells 
Eight week-old female mice were subcutaneously injected with 50 µg of NP(16)-Ovalbumin 
(BIOSEARCH Technologies) in MF59 (AddaVaxTM, InvivoGen). Draining lymph nodes and spleen 
were collected 1 wk post-injection and cells analysed by flow cytometry. For the analysis of secondary 
response, the same immunogen was administered and cells analysed after 1 wk. For adoptive transfer 
of OT-II cells, CD4
+
 cells were enriched with anti-CD4 coated magnetic beads (Miltenyi) and sorted as 
CD4
+
CD8
-
CD25
-
CD44
-
CD62L
+
 naïve cells at FACSAria. Eight-week old CD90.1 mice were injected 
intravenously with 2.5 x10
5
 sorted cells containing at least 90% OT-II
+
 cells. Recipient mice were 
immunized 24 h later with a subcutaneous injection of 50 µg of NP(16)-Ovalbumin (BIOSEARCH 
Technologies) 1:1 in MF59 (AddaVaxTM, InvivoGen). For retransfer of activated OT II effector cells, 
CD4 enriched cells were sorted for CD90.2 cells and 5x10
4
 cells were injected intravenously into naïve 
CD90.1 hosts. To re-activate memory OT-II cells, recipient mice received a subcutaneous injection of 
50 µg of NP(16)-Ovalbumin in MF59 28 days after secondary transfer and draining lymph nodes were 
analyzed 1 week later. For adoptive transfer of polyclonal CD4
+
 T cells from either WT or P2rx7
-/-
 
mice, spleens were collected, CD4
+
 cells enriched with anti-CD4 coated magnetic beads (Miltenyi) and 
then sorted as CD4
+
CD8
-
CD19
-
B220
-
CD11c
-
CD11b
-
 cells at FACSAria. 3.5x10
6
 cells were injected 
into CD90.1 WT mice and 24 h later mice were injected i.p. with 0.5 ml pristane. Spleens were 
collected and analyzed after 1, 2 or 4 months post-injection. 
Histochemistry and Immunohistochemistry 
All animals were euthanatized with CO2, followed by exsanguination. For histological evaluation, the 
kidneys were removed, fixed in 10% neutral buffered formalin for 48 h, trimmed, dehydrated and 
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embedded in paraffin wax. Sections of 3-5 µm thickness were prepared, mounted on glass slides, 
deparaffinized in xylene and rehydrated through graded alcohols, before staining with hematoxylin and 
eosin (HE) or the periodic-acid-Schiff (PAS) reagent. Slides were evaluated in a blinded fashion by a 
board-certified veterinary pathologist (G.P.). Glomerular injury was assessed by light microscopy on 
50 consecutive glomeruli/mouse using a histopathological scoring system modified from Wang et al. 
(Wang et al., 1999). Briefly, a grade of 0 indicated normal glomerular histology; scores 1 to 3 indicated 
progressive severe glomerular injury, i.e.: score 1, mildly thickened and hypereosinophilic mesangium, 
multiple clusters of nuclei, mild reduction in the number of glomerular capillaries; score 2: moderately 
thickened and hypereosinophilic mesangium, moderate diffuse hypercellularity, marked reduction in 
the number of glomerular capillaries, occasional inflammatory cells, mostly neutrophils; score 3:  
noticeable enlargement of the glomerular tuft, abnormal glomerular shape (irregular rather than round), 
severely thickened and hypereosinophilic mesangium, occasional adhesions of the glomerular tuft to 
the Bowman’s capsule (synechiae), severe diffuse hypercellularity, loss of capillaries, occasional 
inflammatory cells, mostly neutrophils. To detect glomerular immune complexes (ICs) by 
immunofluorescence, kidneys were removed and immediately frozen in OCT (Tissue TeK). Cryostat 
sections (4 µm) were stained with the following antibodies: AF488 goat anti-mouse IgG (highly cross-
adsorbed, Southern Biotech), rat anti-mouse C3 (RmC11H9) followed by AF647 labeled goat anti-rat 
IgG (cross-adsorbed against mouse IgG, Southern Biotech). To detect renal infiltrating CD4 T 
lymphocytes, the following antibodies were applied to the sections: rat anti-mouse CD4 (clone: GK1.5; 
BD Pharmingen) followed by AF488 goat anti-rat IgG (Invitrogen), hamster anti-mouse ICOS (clone: 
C398.4A; eBioscience) followed by AF594 goat anti-hamster IgG (Invitrogen). Slides were mounted 
with Gelvatol Mounting Media and stained with DAPI for the detection of nuclei. Images were 
acquired using a Leica TCS SP5 confocal microscope, with a HCX PL APO 40x/1.25 N.A. oil 
immersion objective. Quantification was performed with ImageJ open-source software (Schindelin et 
al., 2012): regions of interests (ROIs) containing the glomeruli were manually defined, and the 
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background was excluded by applying a threshold on the intensity; the area above the threshold in these 
ROIs was measured in 3 different fields of view for each sample, and is expressed as percentage of the 
total glomerulus area. For histological analysis of GCs, spleens were frozen in OCT (Tissue TeK). 
Cryostat sections (4 µm) were stained with the following antibodies: AF594 anti-mouse IgD (clone: 
11-26c.2a; Biolegend), AF647 anti-mouse GL-7 (clone: GL-7; Biolegend), BV405 anti-mouse CD4 
(clone: GK1.5; Biolegend), unconjugated goat anti-mouse PD-1 Ig (Novusbio) followed by AF488 
rabbit anti-goat Ig (Invitrogen). Images were collected on a laser-scanning confocal microscope with a 
HCX PL APO 40x/1.25 N.A. oil immersion objective. GC area was measured using ImageJ open-
source software (Schindelin et al., 2012). To score GCs frequency, total GC numbers were quantitated 
in three separate 10x field of view of 2.4 mm
2
 (1550 µm x 1550 µm) per spleen section. 
Preparation of single-cell suspension from kidney 
Kidneys were removed, minced, and digested with Liberase (0.14 mg/ml; Roche) and DNase I (0.03 
mg/ml; Sigma-Aldrich) in HBSS medium, for 30-40 min at 37°C. Tissue pieces were then pressed 
through a 70 µm strainer to obtain single-cell suspensions. Cells were enriched in leukocytes using an 
80/20 Percoll gradient and centrifuged at 800 g for 20 min at room temperature. Lymphoid fractions 
were collected at the interphase of the Percoll gradient and used for flow cytometry. 
Mouse cell isolation and flow cytometry 
Single cell suspensions were prepared by passing spleens through a 70 µm nylon mesh . After 
centrifugation at 1500 rpm for 5 min, red blood cells were lysed in ACK-lysis buffer for 7 min. Lysis 
buffer was neutralized by washing once in staining buffer. Cells were stained with the following 
monoclonal antibodies: biotin-conjugated anti-CXCR5 (clone: 2G8; BD), PE-labeled anti ICOS (clone: 
7E.17G9; BD) or PerCPCy5-labeled anti-ICOS (clone: C398.4A; Biolegend), APC-labeled anti PD-1 
(clone: RMPI-30; Biolegend), Percp-eFluor710-labeled anti-CD3 (Clone: 17A2; eBioscience), AF488-
labeled TCRβ (clone: H57-597; Biolegend), APC-Cy7-labeled anti-CD4 (clone: RM4-5; Biolegend), 
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BV421 anti-CD162 (PSGL1) (clone 2PH1; BD), PeCy7-labeled anti-CD25 (clone: PC61; Biolegend), 
PE-labeled anti-CD44 (clone: IM7;  Biolegend), APC-labeled CD62L (clone: MEL-14; eBiosceince), 
BV421-labeled anti-CD197 (CCR7) (clone: 4B12; Biolegend). APC-Cy7-labeled anti-CD19 (clone: 
6D5; Biolegend), BV405-labeled B220 (clone: RA3-6B2; Biolegend), PE-labeled anti-Fas (clone: Jo2; 
BD), Fluorescein labelled Peanut Agglutinin (PNA) (Cat. #: FL-10-71; Vectorlabs), biotinylated anti-
CD275 (ICOSL) (clone: HK5.3; Biolegend), PE-labeled anti-CD138 (clone: 281-2; BD) APC-labeled 
anti-CD11c (clone: N418; eBioscience), APC-eFluor780-labeled CD45.2 (clone: 104; eBioscience), 
APC-Cy7-labeled anti-CD90.2 (clone: 30-H12; Biolegend). APC-labeled streptavidin was purchased 
from Biolegend  and efluo405-labeled streptavidin from eBioscience. Intracellular staining was 
performed using the BD Cytofix/Cytoperm and Perm/Wash buffers or, for intracellular FoxP3 (FITC-
labeled, clone: FJK-16s; eBioscience) staining, the eBioscience FoxP3 staining buffer set. For intra-
cellular staining of IL-21 (R&D systems), IFN-γ (PeCy7-labeled, clone: XMG1.2; eBioscience) and IL-
17A (PerCP-Cy5-labeled, clone: eBio17B7; eBioscience)  5 x 10
6
 splenocytes were cultured for 5 h at 
37 °C in 24-well plates in 2 ml culture medium containing ionomycin (750 ng/ml) and PMA (20 
ng/ml). For the last 4 h Monensin (eBioscience, 1000X Solution) was added to the cultures. IL-21 was 
detected with a recombinant mouse IL-21R subunit/human IgG1 Fc chimera (R&D systems) with goat 
anti-human Fcγ conjugated to AF488 (Jackson ImmunoResearch). For detection of activated caspases, 
Tfh cells were incubated with FITC-VAD-FMK (CaspGlow Fluorescein Active Caspase Staining Kit; 
BioVision) for 30-45 min at 37 °C in RPMI-1640 medium according to the manufacturerʼs protocol. 
Cells were then washed and resuspended in PBS for FACS analysis. Samples were acquired on a 
LSRFortessa (BD Biosciences) flow cytometer. Data were analysed using FlowJo software (TreeStar). 
Tetramer staining  
Tetramers were kindly provided by the NIH Tetramer Core Facility. Cells were stained for 2 h at 37 ̊C 
with the following APC-labeled Tetramers: I-A
b
 chicken OVA329-337 AAHAEINEA, I-A
b
 chicken 
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OVA328-337 HAAHAEINEA, I-A
b
 chicken OVA259-277 IINFEKLTEWTSSNVMEER and I-A
b
 human 
CLIP87-101 PVSKMRMATPLLMQA. All OVA tetramers gave comparable results in flow cytometry. 
ELISA and ELISPOT assays 
For total immunoglobulin isotype determination, ELISA plates (Corning® 96 Well Half Area Flat 
Bottom Polystyrene High Bind) were coated for 3 h at room temperature with purified goat anti-mouse 
IgG, IgM and IgA antibodies (Southern Biotech) used at a concentration of 10 µg/ml . After 4 washes 
with PBS 0.025% Tween20 and blocking with PBS 1% BSA for 1h at room temperature, samples and 
standards (relative unlabeled mouse Ig, Southern Biotech) were diluted and incubated at room 
temperature for 4 h. Specific secondary goat-anti mouse Ig conjugated with alkaline-phosphatase were 
added after 4 washes with PBS, 0.025% Tween20 and incubated for 2 h at room temperature. Plates 
were washed again and the assay developed with Sigma 104 phosphatase substrate. Plates were read at 
405 nm. IgG secreting cells (ISCs) were detected using ELISPOT assay: 96-well plates (Millipore, 
MSIPS4510 Sterile, hydrophobic high protein binding immobilion-P membrane) were coated with 10 
µg/ml purified goat anti-mouse IgG (Southern Biotech) for 2 h at room temperature. After 3 washes 
with PBS solution, plates were blocked with PBS, 1% BSA and incubated for 30 min at 37 °C. Serial 
dilutions of splenocytes were added in a final volume of 200 µL of B cell medium (RPMI, 10% 
Hyclone serum) and left at 37 °C for 16 h. Subsequently, plates were washed 3 times with PBS, 0.25% 
Tween20, and 4 times with PBS and incubated for 2 h at room temperature with biotinylated goat anti-
mouse IgG (Southern Biotech). After washing, avidin-peroxidase (horseradish peroxidase, HRP, from 
Sigma-Aldrich) was added and left for 1 h at room temperature. The assay was developed with AEC 
(Sigma-Aldrich). For quantification of ISCs, plates were acquired, counted and quality controlled using 
an ELISPOT reader and ImmunoSpot 5.1 software (CTL, Europe GmbH). For ANAs detection, both 
IFA ANA-Hep-2 fixed cells (Orgentec, ORG 870) and microwell ELISA plates coated with highly 
purified individual antigens plus extracts from Hep-2 nuclei and nucleoli (QUANTA LiteTM, Inova 
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Diagnostics) were used. Briefly, fixed Hep-2 cells were incubated with mouse sera (diluted 1:100) and 
ANAs detected with AF488-labeled goat anti-mouse IgG (Southern Biotech). Slides were stained with 
DAPI and captured with a Nikon Eclipse E800 upright microscope, with a 20X/0.75 N.A. objective. 
Images were analyzed with ImageJ open-source software  for pattern recognition (Schindelin et al., 
2012). The kit ELISA (QUANTA LiteTM) for the semi-quantitative detection of ANAs in human 
serum was used and adapted for the detection of mouse ANAs. The antigens include chromatin 
(dsDNA and histones), Sm/RNP, SS-A, SS-B, Scl-70, centromere, PCNA, Jo-1, mitochondria (M-2) 
and ribosomal-P protein, as well as the extracts. Sera were diluted at 1:200 in ANA sample diluent and 
detected with HRP-conjugated goat anti-mouse IgG (Southern Biotech). Plates were read for the 
absorbance (O.D.) at 450 nm within one hour after addiction of the Stop Solution, as described in the 
protocol. 
Western Blot 
Tfh cells were isolated from mesenteric lymph nodes and PPs, washed with ice cold PBS and lysed 
with RIPA buffer 1x (Sigma) supplemented with protease inhibitor cocktail (Roche). Samples were 
centrifuged at 14.000 rpm for 10 min at 4°C and snap frozen. Cleared protein lysate was denaturated 
with loading buffer supplemented with 0.1 µM DTT for 10 min at 65°C. Samples were run on precast 
4-12% bis-tris protein gels (BioRad) and then transferred onto PVDF membranes using Trans-Blot
Turbo Transfer System (BioRad). Membranes were blocked with 10% (wt/vol) nonfat dry milk (Bio-
Rad), 0.1% Tween-20 in TBS and incubated with appropriate antibodies in TBS with 0.1% Tween-20 
16 h at 4°C. The following antibodies were used: anti-GSDMDC1 (clone: A-7, cat. #sc-393656, Santa 
Cruz Biotechnology), anti-actin (Cat. #A2066, Sigma). Bound antibodies were revealed by incubation 
with secondary HRP-conjugated anti-mouse (Cat. #7076, Cell Signaling Technology) or anti-rabbit 
(Cat. #7074, Cell Signaling Technology) IgG antibodies in TBS with 0.1% Tween-20. Membranes 
were developed using the Pierce ECL Western blotting substrate (Thermo Scientific, Cat.# 32209), 
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signals were detected with the ImageQuant LAS 4000 system in the standard acquisition mode (GE 
Healthcare Life Sciences), and bands were quantified using the Multi Gauge Analysis tool (Fujifilm). 
Human samples and patients 
Peripheral blood samples from patients with SLE and PAPS were obtained after providing informed 
consent (Local Ethics Committee approval n. 192_2016bis) during regular follow-up visits at the Lupus 
Clinic, IASST-Istituto Gaetano Pini, University of Milan, Italy. Inclusion criteria were: age >18 years, 
fulfillment of the American College of Rheumatology 1997 classification criteria for SLE (Hochberg, 
1997) and 2006 classification criteria for APS (Miyakis et al., 2006) (Supplementary Table 1). 
Exclusion criteria were: treatment with B-cell depleting agents or experimental drugs. Disease activity 
was determined with SLE disease activity index (SLEDAI-2K) (Gladman et al., 2002); clinical and 
laboratory data were obtained during the routine follow-up. Patients were characterized for anti-
phospholipid antibodies (Lupus Anticoagulant, anticardiolipin IgG and IgM and anti-beta2GPI IgG and 
IgM) (Andreoli et al., 2015) as well as ANA, anti-ENA and anti-dsDNA antibodies (Ingegnoli et al., 
2014). Blood samples from healthy donors were obtained upon providing informed consent from the 
IRCCS Policlinico Ospedale Maggiore, Milan, Italy. 
Human cell isolation and flow cytometry 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood by density-gradient 
centrifugation using Ficoll-Paque™ Plus gradient (GE-Healthcare). CD4
+
 T cells were enriched by 
positive selection using human CD4 MicroBeads (Miltenyi Biotec) and then CD4
+
 T cell subsets were 
sorted to 99% purity with a FACSAria (BD). PBMCs were stained with the following antibodies: (PE-
Texas Red)-labeled anti-CD4 (clone: MHCD0417; Life Technologies), QD655-labeled anti-CD45RA 
(clone: MEM-56; Life Technologies), PE-labeled anti-CCR7 (clone: G043H7; Biolegend), purified 
mouse monoclonal IgG2b anti-CXCR5 (BRL-1, clone: 51505; R&D System) revealed by FITC-labeled 
anti-mouse IgG2b (Southern Biotech), PE-cyanine 5 (PeCy5)–labeled anti-CD183 (CXCR3) (clone: 
1C6/CXCR3; BD), PE-labeled anti-CD196 (CCR6) (clone: 11A9; BD), BV785-labeled anti-CD279 
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(PD-1) (clone: EH12.2H7; Biolegend). PeCy5–labeled anti-CD56 (clone: A07789; Beckman Coulter), 
anti-CD14 (clone: A07765; Beckman Coulter), anti-CD19 (clone: HIB19; Biolegend), anti-CD25 
(clone: BC96; Biolegend), and anti-CD8 (clone: HIT8a; Biolegend) were included as a dump channel 
to exclude contaminant cells.  
Time monitoring of YO-PRO-1 uptake 
1x10
6
 human PBMCs were stained with the appropriate antibodies, washed, resuspended in RPMI 
1640 complete medium and loaded with YO-PRO-1 iodide (Life technologies) at a final concentration 
of 5 µM. The YO-PRO-1 uptake following cell stimulation with 1 mM BzATP (Sigma) was monitored 
at LSRFortessa for 480 sec, and the kinetics analyzed using FlowJo software (TreeStar). Murine 
splenocytes (1x10
6
) were stimulated with 0.1 mM BzATP. 
In vitro cytokine-driven proliferation assay 
For cytokine-driven proliferation assay, sorted CXCR5
+
 or CCR7
lo/-
PD-1
hi
 CD4 T cells were labeled 
with 5 µM Cell Trace Violet (CTV, Life Technologies) in PBS for 20 min at 37°C; staining was 
blocked by adding an equal volume of filtered pre-warmed FBS. Cells were centrifuged at 1500 rpm 
for 5 min and plated at a minimal density of 25’000 cells/well in RMPI 1640 complete medium. Plated 
cells were stimulated with recombinant IL-7 and IL-15 (R&D System) at 25 ng/ml, with BzATP at a 
final concentration of 100 µM when indicated. Cell proliferation and viability were assessed after 7 
days using LSRFortessa. 
In vitro CD4 cell differentiation to Tfh cell  
CD4
+
 cells were enriched from PBMCs by positive selection with anti-CD4 MicroBeads (Miltenyi 
Biotec). Naive T cells were sorted at FACSAria (BD) to 99% purity as CD8
-
CD25
-
CD14
-
CD19
-
CD4
+
CD45RA
+
CCR7
+
 cells, activated by Dynabeads Human T-Activator CD3/CD28 (Life 
Technologies) and cultured with recombinant activin A (100 ng/ml), human IL-12 (5 ng/ml), IL-7 (4 
ng/ml) (all from R&D System) and BzATP where indicated, in AIM-V medium (Life Technologies), as 
 21 
described (Locci et al., 2016). After 5 d, cells were stained with Zombie Aqua™ dye  (BioLegend) to 
exclude dead cells, anti-human CXCR5 and PD-1 antibodies and analysed at LSRFortessa. 
Real-time quantitative PCR 
CXCR5
+
 CD4 cells were sorted at FACSAria (BD) from PBMCs. RNA was extracted using the 
RNeasy Mini Kit (Qiagen) and converted to cDNA. Random primers and MMLV Reverse 
Transcriptase (Invitrogen) were used for cDNA synthesis. Transcripts were quantified by real-time 
quantitative PCR on an ABI PRISM 7900HT with Applied Biosystem predesigned TaqMan Gene 
expression Assays and reagents according to the manufacturer’s instructions. The following probe was 
used (identified by Applied Biosystem assay identification number): P2RX7 (Hs00175721_m1). For 
each sample, mRNA abundance was normalized to the amount of TBP (TAT-box binding protein, 
Hs00427620_m1), used as gene reference, and expressed as arbitrary units (A.U.). 
Meta-analysis of gene-expression data in CD4 cells 
All data were measured on Affymetrix arrays and have been downloaded from Gene Expression 
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo). The following series of GEO data were used: 
GSE46892 (Huang et al., 2014), GSE49314 (Weber et al., 2015), GSE56883 (Moriyama et al., 2014), 
GSE21381 (Yusuf et al., 2010), GSE24574 (Kitano et al., 2011). Microarray probe fluorescence signals 
were converted to log2 expression values using the Robust Multiarray Average procedure (Irizarry et 
al., 2003) of the affy Bioconductor package. Fluorescence intensities were background-adjusted and 
normalized using quantile normalization, and expression values were calculated using median polish 
summarization and custom chip definition files for a total of 18139 custom probe sets for Mouse 
Genome 430 2.0 Array based on Entrez genes (Mouse4302_Mm_ENTREZG version 21.0.0). All data 
analyses were performed in R version 3.3.3 using Bioconductor libraries and R statistical packages. 
The expression change of any caspase was quantified as the difference between its log2 expression 
level in any sample of Tfh cells and its average log2 gene expression signal in naïve CD4 cells (log2 
fold-change).  
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Principal component analysis (PCA) 
Principal component analysis was performed using the "prcomp{stats}" method in R, and visualized 
with ggplot2 library. Datasets were pruned for missing values before analysis, thus a total of 77 
samples were used for PCA (28 HD, 14 PAPS, 35 SLE). The percent contributions of each variable to 
the segregation process were determined as cumulative sum of absolute values of the PCA loadings, 
which are an estimate of how much each variable used in the PCA analysis contribute to each of the 
new variables (the principal components) after the PCA transformation. 
Statistical analysis 
Statistical analysis was performed with the Prism software (GraphPad). Results were analyzed using 
the nonparametric Mann Whitney test, Student’s unpaired t test and two-way ANOVA with Bonferroni 
post-test analysis, as indicated. Results are presented as mean ± SEM. Values of p were indicated 
throughout as *: p < 0.05, **: p < 0.01, ***: p < 0.001 and ****: p < 0.0001; ns: non-significant. 
Online supplemental material 
Fig. S1 shows the phenotypic analysis of B cells in WT and P2rx7
-/-
 mice. Fig. S2 shows the 
distribution of CD4
+
 T cells for CD44 and CD62L as well as frequencies of Tregs and Tfr in untreated 
and treated WT and P2rx7
-/-
 mice. Fig. S3 shows the increase of ICOS
+ 
CD4 T cells in kidneys and 
IFN-γ secreting CD4 cells selectively within ICOS+ cells in pristane treated P2rx7-/- mice. Fig. S4 
shows the increased representation of CCR7
lo/-
PD-1
hi
 CD4 cells in pristane treated P2rx7
-/-
 mice, the 
distribution of functional cTfh cell subsets and P2RX7 mRNA levels in CXCR5
+
 cells from HD, SLE 
and PAPS patients, and the inhibition of CCR7
lo/-
PD-1
hi
 Tfh cells proliferation by BzATP. Table S1 
lists the demographic, clinical and laboratory characteristics of SLE and PAPS patients and healthy 
donors 
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Figure 1. Increased mortality and lupus nephritis severity in P2rx7
-/-
 mice. (A) WT (black line) and 
P2rx7
-/-
 (grey dashed line) mice were observed until the time of sacrifice. *p=0.0403 by log-rank test. 
(B) Spleen weight of untreated WT (n=7), P2rx7
-/-
 (n=6), pristane-treated WT (n=19) and P2rx7
-/-
 
(n=18) mice. (C) Proteinuria score of pristane-treated WT and P2rx7
-/-
 mice. Each dot represents an 
individual mouse and horizontal lines median values. (D) Representative pristane-induced glomerular 
injury in PAS-stained kidney sections (scale bar: 50 µm) with proportion of affected glomeruli (left 
graph) and glomerular injury score (right graph). (E) Confocal microscopy of kidneys stained for IgG 
(green) and complement C3 (red) to detect glomerular immune deposits. Rag1
-/-
 mice were used as 
negative control for IgG staining (scale bar: 20 µm). Histograms show means ± SEM for glomerular 
IgG (top) and C3 depositions (bottom) of 3 independent experiments. All data are from mice at 33 
weeks post-injection. Two-tailed Mann-Whitney U test. *p<0.05, **p<0.01, ***p < 0.001, ****p < 
0.0001. 
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Figure 2. Increased serum autoantibodies in P2rx7
-/-
 mice. (A) Serum Ig isotype concentrations in 
untreated (n=6 for IgM and IgA, n=16 for total IgG, n=12 for IgG subclasses) and pristane treated (n=15 
for IgM and IgA, n=40 for total IgG, n=15 for IgG subclasses) mice determined by ELISA. Data are 
represented as mean ± SEM.  Two-tailed nonparametric Mann-Whitney U test. (B) Representative 
immunofluorescence of HEp-2 cells and relative distribution of ANA IgG staining patterns with sera 
from pristane-treated WT and P2rx7
-/-
 mice. Scale bar: 50 µm. The number in the circle indicates the 
number of analyzed mice. Fisher's exact test with Chi-square. (C) ELISA (QUANTA-Lite ANA) for the 
semi-quantitative detection of self-reactive IgG. Each dot represents an individual mouse. MRL/lpr sera 
were used as positive controls. Two-tailed Mann-Whitney U test. Distribution of sera from the indicated 
mice as non-reactive or reactive in the assay is shown.  
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Figure 3. Increased germinal center reaction and splenic plasma cells in P2rx7
-/-
 mice. (A) 
Representative contour plots for PNA and Fas staining on gated CD19
+
B220
+
 splenocytes, frequency 
and absolute number in untreated (n=12) and treated (n=37) WT as well as P2rx7
-/-
 mice. (B) Absolute 
number of IgG-secreting cells by ELISpot assay in spleens from the indicated mice. Mean ± SEM of 3 
independent experiments. (C) Representative images of spleen sections from pristane treated WT and 
P2rx7
-/- 
mice stained with anti-IgD, -CD4, -GL-7 and -PD-1 antibodies (scale bar: 100 µm) and inset 
zooming on GC cells (scale bar: 50 µm). The number of GCs per field at 10-fold magnification in 
individual mice and GC areas in WT and P2rx7
-/-
 mice are shown in right panels. Two-tailed Mann-
Whitney U test. Mean ± SEM are shown in bar graphs.  *p < 0.05, **p<0.01, ****p < 0.0001. 
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Figure 4. Enhanced CD4 cells activation in P2rx7
-/-
 mice. Representative contour plots, frequency 
and absolute number of CXCR5
+
ICOS
+
 and CXCR5
+
PD-1
+
 cells [untreated WT (n=10), P2rx7
-/-
 (n=9), 
treated WT (n=30) and P2rx7
-/-
 (n=34) mice] and PD-1 [untreated WT (n=9), P2rx7
-/-
 (n=8), treated 
WT (n=17) and P2rx7
-/-
 (n=22) mice] within gated TCRβ
+
CD4
+
 splenocytes. Bar graphs: mean ± SEM. 
Two-tailed Mann-Whitney U test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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Figure 5. P2X7-mediated control of PSGL-1 downregulation and IFN-γ  secretion in pristane 
treated mice. (A) Frequency of PNA
+
Fas
+
 GC splenic B cells, (B) serum ANA IgG detection by 
ELISA and (C) proteinuria score in the indicated mice at 33 wk after pristane injection. (D) 
Representative contour plots for PSGL-1 and CD62L on splenic CD4
+
 T cells, frequency and absolute 
number (mean ± SEM) of PSGL1
lo/-
CD62L
-
 cells from untreated WT (n=12), P2rx7
-/-
 (n=10), Icos
-/-
P2rx7
-/-
 (n=5),
 
treated WT (n=38), P2rx7
-/-
 (n=37) and Icos
-/-
P2rx7
-/-
 (n=8) mice. (E) Contour plots 
show representative intracellular staining for IL-21, IL-17 and IFN-γ on gated CD4+ICOS+PSGL1lo/- 
cells from spleens of treated WT and P2rx7
-/-
 mice. Statistics from three independent experiments is 
shown (mean ± SEM, untreated mice, n= at least 4; treated mice, n= at least 8). Two-tailed Mann-
Whitney U test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.   
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Figure 6. P2X7 mediated caspase activation and Gsdmd cleavage in Tfh cells. (A) Time-
monitoring of YO-PRO-1 uptake after stimulation with BzATP in ICOS
-
PD-1
-
 and ICOS
+
PD-1
+
 cells 
within CXCR5
+
 CD4
+
 T cells from spleen of WT and P2rx7
-/-
 mice, and frequency of responding cells 
in the two subsets from WT mice (n=13). (B) Heat-map representing the log2 expression levels of 
genes encoding mouse gasdermins in CD4 naïve and Tfh cells based on data derived from publicly 
available gene expression data sets (numbers on the left are accession codes). (C) Heat-map showing 
fold changes of caspases in Tfh compared to naïve CD4 cells (accession codes on top). (D) FACS 
analysis and statistics of caspase activation in purified WT and P2rx7
-/-
 Tfh cells upon stimulation with 
BzATP as indicated (n=4). (E) Representative WB of full length and caspase cleaved Gsdmd (FL and 
Nterm, respectively), and actin on WT and P2rx7
-/-
 Tfh cells either untreated or stimulated with 
BzATP. Histograms show the statistics of Gsdmd
Nterm
/ Gsdmd
FL
 ratio in the indicated conditions (n=4). 
Bar graphs: mean ± SEM. Two-tailed Mann-Whitney U test. *p<0.05; **p<0.01; ****p<0.0001. 
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Figure 7. Selective expansion of P2rx7
-/-
 Tfh cells upon pristane injection but not conventional 
immunization. (A) Scheme of the adoptive transfer and pristane administration experiment, 
representative plots of CD90.2
+ 
donor CD4
+
 T cells from spleen at 2 months post-transfer, frequency of 
recovered donor CXCR5
+
ICOS
+
 CD4
+
 T cells within individual mice at 1, 2 and 4 months post-
injection of pristane (mean ± SEM). (B) Correlation between GC B cells and donor Tfh cell 
frequencies at the indicated time points. The correlation coefficient r and the respective p value were 
calculated with nonparametric Spearman test.  (C) Scheme of the adoptive transfer and immunization 
experiment, representative plots of donor CD4
+
 and CXCR5
+
ICOS
+
 T cells within transgenic cells 
recovered from the draining lymph nodes of recipient mice 1 week after primary immunization and 
frequency of recovered donor cells within individual mice after primary immunization and secondary 
response (mean ± SEM). Two-tailed Mann-Whitney U test. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 8. Impaired primary and secondary responses to NP-Ovalbumin in P2rx7
-/-
 mice. (A) 
Frequency and absolute number of CXCR5
+
ICOS
+
 Tfh cells in the draining lymph nodes from 
untreated or immunized WT and P2rx7
-/-
 mice at 1 wk after s.c. injection of NP-OVA in MF59, 
representative contour plots of staining with human CLIP and OVA tetramers, and statistics of OVA 
tetramer positive cells. (B) Frequency and absolute number of GC B cells (same samples as above) 
gated as PNA
hi
B220
+
 among CD19
+
 B cells (upper bar graphs) and of NP-positive GC B cells (lower 
bar graphs) with representative contour plots. (C) Frequency and absolute number of CXCR5
+
ICOS
+
 
Tfh cells (upper bar graphs), GC B cells (middle bar graphs) and NP-positive GC B cells (lower bar 
graphs) in the spleen of the indicated mice within secondary response to NP-OVA. (D) Representative 
ELISpot assay for antigen specific IgG secreting cells in the spleen and bone marrow of immunized 
mice during secondary response and statistics (lower panel). Unpaired Student T test. *p<0.05; 
**p<0.01. 
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Figure 9. Frequency of cTfh cells and P2X7-mediated regulation in healthy subjects, SLE and 
PAPS patients. (A) Representative dot plots for CXCR5
+
 cells and CCR7
lo/-
PD-1
hi
 cells within cTfh 
cells of the indicated subjects and frequency of CCR7
lo/-
PD-1
hi
 cells within cTfh cells in HD, SLE and 
PAPS subjects. Two-tailed Mann-Whitney U test. (B) Serum CXCL13 concentration in HD, SLE and 
PAPS subjects. (C) Representative time-monitoring of YO-PRO-1 uptake in CD14
-
CD4
+
CD45RA
-
CXCR5
+
CCR7
lo/-
PD-1
hi
 cTfh cells from PBMCs of the indicated subjects after stimulation with 
BzATP. Statistics of YO-PRO-1 permeable cells (two-tailed Mann-Whitney U test) and YO-PRO-1 
uptake expressed as fold increase of mean fluorescence intensity at 250 and 450 sec (two-way ANOVA 
multiple comparisons, with Bonferroni’s correction) are shown. (D) Correlation of fold increase in YO-
PRO-1 uptake at 450 sec and percentage of cTfh cells. The correlation coefficient r and the respective p 
value were calculated with nonparametric Spearman test (upper graph). PCA of HD, SLE and PAPS 
patients according to % cTfh cells, % YO-PRO-1
+
 cTfh cells and YO-PRO-1 uptake at 450 sec. Areas 
of spreading are highlighted to better visualize segregation of groups of subjects (lower graph). (E) 
Representative histograms of CellTrace Violet (CTV) dilution in purified CXCR5
+
CD4
+
 cells from the 
indicated subjects after 7 d culture in the presence of IL-7 and IL-15 either without or with BzATP. 
Percentages of proliferating cells within the marker are indicated. Statistics for proliferation and 
inhibition of proliferation by BzATP (two-tailed Mann-Whitney U test). (F) Representative contour 
plots for in vitro differentiation of naïve CD4 cells from HD and SLE donors into Tfh cells in the 
presence of the indicated stimuli and statistics  (Student T test). *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. 
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Figure S1. Phenotypic analysis of B cells in WT and P2rx7
-/-
 mice. (A) Representative contour plots of B2 B cells in the 
spleen of WT and P2rx7
-/-
 mice. Frequencies and absolute numbers from untreated WT (n=6) and P2rx7
-/-
 (n=6) mice and 
treated WT (n=15) and P2rx7
-/-
 (n=14) mice of marginal zone (Mz) and follicular (Fol) B cells gated as CD21
+
CD23
-
 and 
CD21
lo
CD23
+
 cells (as depicted in dot plots), respectively, among CD19
+
B220
+
 total B cells. (B) Representative contour 
plots, relative frequency and absolute number of splenic plasma cells gated as TCRβ
-
CD138
+
CD44
+
 cells from untreated 
WT (n=6) and P2rx7
-/-
 (n=5) mice and treated WT (n=17) and P2rx7
-/-
 (n=16) mice. (C) Representative dot plots and 
statistics of ICOSL
+
 cells frequency within PNA
+
Fas
+
 GC B cells from untreated WT (n=8) and P2rx7
-/-
 (n=7) mice and 
treated WT (n=19) and P2rx7
-/-
 (n=19) mice, representative histograms and statistics of ICOSL MFI. Two-tailed Mann-
Whitney U test. Data in bar graphs are represent as mean ± SEM . *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
2 
Figure S2. Distribution of CD4
+
 T cells in untreated and treated WT and P2rx7
-/-
 mice. (A) Frequency and absolute 
number of splenic CD4
+
 T cells from untreated WT (n=9), P2rx7
-/-
 (n=8), treated WT (n=23) and P2rx7
-/
 (n=22) mice. (B) 
CD44 and CD62L staining of TCRβ
+
CD4
+
 cells. Numbers indicate percentages of CD44
+
CD62L
-
 (effector) and CD44
-
CD62L
+
 (naïve) cells within displayed quadrants; untreated WT (n=10), P2rx7
-/-
 (n=8), treated WT (n=29) and P2rx7
-/-
 
(n=29). (C) Representative contour plots for CD25 and Foxp3 on gated CD4
+
 T cells and frequency of conventional Tregs 
in the spleen of the indicated mice. (D) Representative contour plots used to define Tfh and Tfr cells on gated 
CXCR5
+
ICOS
+
 CD4
+
 T cells. Bar graphs (mean± SEM) represent ratios of GC B/Tfr (left) and Tfh/Tfr (right) cells in the 
spleen of the indicated mice. Two-tailed Mann-Whitney U test. *p<0.05; **p<0.01; ***p<0.001. 
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Figure S3. Increase of ICOS
+ 
CD4 T cells in kidneys and IFN-γ  secreting CD4 cells selectively within ICOS
+
 cells in 
pristane treated P2rx7
-/-
 mice. (A) Gating strategy for quantifying kidney-infiltrating CD44
+
ICOS
+
 effector CD4 T cells, 
and frequency of CD4
+
 and CD44
+
ICOS
+
 T cells from at least 5 animals. Mean ± SEM, two-tailed Mann-Whitney U test. 
(B) Representative confocal immunofluorescence images of fixed kidney cryosection stained with anti-CD4 (green), anti-
ICOS (red) antibodies and DAPI (blue) showing ICOS
+
 T cells within glomeruli of WT and P2rx7
-/-
 mice. Scale bar 
corresponds to 20 µm. (C) Representative contour plots for intracellular staining of IL-21, IL-17 and IFN-γ in CD4
+
 T cells 
from spleen of pristane treated WT, P2rx7
-/-
 and Icos
-/-
P2rx7
-/-
 mice and frequencies. (D) Representative contour plots for 
ICOS and PSGL-1 staining among CD4
+
 T cells from spleen of pristane treated WT and P2rx7
-/-
 mice, and frequency of 
IFN-γ secreting cells within the indicated subsets. Mean ± SEM (n= 2 independent experiments with at least 5 mice). 
Student T test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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Figure S4. Increased representation of CCR7
lo/-
PD-1
hi
 CD4 cells in pristane treated P2rx7
-/-
 mice, distribution of 
functional cTfh cell subsets and P2RX7 mRNA levels in CXCR5
+
 cells from HD, SLE and PAPS patients, inhibition 
of CCR7
lo/-
PD-1
hi
 Tfh cells proliferation by BzATP. (A) Representative contour plots for CXCR5 as well as CCR7 and 
PD-1 among CXCR5
+
 CD4 T cells, and frequency of CCR7
lo/-
PD-1
hi
 CD4 Tfh cells in the spleen of indicated mice. (B) 
Representative contour plots of CXCR5
+
 cTfh cells from HD, SLE and PAPS subjects for CCR6 and CXCR3, and 
distribution of Tfh1, Tfh1/17, Tfh17 and Tfh2 cells in individual subjects from different groups (see Results for details). (C) 
Ratio between (Tfh17+Tfh2) and Tfh1 cells in different subjects. (D) Semi-quantitative RT-PCR analysis of P2RX7 
transcripts in sorted CXCR5
+
 CD4 T cells from HD, SLE and PAPS donors (n=10, A.U.: arbitrary units). (E) Percentage 
inhibition of proliferation by BzATP in sorted CCR7
lo/-
PD-1
hi
 Tfh cells from HD and SLE individual subjects at day 7 of 
stimulation with IL-7 and IL-15. Mean ± SEM are shown in bar graph. Two-tailed Mann-Whitney U test. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
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Table S1. Demographic, clinical and laboratory characteristics of SLE and PAPS patients and healthy donors 
 
Characteristics SLE (n=42) PAPS (=14) HD (=31) 
Female/Male, n 41/1 8/6 29/2 
Age, years, median (range) 43 (26-76) 51 (39-68) 41 (25-62) 
Disease duration, years, median (range) 17 (0.5-48) 13.65 (2-24) na 
Onset <18 years, n (%) 12 (28) 0 (0) na 
Laboratory tests    
ANA positivity (%) 40 (95) 6 (42.8) na 
anti-ENA positivity 19 (45) 0 (0) na 
anti-SSA/Ro, n (%) 13 (30.9) na na 
anti-Sm, n (%) 6 (14.3) na na 
anti-RNP, n (%) 6 (14.3) na na 
*anti-dsDNA positivity, n (%) 22 (52.4) 1 (7.14) na 
low titre, n (%) 7 (16.7) 1 (7.14) na 
medium/high titre, n (%) 15 (36) 0 (0) na 
LA, n (%) 12 (28.5) 13 (93) na 
ç
anti-β2GPI IgG, n (%) 5 (11.9) 12 (85.7) na 
ç
anti-β2GPI IgM, n (%) 2 (4.7) 5 (35.7) na 
ç
anti-CL IgG, n (%) 7 (16.6) 13 (92.8) na 
ç
anti-CL IgM, n (%) 2 (4.7) 2 (14.3) na 
°Low C3, n (%) 19 (45.2) 4 (28.6) na 
°Low C4, n (%) 27 (64.3) 7 (50) na 
§
Hypergammaglobulinemia, n (%) 14 (33) 3 (21) na 
Clinical manifestations (ever) 
 
  
SLEDAI-2K, median (IQR) 4 (2-6) na na 
Skin rash,n (%) 9 (21.4) na na 
Alopecia, n (%) 2 (4.76) na na 
^Haematological involvement, n (%) 12 (28.6) na na 
Arthritis, n (%) 
 
11 (26) na na 
Myositis, n (%) 
 
1 (2.4) na na 
Glomerulonephritis, n (%) 
 
2 (4.76) na na 
Thrombotic APS, n (%)  6 (14) 11 (78.6) na 
Obstetric APS, (%) 
 
0 (0) 14 (28.6) na 
Therapy 
  
  
Equivalent prednisone dose  
 
   
cumulative dose, mg, median (IQR)  36.5 (15-58.4) na na 
daily dose, mg/die, median (IQR)  5 (2.5-10) na na 
Ongoing DMARDs 
 
  
Hydroxychloroquine, n (%) 
 
28 (66.7) 9 (64) na 
Mycophenolate Mofetil, n (%) 
 
8 (19) 1 (7) na 
Azathioprine, n (%) 
 
5 (11.9) 0 (0) na 
Methotrexate, n (%) 
 
3 (7) 0 (0) na 
Cyclosporine, n (%) 
 
5 (11.9) 0 (0) na 
   
  
 
 
 6 
anti-CL: anti-cardiolipin, anti-β2GPI: anti-β2glycoprotein I, ANA: anti-nuclear antibodies, APS: anti-phospholipid 
syndrome, anti-ENA: anti-extractable anti-nuclear antigens; IQR: inter-quartile range; DMARDs (Disease-Modifying Anti-
rheumatic Drugs); na: not applicable. 
§
Hypergammaglobulinemia: >20% of total serum proteins 
ç
Anti-β2GPI and anti-CL positivity was defined as medium/high titre according to 2006 revised classification criteria for 
APS (>99° percentile for anti-β2GPI and >40 GPL/MPL for anti-CL) (Miyakis et al., 2006) 
GPL/MPL refers to IgG/IgM anti-Phospholipid Units 
  
°Low C3 was defined as <80 mg/dL; low C4 as <15 mg/dL 
^Haematological involvement: leukopenia, thrombocytopenia, Coombs positive haemolytic anemia   based on SLEDAI-2K 
definitions (Gladman et al., 2002). LA: lupus anticoagulans, PAPS: primary APS 
*anti-dsDNA have been detected as previously reported (Ingegnoli et al., 2014). anti-dsDNA titres were defined as low if 
<40 UI/mL, medium/high if >40 UI/mL. 
 
